Medpace (MEDP) 10-K 28 Feb 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Feb. 24, 2017	Jun. 30, 2016
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Trading Symbol	MEDP
Entity Registrant Name	Medpace Holdings, Inc.
Entity Central Index Key	1,668,397
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		40,728,022
Entity Public Float			$ 0

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 37,099	$ 14,880
Restricted cash	308	2,857
Accounts receivable and unbilled, net (includes $2.3 million and $2.9 million with related parties at December 31, 2016 and 2015, respectively)	79,767	65,088
Prepaid expenses and other current assets	16,074	11,896
Total current assets	133,248	94,721
Property and equipment, net	43,805	37,512
Goodwill	660,981	660,981
Intangible assets, net	136,071	186,743
Deferred income taxes	97	157
Other assets	4,903	3,927
Total assets	979,105	984,041
Current liabilities:
Accounts payable	10,911	8,728
Accrued expenses	24,417	20,111
Pre-funded study costs (includes $3.9 million and $3.7 million with related parties at December 31, 2016 and 2015, respectively)	51,948	46,599
Advanced billings (includes $7.6 million and $10.2 million with related parties at December 31, 2016 and 2015, respectively)	65,668	51,051
Current portion of long-term debt	12,375	59
Other current liabilities	3,284	7,469
Total current liabilities	168,603	134,017
Long-term debt, net, less current portion	151,267	377,882
Deemed landlord liability, less current portion	28,527	30,273
Deferred income tax liability	12,030	21,104
Other long-term liabilities	7,968	7,291
Total liabilities	368,395	570,567
Commitments and contingencies (see Note 9)
Shareholders’ equity:
Preferred stock - $0.01 par-value; 5,000,000 shares authorized; no shares issued and outstanding at December 31, 2016; No shares authorized at December 31, 2015
Common stock - $0.01 par-value; 250,000,000 shares and 60,000,000 shares authorized at December 31, 2016 and 2015, respectively 40,662,856 and 32,624,461 shares issued and outstanding at December 31, 2016 and 2015, respectively	407	326
Additional paid-in capital	623,629	438,716
Accumulated deficit	(9,584)	(23,009)
Accumulated other comprehensive loss	(3,742)	(2,559)
Total shareholders’ equity	610,710	413,474
Total liabilities and shareholders’ equity	$ 979,105	$ 984,041

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2015
Statement Of Financial Position [Abstract]
Accounts receivable, Unbilled services with related parties	$ 2.3	$ 2.9
Pre-funded study costs with related parties	3.9	3.7
Advanced billings with related parties	$ 7.6	$ 10.2
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock shares authorized	5,000,000	0
Preferred stock shares issued	0	0
Preferred stock shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock shares authorized	250,000,000	60,000,000
Common stock shares issued	40,662,856	32,624,461
Common stock shares outstanding	40,662,856	32,624,461

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Revenue:
Service revenue, net (includes $24.1 million, $24.0 million, $11.8 million and $2.0 million with related parties for the Successor years ended December 31, 2016 and 2015, the Successor period ended December 31, 2014, and the Predecessor period ended March 31, 2014, respectively)		$ 219,791	$ 370,621	$ 320,101
Reimbursed out-of-pocket revenue (includes $5.4 million, $6.9 million, $2.0 million and $0.1 million with related parties for the Successor years ended December 31, 2016 and 2015, the Successor period ended December 31, 2014, and the Predecessor period ended March 31, 2014, respectively)		28,708	50,961	38,958
Total revenue		248,499	421,582	359,059
Operating expenses:
Direct costs, excluding depreciation and amortization		117,550	198,510	163,707
Reimbursed out-of-pocket expenses (includes $5.4 million, $6.9 million, $2.0 million and $0.1 million with related parties for the Successor years ended December 31, 2016 and 2015, the Successor period ended December 31, 2014, and the Predecessor period ended March 31, 2014, respectively)		28,708	50,961	38,958
Selling, general and administrative		29,465	61,507	56,998
Acquisition and integration		9,297	0	0
Impairment of goodwill		0	0	9,313
Depreciation		4,610	7,442	6,379
Amortization		56,422	50,672	63,142
Total operating expenses		246,052	369,092	338,497
Income from operations		2,447	52,490	20,562
Other (expense) income, net:
Loss on extinguishment of debt		0	(10,726)	0
Miscellaneous (expense) income, net		(301)	(423)	(1,133)
Interest expense, net		(23,185)	(19,384)	(27,259)
Total other expense, net		(23,486)	(30,533)	(28,392)
Income (loss) before income taxes		(21,039)	21,957	(7,830)
Income tax provision (benefit)		(6,703)	8,532	843
Net income (loss)		$ (14,336)	$ 13,425	$ (8,673)
Net income (loss) per share attributable to common shareholders:
Basic		$ (0.46)	$ 0.38	$ (0.28)
Diluted		$ (0.46)	$ 0.37	$ (0.28)
Weighted average common shares outstanding:
Basic		30,869	35,690	31,346
Diluted		30,869	36,329	31,346
Predecessor
Revenue:
Service revenue, net (includes $24.1 million, $24.0 million, $11.8 million and $2.0 million with related parties for the Successor years ended December 31, 2016 and 2015, the Successor period ended December 31, 2014, and the Predecessor period ended March 31, 2014, respectively)	$ 70,250
Reimbursed out-of-pocket revenue (includes $5.4 million, $6.9 million, $2.0 million and $0.1 million with related parties for the Successor years ended December 31, 2016 and 2015, the Successor period ended December 31, 2014, and the Predecessor period ended March 31, 2014, respectively)	7,679
Total revenue	77,929
Operating expenses:
Direct costs, excluding depreciation and amortization	38,759
Reimbursed out-of-pocket expenses (includes $5.4 million, $6.9 million, $2.0 million and $0.1 million with related parties for the Successor years ended December 31, 2016 and 2015, the Successor period ended December 31, 2014, and the Predecessor period ended March 31, 2014, respectively)	7,679
Selling, general and administrative	10,203
Acquisition and integration	12,420
Impairment of goodwill	0
Depreciation	1,832
Amortization	5,199
Total operating expenses	76,092
Income from operations	1,837
Other (expense) income, net:
Loss on extinguishment of debt	0
Miscellaneous (expense) income, net	1,213
Interest expense, net	(3,272)
Total other expense, net	(2,059)
Income (loss) before income taxes	(222)
Income tax provision (benefit)	1,014
Net income (loss)	$ (1,236)
Net income (loss) per share attributable to common shareholders:
Basic	$ (0.05)
Diluted	$ (0.05)
Weighted average common shares outstanding:
Basic	25,047
Diluted	25,047

CONSOLIDATED STATEMENTS OF OPE5

CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($) $ in Millions	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Service revenue with related parties		$ 11.8	$ 24.1	$ 24
Reimbursed out-of-pocket revenue with related parties		2	5.4	6.9
Reimbursed out-of-pocket expenses with related parties		$ 2	$ 5.4	$ 6.9
Predecessor
Service revenue with related parties	$ 2
Reimbursed out-of-pocket revenue with related parties	0.1
Reimbursed out-of-pocket expenses with related parties	$ 0.1

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Net income (loss)		$ (14,336)	$ 13,425	$ (8,673)
Other comprehensive loss
Foreign currency translation adjustments, net of taxes		(1,560)	(1,183)	(999)
Comprehensive income (loss)		$ (15,896)	$ 12,242	$ (9,672)
Predecessor
Net income (loss)	$ (1,236)
Other comprehensive loss
Foreign currency translation adjustments, net of taxes	(11)
Comprehensive income (loss)	$ (1,247)

CONSOLIDATED STATEMENTS OF SHAR

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	(Accumulated Deficit) Retained Earnings	Accumulated Other Comprehensive Income (Loss)
Balance (Predecessor) at Dec. 31, 2013	$ 249,231	$ 25	$ 254,446	$ (3,877)	$ (1,363)
Net income (loss) | Predecessor	(1,236)			(1,236)
Issuance of common stock | Predecessor	414,000	307	413,693
Foreign currency translation | Predecessor	(11)				(11)
Stock-based compensation expense | Predecessor	7,340		7,340
Stock options exercised | Predecessor	15,221	2	15,219
Tax benefit excess (deficiency) from stock-based compensation | Predecessor	5,270		5,270
Balance (Predecessor) at Mar. 31, 2014	275,815	27	282,275	(5,113)	(1,374)
Balance at Mar. 31, 2014	414,000	307	413,693
Close Predecessor shareholders' equity | Predecessor	(275,815)	(27)	(282,275)	5,113	1,374
Net income (loss)	(14,336)			(14,336)
Foreign currency translation	(1,560)				(1,560)
Stock-based compensation expense	3,057	6	3,051
Tax benefit excess (deficiency) from stock-based compensation	809		809
Balance at Dec. 31, 2014	401,970	313	417,553	(14,336)	(1,560)
Net income (loss)	(8,673)			(8,673)
Issuance of common stock	608	1	607
Foreign currency translation	(999)				(999)
Stock-based compensation expense	21,127	12	21,115
Stock options exercised	250		250
Tax benefit excess (deficiency) from stock-based compensation	(809)		(809)
Balance at Dec. 31, 2015	413,474	326	438,716	(23,009)	(2,559)
Net income (loss)	13,425			13,425
Issuance of common stock	173,578	80	173,498
Foreign currency translation	(1,183)				(1,183)
Stock-based compensation expense	2,777	1	2,776
Stock options exercised	678		678
Common stock issuance costs	(2,719)		(2,719)
Reclassification of liability classified stock options upon IPO	10,463		10,463
Tax benefit excess (deficiency) from stock-based compensation	25		25
Tax effect of initial public offering related costs	192		192
Balance at Dec. 31, 2016	$ 610,710	$ 407	$ 623,629	$ (9,584)	$ (3,742)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended					9 Months Ended	12 Months Ended		24 Months Ended
	Dec. 31, 2016	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$ (21)	$ 3,448	$ (8,576)	$ (59)		$ (14,336)	$ 13,425	$ (8,673)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation						4,610	7,442	6,379
Amortization						56,422	50,672	63,142
Stock-based compensation expense						5,423	9,815	22,324
Amortization of debt issuance costs and discount						2,064	2,576	2,687
Loss on extinguishment of debt						0	10,726	0
Deferred income tax benefit						(9,557)	(9,006)	(12,690)
Impairment of goodwill			9,300			0	0	9,313	$ 9,313
Other						(225)	(1,019)	(242)
Changes in assets and liabilities:
Accounts receivable and unbilled, net						(1,103)	(13,727)	337
Prepaid expenses and other current assets						(846)	(3,661)	(181)
Accounts payable						558	691	2,481
Accrued expenses						10,987	4,516	320
Pre-funded study costs						299	5,400	9,981
Advanced billings						5,995	14,723	(7,002)
Other assets and liabilities, net						1,704	(841)	(2,306)
Net cash provided by operating activities						61,995	91,732	85,870
CASH FLOWS FROM INVESTING ACTIVITIES:
Property and equipment expenditures						(4,225)	(13,537)	(6,465)
Acquisition of Predecessor, net of cash and restricted cash received						(901,805)	0	0
Other						38	115	33
Net cash used in investing activities						(905,992)	(13,422)	(6,432)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payment for common stock issuance costs						0	(2,719)	0
Proceeds from stock option exercises						0	537	250
Excess tax benefit from stock-based compensation						809	25	0
Proceeds from issuance of debt, net of original issue discount						527,350	164,506	0
Payment of debt						(25,217)	(390,060)	(116,055)
Proceeds from revolving loan						1,575	0	0
Payment on revolving loan						(1,575)	0	0
Debt issuance costs						(15,487)	(1,802)	0
Payment of deemed landlord liability						(1,284)	(1,525)	(1,292)
Payment on debt extinguishment						0	(548)	0
Proceeds from common stock issued, net						414,000	173,578	608
Net cash (used in) provided by financing activities						900,171	(58,008)	(116,489)
EFFECT OF EXCHANGE RATES ON CASH, CASH EQUIVALENTS, AND RESTRICTED CASH						(785)	(632)	(601)
INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH						55,389	19,670	(37,652)
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — Beginning of period		$ 17,737		$ 55,389		0	17,737	55,389	55,389
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — End of period	$ 37,407		$ 17,737		$ 0	55,389	37,407	17,737	$ 37,407
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION—
Cash paid during the period for income taxes						4,513	17,654	10,552
Cash paid during the period for interest						21,060	16,895	24,435
Acquisition of property and equipment—non-cash						153	$ 1,687	$ 176
Predecessor
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)					(1,236)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation					1,832
Amortization					5,199
Stock-based compensation expense					7,340
Amortization of debt issuance costs and discount					371
Loss on extinguishment of debt					0
Deferred income tax benefit					300
Impairment of goodwill					0
Other					(721)
Changes in assets and liabilities:
Accounts receivable and unbilled, net					(10,543)
Prepaid expenses and other current assets					(4,617)
Accounts payable					13,708
Accrued expenses					(4,957)
Pre-funded study costs					1,561
Advanced billings					6,330
Other assets and liabilities, net					(1,360)
Net cash provided by operating activities					13,207
CASH FLOWS FROM INVESTING ACTIVITIES:
Property and equipment expenditures					(1,090)
Acquisition of Predecessor, net of cash and restricted cash received					0
Other					263
Net cash used in investing activities					(827)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payment for common stock issuance costs					0
Proceeds from stock option exercises					0
Excess tax benefit from stock-based compensation					5,270
Proceeds from issuance of debt, net of original issue discount					0
Payment of debt					(23,073)
Proceeds from revolving loan					0
Payment on revolving loan					0
Debt issuance costs					0
Payment of deemed landlord liability					(165)
Payment on debt extinguishment					0
Proceeds from common stock issued, net					0
Net cash (used in) provided by financing activities					(17,968)
EFFECT OF EXCHANGE RATES ON CASH, CASH EQUIVALENTS, AND RESTRICTED CASH					(25)
INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH					(5,613)
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — Beginning of period					25,106	$ 19,493
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — End of period					19,493
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION—
Cash paid during the period for income taxes					125
Cash paid during the period for interest					2,961
Acquisition of property and equipment—non-cash					$ 312

Basis of Presentation

Basis of Presentation	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Basis of Presentation	1. BASIS OF PRESENTATION Description of Business Medpace Holdings, Inc. together with its subsidiaries, (“Medpace” or the “Company”), a Delaware corporation, is a global provider of clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia. Stock Split On July 25, 2016, the Board of Directors (the “Board”) of the Company approved, and made legally effective, a 1-for-1.35 reverse stock split of the Company’s common stock. All share, stock option and per share information presented in the consolidated financial statements have been adjusted to reflect the reverse stock split on a retroactive basis for all periods presented. There was no change in the par value of the Company’s common stock. Initial Public Offering On August 11, 2016, the Company's common stock began trading on the NASDAQ Global Select Market (“NASDAQ”) under the symbol "MEDP". On August 16, 2016, the Company completed its initial public offering (“IPO”) of its common stock at a price to the public of $23.00 per share. The Company issued and sold 8,050,000 shares of common stock in the IPO, including 1,050,000 common shares issued pursuant to the full exercise of the underwriters' option to purchase additional shares. The IPO raised net proceeds of approximately $173.6 million after deducting underwriting discounts and commissions. As contemplated in the Company’s prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Securities Act”), with the Securities and Exchange Commission on August 11, 2016, the net proceeds from the IPO, along with cash on hand, were used to repay $175.0 million of outstanding borrowings under the 2014 Senior Secured Term Loan Facility (as defined below) and $2.7 million of offering expenses.

Change in Control

Change in Control	12 Months Ended
	Dec. 31, 2016
Change In Control [Abstract]
Change in Control	2. CHANGE IN CONTROL In February 2014, investment funds managed by Cinven Capital Management (V) General Partner Limited (“Cinven”), a private equity firm, incorporated Scioto Holdings, Inc. in the first of multiple steps that would result in a change of control for the Company. Pursuant to the terms and conditions of the Agreement and Plan of Merger (the “Merger Agreement”) dated February 22, 2014, Scioto Holdings, Inc. (the “Successor”), through its wholly owned subsidiary Scioto Acquisition, Inc. (the “Purchaser”) and the Purchaser’s wholly owned subsidiary Scioto Merger Sub, Inc. (the “Merger Sub”), purchased 100% of the outstanding shares of Medpace Holdings, Inc. (“Predecessor”) for an aggregate purchase price of $921.3 million on April 1, 2014 (the “Transaction”). Per the terms of a Contribution and Subscription Agreement, Medpace Investors, LLC (“Medpace Investors” or “MPI”), owned by certain employees of the Company, agreed to contribute shares held in the Predecessor in exchange for a percentage stake in the Successor. The Transaction was financed through the sale of the Successor’s equity and debt financing under a new credit facility entered into by Merger Sub as the initial borrower. Upon Transaction consummation, Merger Sub ceased to exist and Medpace Holdings, Inc. became the borrower under the credit facility. The proceeds from the transaction were used to purchase Predecessor’s equity interests, extinguish debt which had immediately come due as a result of the change in control, and pay Predecessor’s acquisition-related selling expenses. The Predecessor’s acquisition-related selling expenses of $12.4 million, including $10.1 million related to success based advisory fees, are reflected in the Acquisition and integration expense line in the consolidated statement of operations for the Predecessor January 1 through March 31, 2014 period. The Successor’s acquisition-related buying expenses of $9.3 million, including $3.3 million related to success based advisory fees, are reflected in the Acquisition and integration expense line in the consolidated statement of operations for the Successor April 1, 2014 through December 31, 2014 period. Prior to the Transaction, CCMP Capital (“CCMP”), a private equity firm, held 80% of the Predecessor’s equity interests and the noncontrolling interests were held by certain current and former members of management, along with former members of the Board of Directors of Medpace, Inc., a wholly owned subsidiary of Medpace Holdings, Inc. The sources and uses of the purchase price consideration were as follows (in thousands): Sources of cash consideration: Sale of Successor common stock $ 414,000 Long-term debt issuance 530,000 Revolving loan 1,575 Original issue discount (2,650 ) Loan origination fees (15,487 ) Debt proceeds, net 513,438 Total sources of consideration paid $ 927,438 Uses of cash consideration: Purchase of Predecessor common stock 780,829 Proceeds from stock option exercise (15,221 ) Payment of Predecessor debt 143,728 Payment of Predecessor's selling expenses 11,962 Total uses of consideration paid $ 921,298 The excess cash generated from the transaction of $6.1 million is not considered purchase price consideration as the funds were used to pay a portion of the Successor’s acquisition related expenses. The Successor’s acquisition related expenses are reflected in the Acquisition and integration expense line in the consolidated statements of operations for the Successor period ended December 31, 2014. In May 2014, Scioto Holdings, Inc. was renamed Medpace Holdings, Inc. (“Successor”). Furthermore, the Predecessor Medpace Holdings, Inc. was merged with another wholly owned subsidiary and renamed Medpace IntermediateCo, Inc. For the avoidance of doubt and for purposes of these consolidated financial statements, Successor refers to the consolidated Medpace Holdings reporting entity after the Transaction and Predecessor refers to the consolidated Medpace Holdings reporting entity prior to the Transaction. Immediately following the Transaction, Cinven and Medpace Investors owned approximately 75% and 25%, respectively, of the Successor entity. The following table reconciles the fair value of the assets acquired and liabilities assumed to the total purchase price (in thousands): Assets Acquired: Cash and cash equivalents $ 17,845 Restricted cash 1,648 Accounts receivable 39,311 Unbilled services 13,065 Reimbursable pass-through expenses 12,184 Prepaid expenses and other current assets 12,205 Property and equipment 39,661 Goodwill 670,294 Intangible assets 306,307 Deferred income taxes 26,246 Other assets 3,237 Total assets acquired 1,142,003 Liabilities assumed: Accounts payable and accrued expenses 16,608 Pre-funded study costs 36,483 Advanced billings 52,475 Deemed landlord liability 34,251 Debt 1,551 Deferred income taxes 69,448 Other liabilities 9,889 Total liabilities assumed 220,705 Net assets acquired $ 921,298 The Company accounts for acquisitions using the acquisition method of accounting. The Successor consolidated financial statements reflect the final allocation of the aggregate purchase price of $921.3 million to the assets acquired and liabilities assumed based on fair values at the date of the Transaction. The fair values assigned to identifiable intangible assets acquired were determined primarily by using an income approach which was based on assumptions and estimates made by management. Significant assumptions utilized in the income approach were based on company-specific information and projections, which are not observable in the market and are thus considered Level 3 measurements by authoritative guidance. The excess of the purchase price over the fair value of the assets acquired and liabilities assumed has been recorded as goodwill and represents the estimated future economic benefits arising from other assets acquired that could not be individually identified and separately recognized such as assembled workforce and growth opportunities. The Merger Agreement includes certain indemnifications between the sellers (led by CCMP) and the buyers (led by Cinven) with regard to Predecessor contingencies that arise after the Transaction and through April 1, 2015, as well as tax payments or refunds that are finalized after April 1, 2014 but which relate to periods prior to the Transaction. In December 2016, final settlement of these indemnifications was agreed upon resulting in a gain of $0.5 million within Miscellaneous (expense) income in the Successor year ended December 31, 2016. The Successor had $0.0 million and $0.3 million in Prepaid expenses and other current assets and $0.0 million and $0.5 million in Other assets on the consolidated balance sheets at December 31, 2016 and 2015, respectively, associated with refunds due from various taxing authorities that were generated in a Predecessor period. The Successor had less than $0.1 million and $1.4 million in Other current liabilities and $0.0 million and $0.5 million in Other long-term liabilities on the consolidated balance sheets at December 31, 2016 and 2015, associated with the agreed settlement of these items, net of consulting fees and related tax, and other tax refunds received by the Successor prior to December 31, 2016 and 2015, respectively. The remaining liabilities are expected to be fully paid to the Predecessor in the first quarter of 2017. Immediately prior to the Transaction, the Predecessor’s Board of Directors approved a plan to accelerate the vesting on unvested stock options and restricted share awards.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation and Presentation The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and include the accounts and operations of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The Company’s consolidated balance sheets as of December 31, 2016 and 2015 and its related statements of operations, comprehensive (loss) income, shareholders’ equity, and cash flows presented subsequent to the Transaction for the years ended December 31, 2016 and 2015 and the period from April 1 through December 31, 2014 are referenced herein as the successor financial statements (the “Successor” or “Successor Financial Statements”). The period April 1 through December 31, 2014 is referenced herein as the “Successor Period ended December 31, 2014.” The Company’s consolidated statements of operations, comprehensive (loss) income, shareholders’ equity and cash flows for the period from January 1 through March 31, 2014 is referenced herein as the predecessor financial statements (the “Predecessor” or “Predecessor Financial Statements”). The January 1 through March 31, 2014 period is referenced herein as the “Predecessor Period ended March 31, 2014.” Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates. Significant items that are subject to management estimates and assumptions include service revenue, net, allowances for doubtful accounts, acquisition purchase price allocations, long-lived asset impairment and useful lives, exit liabilities, stock-based compensation, uncertain income tax positions and contingencies. Reportable Segments The Company emphasizes its full service outsourcing model, providing services focused on the development, management and execution of clinical trials. As part of this full service approach, the Company utilizes centralized systems, customer interface technology, support functions and processes that cross service offerings and align resources to deliver efficient clinical trial services. Given the full service approach, the chief executive officer, who is the chief operating decision maker (“CODM”) assesses the allocation of resources based on key metrics including revenue, backlog, and net awards by service offering and consolidated profitability and consolidated cash flows. Based on the Company’s full service model, internal management and reporting structure, and key metrics used by the CODM to make resource allocation decisions, management has determined that the Company’s operations consist of a single operating segment. Therefore, results of operations are presented as a single reportable segment. Foreign Currencies Assets and liabilities recorded in foreign currencies on foreign subsidiary financial statements are translated at the exchange rate on the balance sheet date, while equity accounts are translated at historical exchange rates. Revenue and expenses are recorded at average rates of exchange during the year. Translation adjustments are recorded to Accumulated other comprehensive loss in the consolidated statements of shareholders’ equity and consolidated statements of comprehensive (loss) income. Separately, net realized gains and losses on foreign currency transactions are included in Miscellaneous (expense) income, net, on the consolidated statements of operations. Foreign currency transactions resulted in net losses of $0.7 million, $1.3 million, $1.2 million and $0.1 million during the Successor years ended December 31, 2016 and 2015, the Successor Period ended December 31, 2014 and the Predecessor Period ended March 31, 2014, respectively. Revenue Recognition The Company generally enters into contracts with customers to provide services ranging in duration from a few months to several years. The contract terms generally provide for payments based on a fixed fee or unit-of-service arrangement. Revenue on these arrangements is recognized when there is persuasive evidence of an arrangement, the service offering has been delivered to the customer, the arrangement consideration is determinable and the collection of the fees is reasonably assured. The Company recognizes revenue for services provided on fixed fee arrangements based on the proportional performance methodology, which is determined by assessing the proportion of performance completed or delivered to date compared to total specific measures to be delivered or completed under the terms of the arrangement. The measures utilized to assess performance are specific to the service provided, and the Company generally compares the ratio of hours completed to the total estimated hours necessary to complete the contract. A detailed project budget by hours is developed based on many factors, including but not limited to the scope of the work, the complexity of the study, the participating geographic locations, and the Company’s historical experience. Management believes the reporting and estimation of hours is the best available measure of progress on many of the services provided and best reflects the pattern in which obligations to customers are fulfilled. To assist with the estimation of hours expected to complete a project, regular contract reviews for each project are performed in which performance to date is compared to the most current estimate to complete assumptions. The reviews include an assessment of effort incurred to date compared to expectations based on budget assumptions and other circumstances specific to the project. The total estimated hours necessary to complete a fixed-fee contract, based on these reviews, are updated and any revisions to the existing hours budget result in cumulative adjustments to the amount of revenue recognized in the period in which the revisions are identified. Fixed-fee contracts provide for pricing modifications upon scope of work changes. The Company recognizes revenue related to work performed in connection with scope changes when the underlying services are performed, a binding contractual commitment has been executed with the customer and collectability is reasonably assured. Costs are not deferred in anticipation of contracts being awarded or amendments being finalized, but are expensed as incurred. For unit-of-service arrangements, the Company recognizes revenue in the period in which the unit is delivered. Service unit elements largely consist of various project management, consulting and analytical testing services. Many contractual arrangements combine multiple service elements. For these contracts, arrangement consideration is allocated to identified units of account based on the relative selling price of each unit of account. The best evidence of selling price of a unit of account is vendor specific objective evidence (“VSOE”), which is the price charged when the deliverable is sold separately. When VSOE is not available to determine selling price, management uses relative third party evidence, if available. When neither VSOE nor third party evidence of selling price exists, management uses its best estimate of selling price considering all relevant information that is available. Most contracts are terminable by the customer, either immediately or according to advance notice terms specified within the contracts. These contracts require payment of fees to the Company for services rendered through the date of termination and may require payment for subsequent services necessary to conclude the study or close out the contract. Final settlement amounts are typically subject to negotiation with the customer. These amounts are included in Service revenue, net when realization is reasonably assured. The Company occasionally enters into volume rebate arrangements with customers that provide for rebates if certain specified spending thresholds are met. These rebate obligations are recorded as a reduction of revenue when it appears probable that the customer will earn the rebates and the related amount is estimable. Service revenue is presented net of rebates of less than $0.1 million, $0.1 million, $0.4 million and $0.1 million in the consolidated statements of operations during the Successor years ended December 31, 2016 and 2015, the Successor Period ended December 31, 2014 and the Predecessor Period ended March 31, 2014. The Company records revenue net of any tax assessments by governmental authorities that are imposed and concurrent with specific revenue generating transactions. Concentration of Credit Risk Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents and accounts receivable. The cash and cash equivalent balances are held and maintained with financial institutions with reputable credit ratings and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company generally does not require collateral or other securities to support customer receivables. In the Successor years ended December 31, 2016 and 2015, the Successor Period ended December 31, 2014 and the Predecessor Period ended March 31, 2014, credit losses have been immaterial and within management’s expectations. At December 31, 2016 and 2015, there were no customers accounting for more than 10% of the Company’s accounts receivable. Costs and Expenses Direct costs, excluding depreciation and amortization, include direct labor and related employee benefits, laboratory supplies, and other expenses contributing to service delivery. Direct costs, excluding depreciation and amortization, are expensed as incurred and are not deferred in anticipation of contracts being awarded or finalization of changes in scope. Selling, general and administrative includes administrative payroll and related employee benefits, sales and marketing expenses, administrative travel, and other expenses not directly related to service delivery. Rent, utilities, supplies, and software license expenses are allocated between Direct costs, excluding depreciation and amortization, and Selling, general and administrative based on the estimated contribution among service delivery and support function efforts on a percentage basis. Depreciation and amortization is reported separately in the accompanying consolidated statements of operations. Costs of sales and marketing activities not subject to recovery pursuant to customer contracts, such as feasibility assessments and negotiation of contracts, are expensed as incurred and recorded as a component of Selling, general and administrative in the accompanying consolidated statements of operations. Advertising expenses are recorded as a component of Selling, general and administrative expenses in the accompanying consolidated statements of operations. Total advertising expenses of $0.6 million, $0.4 million, $0.2 million and $0.1 million were incurred during the Successor years ended December 31, 2016 and 2015, the Successor Period ended December 31, 2014 and the Predecessor Period ended March 31, 2014, respectively. Reimbursed Out-of-Pocket Expenses The Company incurs on behalf of its clients various out-of-pocket expenditures including, but not limited to, travel, meetings, printing, and shipping and handling fees, which are reflected as a separate component of operating expenses and recorded in Reimbursed out-of-pocket expenses in the accompanying consolidated statements of operations. Reimbursements received are reflected in Reimbursed out-of-pocket revenue without mark-up or profit in the consolidated statements of operations. Fees paid to investigators and other disbursements in which the Company acts as an agent on behalf of the client are recorded net in the consolidated statements of operations with no impact on the Company’s revenue or expenses. Funds received in advance of study expenditures are recorded as Pre-funded study cost liabilities on the consolidated balance sheets. Any pre-funded amounts remaining at the conclusion of a study are returned to the client. Pre-funded study cost disbursements of $150.3 million, $114.4 million, $92.5 million and $30.9 million were made during the Successor years ended December 31, 2016 and 2015, the Successor Period ended December 31, 2014 and the Predecessor Period ended March 31, 2014, respectively. Income Taxes The Company’s consolidated U.S. federal income tax return is comprised of its U.S. subsidiaries and one of its foreign subsidiaries located in Korea. All foreign subsidiaries of the Company file tax returns in their local jurisdictions. The Company provides for income taxes on all transactions that have been recognized in the consolidated financial statements in accordance with accounting guidance governing income tax accounting. Accordingly, the impact of changes in income tax laws on deferred tax assets and deferred tax liabilities are recognized in net earnings in the period during which such changes are enacted. The Company records deferred tax assets and liabilities based on temporary differences between the financial statement bases and tax bases of assets and liabilities. Deferred tax assets are recorded for tax benefit carryforwards using tax rates anticipated to be in effect in the year in which the temporary differences are expected to reverse. If it does not appear more likely than not that the full value of a deferred tax asset will be realized, the Company records a valuation allowance against the deferred tax asset, with an offsetting charge to the Company’s income tax provision or benefit. The value of the Company’s deferred tax assets is estimated based on, among other things, the Company’s ability to generate a sufficient level of future taxable income. In estimating future taxable income, the Company has considered both positive and negative evidence, such as historical and forecasted results of operations, and has considered the implementation of prudent and feasible tax planning strategies. A provision has not been made for U.S. or additional foreign taxes on the undistributed portion of earnings of foreign subsidiaries as those earnings of $15.1 million as of December 31, 2016, have been permanently reinvested. The Company follows accounting guidance related to accounting for uncertainty in income taxes which requires significant judgment in determining what constitutes an individual tax position as well as assessing the possible outcome of each tax position. Changes in judgments as to recognition or measurement of tax positions can materially affect the estimate of the effective tax rate, and, consequently, the Company’s consolidated financial results. The Company considers many factors when evaluating and estimating tax positions and tax benefits, which may require periodic adjustments and which may not accurately anticipate actual outcomes. In addition, the calculation of tax liabilities involves dealing with uncertainties in the application of complex tax regulations in a multitude of jurisdictions. The Company determines its liability for uncertain tax positions globally. If the payment of these amounts ultimately proves to be unnecessary, the reversal of liabilities would result in tax benefits being recognized in the period when it is determined the liabilities are no longer necessary. If the calculation of the liability related to uncertain tax positions proves to be more or less than the ultimate assessment, a tax expense or tax benefit would result. Interest and penalties associated with uncertain tax positions are recognized as components of the Company’s Income tax provision (benefit). Research and Development Credits Research and development credits are available to the Company under tax laws in certain jurisdictions, based on qualifying research and development spend as defined under those tax laws. Certain tax jurisdictions provide refundable credits that are not wholly dependent on the Company’s income tax status or income tax position. In these circumstances the benefit of the credits is recorded as a reduction of operating expense. When they are wholly dependent upon the Company’s income tax position, research and development credits are recognized as a reduction of income tax expense. Stock-Based Compensation The Company has stock-based employee compensation plans for which it incurs compensation expense. Successor Equity Awards In connection with the Company's IPO, the Board approved the formation of the 2016 Incentive Award Plan (the “2016 Plan”), which replaced our 2014 Equity Incentive Plan (the “2014 Plan”). The 2016 Plan provides for long-term equity incentive compensation for key employees, officers and non-employee directors. A variety of discretionary awards (collectively, the “Awards”) for employees and non-employee directors are authorized under the 2016 Plan, including vested common shares, stock options, stock appreciation rights (“SARs”), restricted stock awards (“RSAs”), restricted stock units (“RSUs”), or other cash based or stock dividend equivalent awards. The vesting of such awards may be conditioned upon either a specified period of time or the attainment of specific performance goals as determined by the administrator of the 2016 Plan. The option price and term are also subject to determination by the administrator with respect to each grant. Option prices are generally expected to be set at the market price of our common stock at the date of grant and option terms are not expected to exceed ten years. All outstanding Awards under the 2016 Plan are equity classified awards. The Successor, coinciding with the Transaction, created the 2014 Plan, providing for the future issuance of vested shares, stock options, RSAs and RSUs in Medpace Holdings, Inc.’s common stock (the “2014 Plan Awards”). The 2014 Plan Awards were subject to either equity or liability-classification pursuant to the terms of the participant’s award agreement and the Successor Plan based on accounting guidance which governs such transactions. Stock-based compensation expense for both the 2016 Plan and 2014 Plan is calculated using the fair value method on the grant date. The Successor expenses stock-based compensation using a graded vesting schedule. For liability-classified awards under the 2014 Plan, the Company recorded fair value adjustments up to and including the settlement date. Changes in the fair value of the stock compensation liability that occurred during the requisite service period were recognized as compensation cost over the vesting period. Changes in the fair value of the stock compensation liability that occurred after the end of the requisite service period but before settlement, were compensation cost of the period in which the change occurred. As a result of the Company’s IPO, a condition of all outstanding stock options issued before August 10, 2016 under the 2014 Plan that previously required the exchange of the shares issued for incentive units in the equity of a non-consolidated related party was dissolved. All future exercises of options issued pursuant to the 2014 Plan will settle in unregistered shares of the Company. As a result of the modification in the settlement condition, the options are equity-classified instruments and changes in the fair value of the stock compensation liability that occur during the requisite service period are no longer recognized. Stock-based compensation expense is allocated between Direct costs, excluding depreciation and amortization, and Selling, general and administrative in the consolidated statements of operations based on the underlying classification and scope of work for the employees receiving the Successor Awards. The stock-based compensation expense represents awards ultimately expected to vest and, as such, has been reduced for estimated forfeitures. Predecessor Equity Awards The Predecessor awards, consisting of stock options and restricted share awards, are equity-classified instruments based on the terms of the Predecessor’s equity incentive plans and on accounting guidance which governs such transactions. The Predecessor determined the fair value of stock options and restricted shares on the grant date and recognized the associated compensation expense, net of assumed forfeitures, according to a graded vesting schedule as the requisite services were rendered. Restricted shares and stock options vested ratably over three and four years, respectively, from the date of grant. Net Income (Loss) Per Share Basic and diluted earnings or loss per share (“EPS”) are computed using the two-class method, which is an earnings allocation that determines EPS for each class of common stock and participating securities according to dividends declared and participation rights in undistributed earnings. The Successor’s RSAs are considered participating securities because they are legally issued at the date of grant and holders are entitled to receive non-forfeitable dividends during the vesting term. The computation of diluted EPS includes additional common shares, such as unvested RSUs and stock options with exercise prices less than the average market price of the Company’s common stock during the period (“in-the-money options”), which would be considered outstanding under the treasury stock method. The treasury stock method assumes that additional shares would have to be issued in cases where the exercise price of stock options is less than the value of the common stock being acquired because the cash proceeds received from the stock option holder would not be sufficient to acquire that same number of shares. The Company does not compute diluted EPS in cases where the inclusion of such additional shares would be anti-dilutive in effect. The following table sets forth the computation of basic and diluted earnings per share for the Successor years ended December 31, 2016 and 2015, the Successor Period ended December 31, 2014 and the Predecessor Period ended March 31, 2014 (in thousands, except for earnings per share): SUCCESSOR PREDECESSOR Year Ended Year Ended Period Ended Period Ended December 31, December 31, December 31, March 31, 2016 2015 2014 2014 Weighted-average shares: Common shares outstanding 35,690 31,346 30,869 25,047 RSAs 88 - - - Total weighted-average shares 35,778 31,346 30,869 25,047 Earnings per common share—Basic Net income (loss) $ 13,425 $ (8,673 ) $ (14,336 ) $ (1,236 ) Less: Undistributed earnings allocated to RSAs 33 - - - Net income (loss) available to common shareholders—Basic $ 13,392 $ (8,673 ) $ (14,336 ) $ (1,236 ) Net income (loss) per common share—Basic $ 0.38 $ (0.28 ) $ (0.46 ) $ (0.05 ) Basic weighted-average common shares outstanding 35,690 31,346 30,869 25,047 Effect of diluted shares 639 - - - Diluted weighted-average shares outstanding 36,329 31,346 30,869 25,047 Net income (loss) per common share—Diluted $ 0.37 $ (0.28 ) $ (0.46 ) $ (0.05 ) During the Successor year ended December 31, 2016, there was fewer than one thousand shares excluded from the computation of EPS because they were antidilutive under the treasury method calculation of diluted weighted average shares outstanding. For the Successor year ended December 31, 2015, the Successor Period ended December 31, 2014 and the Predecessor Period ended March 31, 2014, the computation of diluted EPS excludes the effect of (in thousands) 660, 302 and 237 combined RSAs and RSUs, and 1,794, 1,091 and 0 stock options, respectively, due to the Company’s net loss position as well as the respective period’s average fair value of the Company’s common stock exceeded the exercise prices. Fair Value Measurements The Company follows accounting guidance related to fair value measurements that defines fair value, establishes a framework for measuring fair value, and establishes a hierarchy for inputs used in measuring fair value. This hierarchy maximizes the use of “observable” inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. The hierarchy specifies three levels based on the inputs, as follows: Level 1: Valuations based on quoted prices in active markets for identical assets or liabilities. Level 2: Valuations based on directly observable inputs or unobservable inputs corroborated by market data. Level 3: Valuations based on unobservable inputs supported by little or no market activity representing management’s determination of assumptions of how market participants would price the assets or liabilities. The fair value of financial instruments such as cash and cash equivalents, accounts receivable and unbilled, net, accounts payable, accrued expenses, and advanced billings approximate their carrying amounts due to their short term maturities. The Company does not have any recurring fair value measurements as of December 31, 2016. There were no transfers between Level 1, Level 2, or Level 3 during the Successor years ended December 31, 2016 and 2015, the Successor Period ended December 31, 2014 or the Predecessor Period ended March 31, 2014. Cash and Cash Equivalents, including Restricted Cash Cash and cash equivalents, including restricted cash, are invested in demand deposits, all of which have an original maturity of three months or less. Restricted cash consists of customer funds received in advance and subject to specific restrictions, as well as amounts placed in escrow for contingent payments resulting from acquisitions or other contractual arrangements. In addition, Prepaid expenses and other current assets and Other assets in the consolidated balance sheets include $0.7 million of cash held as collateral in support of a property mortgage in Leuven, Belgium at December 31, 2015. The property mortgage was fully repaid during 2015 and the Company received a full refund during the first quarter of 2016. Accounts Receivable and Unbilled, Net Accounts receivable represent amounts due from the Company’s customers who are concentrated primarily in the pharmaceutical, biotechnology, and medical device industries. Unbilled services represent service revenue recognized to date that is currently not billable to the customer pursuant to contractual terms. In general, amounts become billable upon the achievement of negotiated contractual events or in accordance with predetermined payment schedules. Amounts classified to Unbilled services are those billable to customers within one year from the respective balance sheet date. The Company grants credit terms to its customers prior to signing a service contract and monitors the creditworthiness of its customers on an ongoing basis. The Company maintains an allowance for doubtful accounts based on specific identification of accounts receivable that are at risk of not being collected. Uncollectible accounts receivable are written off only after all reasonable collection efforts have been exhausted. Moreover, in some cases the Company requires advance payment from its customers for a portion of the study contract price upon the signing of a service contract. These advance payments are deferred and recognized as revenue as services are performed. Inventory Inventory, which consists primarily of laboratory supplies, is valued at the lower of cost or market. Inventory is stated at purchased cost using the first-in, first out (FIFO) cost method. The inventory balance is included in Prepaid expenses and other current assets in the consolidated balance sheets. Property and Equipment Property and equipment is recorded at cost. Depreciation is provided on the straight-line method at rates adequate to allocate the cost of the applicable assets over their estimated useful lives, which is three to five years for computer hardware, software, phone, and medical imaging equipment, five to seven years for furniture and fixtures and other equipment, and thirty to forty years for buildings. The Company capitalizes costs of computer software developed for internal use and amortizes these costs on a straight-line basis over the estimated useful life, not to exceed three years. Leasehold improvements and deemed assets from landlord building construction are capitalized and amortized on a straight-line basis over the shorter of the estimated useful life of the improvement or the associated remaining lease term. Repairs and maintenance are expensed as incurred. Leases The Company leases facilities and equipment to be used in its operations, some of which require capitalization in accordance with US GAAP. Upon the execution of new leases, the Company determines the appropriate classification of the lease as operating or capital and reflects the impact of this classification in its consolidated financial statements. Goodwill and Intangible Assets Goodwill Goodwill represents the excess of purchase price over the fair value of net assets acquired in business combinations. The carrying value of goodwill is reviewed at least annually for impairment, or as indicators of potential impairment are identified, at the reporting unit level. The reporting units are Phase II-IV clinical research services, Laboratories, and Clinics as of December 31, 2016. The Company performs its annual impairment tests during the fourth quarter each year, utilizing the quantitative two step model defined by accounting guidance which governs such assessments. The first step involves the Company comparing each of its reporting unit carrying values, inclusive of assigned goodwill, to their respective estimated fair values. Fair value is estimated using a combination of the income approach, a discounted cash flow analysis, and the market approach, utilizing the guideline company method. If the calculation in the first step results in any of the reporting units’ carrying values exceeding their respective estimated fair values, a second step is performed. The second step requires the Company to allocate the fair value of the reporting unit derived in the first step to the fair value of the reporting unit’s net assets. Any fair value in excess of amounts allocated to such net assets represent the implied fair value of goodwill for that reporting unit. Any excess of reporting unit carrying value of goodwill over the implied fair value of goodwill results in an impairment. There was no indication of impairment related to goodwill based on the fourth quarter 2016 assessment. Intangible Assets The Company has an indefinite lived intangible asset related to its trade name. The carrying value of the trade name asset is reviewed at least annually for impairment, or as indicators of potential impairment are identified. The Company performs its annual impairment test in the fourth quarter each year in conjunction with its annual assessment of goodwill. The assessment consists of comparing the carrying value of the indefinite lived intangible asset to its estimated fair value, utilizing the relief from royalty method, an income approach valuation. There was no indication of impairment related to the trade name asset based on the fourth quarter 2016 assessment. Finite-lived intangible assets consist mainly of the value assigned to customer relationships, backlog and developed technologies. Finite-lived intangible assets are amortized straight-line or using an accelerated method over their estimated useful lives, which range in term from seventeen months to fifteen years. Impairment of Long-Lived Assets Long-lived assets, primarily property and equipment and finite-lived intangible assets, are reviewed for impairment and the reasonableness of the estimated useful lives whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be recoverable or that a change in useful life may be appropriate. Recoverability for long-lived assets is determined by comparing the forecasted undiscounted cash flows of the operation to which the assets relate to the carrying amount of the assets. If the undiscounted cash flows are less than the carrying amount of the assets, then the Company reduces the carrying value of the assets to estimated fair values, which are primarily based upon forecasted discounted cash flows. Fair value of long-lived assets is determined based on a combination of discounted cash flows and market multiples. Advanced Billings Advanced billings represents cash received from customers, or billed amounts per an agreed upon payment schedule, in advance of services being performed

Accounts Receivable And Unbille

Accounts Receivable And Unbilled, Net	12 Months Ended
	Dec. 31, 2016
Receivables [Abstract]
Accounts Receivable And Unbilled, Net	4. ACCOUNTS RECEIVABLE AND UNBILLED, NET Accounts receivable and unbilled, net includes service revenue and reimbursed out-of-pocket revenue. Accounts receivable and unbilled, net consisted of the following at December 31 (in thousands): SUCCESSOR 2016 2015 Accounts receivable $ 48,270 $ 40,721 Unbilled 34,719 26,091 Less allowance for doubtful accounts (3,222) (1,724) Total accounts receivable and unbilled, net $ 79,767 $ 65,088 A rollforward of allowance for doubtful account activity is as follows: SUCCESSOR PREDECESSOR Year December 31, Year Ended December 31, Period Ended December 31, Period Ended March 31, 2016 2015 2014 2014 Allowance for doubtful accounts - beginning balance $ (1,724 ) $ (5,855 ) $ (5,595 ) $ (5,573 ) Current year provision (2,166) (642 ) (624 ) (49 ) Write-offs and recoveries 668 4,773 364 27 Allowance for doubtful accounts - ending balance $ (3,222 ) $ (1,724 ) $ (5,855 ) $ (5,595 )

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2016
Property Plant And Equipment [Abstract]
Property and Equipment, Net	5. PROPERTY AND EQUIPMENT, NET Property and equipment, net consisted of the following at December 31 (in thousands): SUCCESSOR 2016 2015 Land $ 543 $ 940 Equipment 10,094 8,218 Furniture, fixtures, and leasehold improvements 15,415 8,563 Computer hardware, software, and phone equipment 7,535 4,569 Buildings 2,253 2,839 Deemed assets from landlord building construction 22,752 22,752 Construction-in-progress 2,840 304 Property and equipment at cost 61,432 48,185 Less: Accumulated depreciation (17,627 ) (10,673 ) Property and equipment, net $ 43,805 $ 37,512 Depreciation expense, which includes amortization from capital leases, was $7.4 million and $6.4 million for the years December 31, 2016 and 2015, respectively. In 2011, Medpace, Inc. entered into two multi-year lease agreements governing the future occupancy of additional office space in Cincinnati, Ohio. The Company assumed occupancy of both spaces during 2012 and began making lease payments at that time. The leases expire in 2027 and the Company has one 10-year option to extend the term of the leases. In accordance with the accounting guidance related to leases, the Company was deemed in substance to be the owner of the property during the construction phase. The accounting guidance requires that a lessee be considered the owner of a real estate project during the construction period if a related party of the lessee is an owner of the real estate. Given that a related party of Medpace made an equity investment in the lessor, Medpace was considered the owner of the property for accounting purposes during the buildings’ construction. Accordingly, the Company reflected the building and related liabilities as Deemed assets from landlord building construction (“Deemed Assets”) and Deemed landlord liabilities, respectively in the consolidated balance sheets. The Deemed Assets are being fully depreciated, on a straight line basis, over the 15-year term of the lease.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	6. GOODWILL AND INTANGIBLE ASSETS Goodwill The changes in the carrying amount of goodwill are as follows (in thousands): Balance as of December 31, 2014 - Successor $ 670,294 Impairment of Goodwill (9,313) Balance as of December 31, 2016 and 2015 - Successor $ 660,981 The annual impairment test performed in the fourth quarter of 2015 resulted in an impairment charge of $9.3 million related to the Company’s Clinics reporting unit. The 2015 goodwill impairment charge represents the total accumulated goodwill impairment losses recognized to date on existing goodwill through December 31, 2016. Total assets carried on the balance sheet and not remeasured to fair value on a recurring basis, identified as Level 3 measurements, as of December 31, 2016 are $692.6 million, comprised of $661.0 million of goodwill and Intangible Assets, Net Intangible assets, net consisted of the following (in thousands): Gross Accumulated Amount Amortization Net Balances as of December 31, 2016 - Successor: Backlog $ 72,630 $ 72,630 $ - Customer relationships 145,051 66,267 78,784 Developed technologies 54,475 29,961 24,514 Trade name (indefinite-lived) 31,646 - 31,646 Other 2,505 1,378 1,127 $ 306,307 $ 170,236 $ 136,071 Balances as of December 31, 2015 - Successor: Backlog $ 72,630 $ 72,630 $ - Customer relationships 145,051 26,991 118,060 Developed technologies 54,475 19,066 35,409 Trade name (indefinite-lived) 31,646 - 31,646 Other 2,505 877 1,628 $ 306,307 $ 119,564 $ 186,743 As of December 31, 2016, estimated amortization expense of the Company’s intangible assets for each of the next five years and thereafter is as follows (in thousands): Amortization 2017 $ 37,790 2018 29,371 2019 14,639 2020 7,797 2021 5,114 Later years 9,714 Total $ 104,425

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2016
Payables And Accruals [Abstract]
Accrued Expenses	7. ACCRUED EXPENSES Accrued expenses consisted of the following at December 31 (in thousands): SUCCESSOR 2016 2015 Employee compensation and benefits $ 21,453 $ 17,195 Other 2,964 2,916 Total accrued expenses $ 24,417 $ 20,111

Debt

Debt	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Debt	8. DEBT Debt consisted of the following at December 31 (in thousands): SUCCESSOR 2016 2015 Term loan $ 165,000 $ 390,000 Capital lease - 59 165,000 390,059 Less unamortized discount (534 ) (1,984 ) Less unamortized term loan debt issuance costs (824 ) (10,134 ) Less current portion of long-term debt (12,375 ) (59 ) Long-term debt, net, less current portion $ 151,267 $ 377,882 Principal payments on debt are due as follows (in thousands): 2017 $ 12,375 2018 16,500 2019 16,500 2020 20,625 2021 99,000 Total $ 165,000 The estimated fair value of the Company’s term loan based on Level 2 inputs using the market approach, which is primarily based on rates at which the debt is traded among financial institutions, 2016 Credit Agreement On December 8, 2016 (the “Closing Date”), Medpace IntermediateCo, Inc., as borrower (the “Borrower”), and Medpace Acquisition, Inc., a wholly-owned subsidiary of Medpace Holdings, Inc. (the “Company”), as parent guarantor (the “Parent Guarantor”), entered into a credit agreement (the “Senior Secured Credit Agreement”) consisting of a $165.0 million term loan (the “Senior Secured Term Loan Facility”) issued at 99.7% and a $150.0 million revolving credit facility (the “Senior Secured Revolving Credit Facility” and, together with the Senior Secured Term Loan Facility, the “Senior Secured Credit Facilities”). The Senior Secured Term Loan Facility and Senior Secured Revolving Credit Facility expire in December 2021. The Senior Secured Credit Facilities provide for, at the Company’s option, interest at the Eurocurrency rate or Base rate for the Senior Secured Term Loan Facility and the Senior Secured Revolving Credit Facility borrowings. The Company, at its discretion, may choose interest periods of one, two, three or six months, which determines the interest rate to be applied. Interest on Eurocurrency loans continues to be payable at the end of the selected Eurocurrency term and interest on Base rate loans are payable quarterly in conjunction with any required principal payments. Borrowings under the Senior Secured Credit Facilities bear interest at a rate equal to, at our option, either (i) the adjusted Eurocurrency rate based on LIBOR for U.S. dollar deposits for loans denominated in dollars, EURIBOR for Euro deposits for loans denominated in Euros and the offer rate for any other currencies for loans denominated in such other currencies for the relevant interest period plus an applicable margin from 1.25% to 2.25% based on the total net leverage ratio from less than 1.50:1.00 to greater than 3.75:1:00, or (ii) an alternative base rate (determined by reference to the highest of (a) the prime commercial lending rate of the administrative agent, as established from time to time, (b) the Federal Funds Rate plus 0.50% and (c) the one-month adjusted Eurocurrency rate for loans in U.S. dollars plus 1.00%) plus an applicable margin from 0.25% to 1.25% based on the total net leverage ratio from less than 1.50:1.00 to greater than 3.75:1:00. The applicable margin as of December 31, 2016 was 1.50% for eurocurrency loans and 0.5% for base rate loans. The Company may voluntarily prepay outstanding loans under the Senior Secured Credit Facilities without premium or penalty. As of December 31, 2016, the interest rate applicable on the term loan was the Eurocurrency interest rate of 2.15%. In addition, the Company is required to pay to the lenders a commitment fee on a quarterly basis at an annual rate of 0.375% of the unused borrowings under the Senior Secured Revolving Credit Facility for the first full fiscal quarter after the closing date, and thereafter 0.50% if the total net leverage ratio is greater than or equal to 3.00:1.00, or 0.375% if the total net leverage ratio is less than 3.00:1.00. At December 31, 2016 the Company had no outstanding borrowings under the Senior Secured Revolving Credit Facility, resulting in $150.0 million in undrawn capacity available under the Senior Secured Revolving Credit Facility. In addition, the Company had $0.1 million in undrawn letters of credit outstanding, which are secured by the Senior Secured Revolving Credit Facility at December 31, 2016. The original issue discount of $0.5 million related to the issuance of the Senior Secured Term Loan Facility was recorded as a reduction of the underlying debt issuances within Long-term debt, net, less current portion and is being amortized over the life of the debt using the effective-interest method. Per the terms of the Senior Secured Credit Term Loan Facility, principal is scheduled to be paid quarterly on the last business day of March, June, September and December of each year, beginning March 2017. Origination fees of $0.8 million related to the Senior Secured Term Loan Facility were recorded as a reduction of the underlying debt issuances in Long-term debt, net. These fees are being amortized over the life of the debt using the effective-interest method. The unamortized portion of the origination fees related to the Senior Secured Term Loan Facility was $0.8 million at December 31, 2016. Origination fees of $1.6 million related to the Senior Secured Revolving Credit Facility were originally capitalized as a component of Other assets. These fees are being amortized over the life of the debt using the effective-interest method. The unamortized portion of the origination fees related to the Senior Secured Revolving Credit Facility was $1.6 million at December 31, 2016. The Senior Secured Credit Facilities are guaranteed by the Parent Guarantor and its material, direct or indirect wholly owned domestic subsidiaries, with certain exceptions, including where providing such guarantees is not permitted by law, regulation or contract or would result in adverse tax consequences. The Senior Secured Credit Facilities are subject to customary covenants relating to financial ratios and restrictions on certain types of transactions, including restricting the Company's ability to incur additional indebtedness, acquire and dispose of assets, make investments, pay dividends, or engage in mergers and acquisitions. The Company is required to maintain a ratio of consolidated funded indebtedness minus unrestricted cash and cash equivalents (in the aggregate not to exceed $50 million and to include not more than $25 million of foreign unrestricted cash and cash equivalents) to consolidated EBITDA for the most recent four fiscal quarter period not to exceed 4.00:1.00; provided that the Company shall be permitted to increase the ratio to 4.50:1.00 in connection with any permitted acquisition or any other acquisition consented to by the Administrative Agent and the Required Lenders (as defined in the Senior Secured Credit Agreement) with total cash consideration in excess of $25 million. Such increase shall be applicable for the fiscal quarter in which such acquisition is consummated and the three consecutive test periods thereafter. The Company is also required to maintain a ratio of consolidated EBITDA to consolidated interest expense, in each case for the most recent four fiscal quarter period, of not less than 3.00:1.00. The Company was in compliance with all financial covenants as of December 31, 2016. Borrowings under the Senior Secured Credit Facilities were utilized to repay and extinguish our obligations under the 2014 Senior Secured Credit Facilities (as defined below). In accordance with accounting guidance governing such transactions, upon closing the 2014 Senior Secured Credit Facility (as defined below) and commencement of the Senior Secured Credit Facilities, the Company recognized a loss on extinguishment of debt totaling $10.7 million, of which $10.2 million related to unamortized loan origination fees from the credit agreement for our 2014 Senior Secured Credit Facilities (as defined below) and $0.5 million related to third party fees incurred during the fourth quarter of 2016. 2014 Credit Agreement On April 1, 2014, the Company entered into a credit agreement, consisting of a $530 million term loan (“2014 Senior Secured Term Loan Facility”) and a $60 million revolving credit facility ("2014 Senior Secured Revolving Credit Facility" and together with the 2014 Senior Secured Term Loan Facility, the “2014 Senior Secured Credit Facilities”). The 2014 Senior Secured Term Loan Facility, which was terminated in 2016 in connection with the new borrowings under the Senior Secured Credit Facility, was guaranteed by the Company and its subsidiaries and was subject to customary covenants relating to financial ratios and restrictions on certain types of transactions, including restricting the Company's ability to incur additional indebtedness, acquire and dispose of assets, make investments, pay dividends, or engage in mergers and acquisitions. The Successor was in compliance with all financial covenants as of December 31, 2015. Borrowings under the 2014 Senior Secured Credit Facilities incurred interest at a rate equal to, at our option, either (a) a Eurocurrency rate based on LIBOR for U.S. dollar deposits for loans denominated in dollars, EURIBOR for Euro deposits for loans denominated in Euros and the offer rate for any other currencies for loans denominated in such other currencies for the relevant interest period, plus 4.00% per annum if our total net leverage ratio was greater than 4.75:1.00, or 3.75% if our total net leverage ratio was less than or equal to 4.75:1.00; provided that the relevant Eurocurrency rate was deemed to be no less than 1.00% per annum; (b) a base rate, which was defined as the highest of (i) the Federal Funds Rate on such day plus ½ of 1.00%, (ii) the Prime Lending Rate on such day, (iii) the Adjusted Eurocurrency Rate for loans denominated in U.S. dollars published on such day for an Interest Period of one month plus 1.00% and (iv) 2.00%, plus 3.00% per annum if our total net leverage ratio was greater than 4.75:1.00, or 2.75% if our total leverage ratio was less than or equal to 4.75:1.00; provided that the base rate was deemed to be no less than 2.00% per annum. The Company was able to voluntarily prepay outstanding loans under the 2014 Senior Secured Credit Facilities without premium or penalty. In addition, the Company was required to pay to the lenders a commitment fee of 0.5% quarterly for unused commitments on the 2014 Senior Secured Revolving Credit Facility, subject to a step-down to 0.375% based upon achievement of a certain leverage ratio as defined within the 2014 Senior Secured Credit Facilities. As of December 31, 2015, the Company had met the requirements for the pricing level reduction. At December 31, 2015 the Company had no outstanding borrowings under the 2014 Senior Secured Revolving Credit Facility, resulting in $60.0 million in undrawn capacity available under the 2014 Senior Secured Revolving Credit Facility. In addition, the Company did not have any outstanding letters of credit, which were secured by the 2014 Senior Secured Revolving Credit Facility at December 31, 2015. Origination fees of $15.5 million were originally capitalized related to the issuance of the 2014 Senior Secured Credit Facilities and were being amortized over the life of the debt using the effective-interest method. The unamortized portion of these fees related to the 2014 Senior Secured Term Loan Facility was $10.1 million at December 31, 2015 and was recorded within Long-term debt, net. The unamortized portion of the origination fees attributable to the 2014 Senior Secured Revolving Credit Facility was $1.3 million at December 31, 2015 and was recorded as a component of Other assets in the consolidated balance sheets. Mortgage Notes Payable Medpace entered into a mortgage contract with a European bank in 2006 related to the purchase of a laboratory facility in Leuven, Belgium. The Euro-denominated mortgage bore a fixed annual interest rate of 4.90%, required monthly payments of principal and interest, and had a final maturity of December 2021. The mortgage was secured by building and land and also required that Medpace maintain a cash balance held as collateral with the bank. During 2015, the mortgage was fully repaid and the Company received a full refund of cash collateral during the first quarter of 2016.

Commitments, Contingencies, and

Commitments, Contingencies, and Guarantees	12 Months Ended
	Dec. 31, 2016
Commitments And Contingencies Disclosure [Abstract]
Commitments, Contingencies, and Guarantees	9. COMMITMENTS, CONTINGENCIES, AND GUARANTEES Lease Obligations The Company has payment obligations under non-cancellable operating leases, primarily for office space and furniture and fixtures to support its global operations. These leases often contain customary scheduled rent increases or escalation clauses and renewal options. Rent expense is recorded on a straight line basis. As of December 31, 2016, minimum future lease payments required under these leases are as follows (in thousands): Non-Related Total Related Party Parties Operating Operating Operating Lease Leases Leases 2017 $ 2,112 $ 4,844 $ 6,956 2018 2,112 3,715 5,827 2019 2,112 2,206 4,318 2020 2,112 1,559 3,671 2021 2,112 1,368 3,480 Thereafter 1,760 3,340 5,100 Total minimum lease payments $ 12,320 $ 17,032 $ 29,352 The related party operating lease is for one of the Company’s three buildings within its corporate headquarters. The non-related party operating leases are for the Company’s remaining leases throughout the world consisting primarily of office space, fixtures and vehicles. Rental expense under operating leases totaled $6.7 million, $5.8 million, $4.3 million and $1.4 million for the Successor years ended December 31, 2016 and 2015, the Successor Period ended December 31, 2014 and the Predecessor Period ended March 31, 2014, respectively, and is allocated between Direct costs, excluding depreciation and amortization, and Selling, general and administrative in the consolidated statements of operations. Deemed Landlord Liabilities As of December 31, 2016, minimum annual payments required in conjunction with the Deemed landlord liabilities are as follows (in thousands): Related Party Total Minimum Lease Less: Principal Payments Interest Amounts Due 2017 $ 3,792 $ 2,089 $ 1,703 2018 3,886 1,961 1,925 2019 3,937 1,819 2,118 2020 3,988 1,662 2,326 2021 4,040 1,490 2,550 Thereafter 23,934 4,326 19,608 Total $ 43,577 $ 13,347 $ 30,230 Purchase Commitments In May 2013, Medpace committed to the aggregate purchase of $2.0 million of software services from a vendor during the period from June 1, 2013 through May 31, 2016. In return for the commitment, Medpace received preferential fixed rate pricing and a 5% discount on all purchases made pursuant to this agreement during its three-year term. As of December 31, 2014, the Company had met the aggregate purchase commitment. There are no other material (individually or in aggregate) outstanding purchase commitments as of December 31, 2016. Legal Proceedings Medpace periodically becomes involved in various claims and lawsuits that are incidental to its business. Management believes, after consultation with counsel, that no matters currently pending would, in the event of an adverse outcome, have a material impact on the Company’s consolidated balance sheets, statements of operations, or cash flows. In March 2012, the Company filed a legal claim against one of its customers, citing as a basis for its claim the customer’s non-payment of more than $6.5 million in outstanding invoices. In response, the customer filed a counterclaim against the Company for compensatory damages, asserting that the Company had willfully and wrongly withheld clinical study data alleged to be owned by the customer. The Company objected to these allegations and believed it had meritorious defenses against these claims and also believed that it would ultimately prevail in this matter. During 2015, a Settlement and Mutual Release Agreement (the “Agreement”) was entered into whereas the Company agreed to settle all outstanding claims for payment of $2.0 million from the customer and both parties waived the right to file any future suits. The customer paid the $2.0 million settlement during 2015 and the Company recorded a bad debt recovery of $2.0 million in Selling, general and administrative in the consolidated statements of operations.

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Shareholders' Equity	10. SHAREHOLDERS’ EQUITY Authorized Shares On August 16, 2016 the Company amended its Certificate of Incorporation in connection with the closing of its IPO to increase the authorized number of shares of common stock to 250,000,000 and to authorize 5,000,000 shares of preferred stock that may be issued from time to time by the Company’s Board of Directors. Stock-Based Compensation 2016 Incentive Award Plan On August 11, 2016 in connection with the Company's IPO, the Board approved the formation of the 2016 Incentive Award Plan (the “2016 Plan”), which replaced our 2014 Equity Incentive Plan (the “2014 Plan”). The 2016 Plan provides for long-term equity incentive compensation for key employees, officers and non-employee directors. A variety of discretionary awards (collectively, the “Awards”) for employees and non-employee directors are authorized under the 2016 Plan, including vested shares, stock options, stock appreciation rights (“SARs”), restricted stock awards (“RSAs”), restricted stock units (“RSUs”), or other cash based or stock dividend equivalent awards, which are all equity-classified instruments under the 2016 Plan. The number of shares registered and available for grant under the 2016 Plan is 6,000,000. The vesting of such awards may be conditioned upon either a specified period of time or the attainment of specific performance goals as determined by the administrator of the 2016 Plan. The option price and term are also subject to determination by the administrator with respect to each grant. Option prices are generally expected to be set at the market price of the Company’s common stock at the date of grant and option terms are not expected to exceed ten years. The Company granted 648,180 stock options under the 2016 Plan during the Successor year ended December 31, 2016, consisting of 626,650 stock options vesting after four years and 21,530 stock options with various vesting schedules, but all of which vest within a calendar year of the respective grant . reserved 6,000,000 shares for issuance of RSAs, RSUs or stock options, of which approximately 5,400,000 awards were available for future grants as of December 31, 2016. The company satisfies stock option exercises and vested stock awards with newly issued shares. Shares available for future stock compensation grants totaled 5.4 million at December 31, 2016. 2014 Equity Incentive Plan The 2014 Plan for employees and directors provided the issuance of vested shares, stock options, RSAs and RSUs in Medpace Holdings, Inc.’s common stock. The awards were granted to key employees as additional compensation for services rendered and as a means of retention over the vesting period, typically three to four years. RSAs awarded under the 2014 Plan were subject to automatic forfeiture upon departure until vested and entitle the shareholder to all rights of common stock ownership except that they may not be sold, transferred, pledged or otherwise disposed of during the restriction period, except as noted in the following paragraph. The 2014 Plan allowed for the issuance of non-qualified stock options to employees, officers, and directors under this plan (collectively, “the Participants”). Under the 2014 Plan, options could be granted with an exercise price equal to or greater than the fair value of common stock at the grant date as determined by the Board of Directors. The stock options, if unexercised, expired seven years from the date of grant. As a condition to exercising stock options and acceptance of certain restricted shares, employees must have executed a Contribution and Subscription Agreement (the “Subscription Agreement”) that provided for the exchange of the shares issued for incentive units (the “Incentive Units”) in Medpace Investors upon the occurrence of certain events. The Incentive Units were tied directly to common stock ownership in Medpace Holdings, Inc. and entitled the Incentive Unit holder to participate in the risks and rewards of owning the Successor’s stock through ownership in Medpace Investors. The awards containing this condition were liability-classified instruments as they were inevitably settled in the equity of a non-consolidated related party. Restricted share awards excluding the requirement to execute a Contribution and Subscription Agreement and settlement in common shares of Medpace Holdings, Inc. were equity-classified instruments. At the grant date for RSAs that were liability-classified, restricted shares were legally issued and exchanged for MPI Incentive Units on behalf of the employee. If the RSAs were not yet vested and an employee left the Successor’s employment, the restricted shares of Medpace Holdings, Inc. reverted back to the Successor and were available for re-issuance under the Successor Plan. Upon the vesting of RSAs and RSUs and upon the exercise of stock options, the stock-based compensation liability was settled by exchanging the Successor’s stock for MPI Incentive Units. If an employee left the Successor’s employment after they vested in the Awards and the exchange for Incentive Units was made, Medpace Investors may exercise a call option to repurchase an employee’s Incentive Units at a price determined by the manager and majority unit holder of Medpace Investors, who is also the chief executive officer of Medpace. If Medpace Investors exercised the call right, it could do so up to the later of twelve months following the employee’s departure date or six months following the determination that the former employee was directly or indirectly engaged in competitive business activities. Restricted Awards Modification On December 17, 2015, the Board of Directors approved a resolution to accelerate the vesting period for all issued, outstanding and unvested RSAs and RSUs to vest on December 31, 2015, so long as the recipient of each restricted share or unit was in good standing, had not provided notice of resignation and continued to be employed by the Company as of December 31, 2015. In total, 688,599 unvested restricted awards held by 158 current employees were modified resulting in settlement of 688,599 shares. According to the authoritative guidance for stock-based compensation, under these circumstances a company should recognize additional stock-based compensation expense in the amount of the incremental fair value of the modified award. Because the restricted awards that were modified were liability-classified, the awards were at fair value at the time of the modification and no incremental cost was recognized. While there was no incremental cost related to fair value of the awards, $5.7 million of stock-based compensation expense was recorded in 2015 related to previously unrecognized stock-based compensation cost for awards expected to vest in 2016, 2017 and 2018. Option Awards Modification As a result of the Company’s IPO, a condition of all outstanding stock options issued before August 10, 2016 under the 2014 Plan that previously required the exchange of the shares issued for incentive units in the equity of a non-consolidated related party was dissolved. All future exercises of options issued pursuant to the 2014 Plan will now settle in shares of the Company. As a result of the modification in the settlement condition, the options will now be equity-classified instruments and changes in the fair value of the stock compensation liability that occur during the requisite service period are no longer recognized. According to the authoritative guidance for stock-based compensation, at modification the Company should recognize additional stock-based compensation expense in the amount of the incremental fair value of the modified award. As a result, the Company recognized $3.1 million of incremental stock-based compensation expense during the Successor year ended December 31, 2016. In addition, the $10.5 million stock-based compensation liability associated with the modified stock options was reclassified to additional paid-in capital as a result of the change to equity classification. There is no stock-based compensation liability at December 31, 2016. The stock-based compensation liability was $3.6 million at December 31, 2015, of which $1.7 million was included in Other current liabilities and $1.9 million was included in Other long-term liabilities in the consolidated balance sheet. Predecessor Awards In 2011, the Predecessor adopted a stock option plan (the “2011 Stock Option Plan”) and was authorized to issue non-qualified stock options to employees, officers, and directors under this plan (collectively “the Participants”). Under the 2011 Stock Option Plan, options may be granted with an exercise price equal to or greater than the fair value of common stock at the date of the grant as determined by the Board of Directors. In April 2012, the Board of Directors amended the 2011 Stock Option Plan to increase the maximum number of shares available for issuance as options to the Participants. Options granted under the plans may be exercised at certain times subsequent to certain events, as set forth in the grant. The stock options, if unexercised, expire ten years from the date of grant. In December 2012, the Predecessor’s Board of Directors established a restricted stock plan (the “2012 Restricted Stock Plan”) and approved the issuance of RSAs and RSUs (collectively, the “Restricted Shares”) up to an authorized amount of 350,000 total Restricted Shares. These shares are subject to certain restrictions, and are issued to key employees of the Company as a means of retention. RSAs awarded under the plan entitle the shareholder to all rights of common stock ownership except that they may not be sold, transferred, pledged, exchanged or otherwise disposed of during the restriction period. The terms of the 2011 Stock Option Plan and the 2012 Restricted Stock Plan (collectively, the “Predecessor Equity Plans”) permitted, but did not require, the acceleration of vesting for awards upon a change in control. On March 24, 2014, the Predecessor’s Board of Directors approved the acceleration of vesting for outstanding Restricted Share awards and stock options, the effect of which took place immediately prior to the April 1, 2014 Transaction. The Predecessor’s Board of Directors, at the same time, also approved the cancellation of any remaining unvested equity awards and terminated the Predecessor Equity Plans. The acceleration of vesting was determined to be a modification of the Predecessor Equity Plans and, pursuant to accounting guidance governing such transactions, the Predecessor recorded incremental stock-based compensation expense of $7.1 million. The modification of the Predecessor Equity Plans resulted in accelerated vesting for 172,492 Restricted Shares and 992,412 stock options. This change impacted 266 employees. In connection with the Transaction, all Participants exercised their options, resulting in exercise proceeds aggregating $15.2 million. Treasury Shares The Predecessor’s Shareholder Agreement (the “Predecessor Shareholder Agreement”) permitted the Company to directly purchase the shares of employee shareholders that separated from the Company. The Predecessor did not exercise its option to repurchase shares from separated employees during any Predecessor period covered by the Predecessor’s Financial Statements. Successor and Predecessor Equity Awards Valuation Assumptions The Company determines the fair value of stock options using the Black-Scholes-Merten option pricing model (the “BSM Model”). The BSM Model is primarily affected by the fair value of the Successor’s common stock (see restricted share valuation discussion below), the expected holding period for the option, expected stock price volatility over the term of the awards, the risk-free interest rate, and expected dividends. The following table sets forth the key weighted-average assumptions used in the BSM Model to calculate the fair value of options: SUCCESSOR PREDECESSOR Year Ended Year Ended Period Ended Period Ended December 31, December 31, December 31, March 31, 2016 2015 2014 2014 Expected holding period - years 3.6 4.2 5.4 N/A Expected volatility 30.2% 36.4% 41.8% N/A Risk-free interest rate 1.0% 1.2% 1.7% N/A Expected dividend yield 0.0% 0.0% 0.0% N/A The assumptions used in the table above reflect both grant date inputs to arrive at the grant date fair values for stock options subject to equity-classified stock compensation accounting and reflect a fair value calculation for stock options outstanding in the period subject to liability-classified stock compensation accounting. As of December 31, 2016 all outstanding stock based awards are subject to equity classification through either modifications of the award terms and conditions that occurred during the Successor year ended December 31, 2016, or based on terms and conditions applicable as of the grant date. The expected holding period represents the period of time the grants are expected to be outstanding. The Company uses the simplified method, as prescribed by accounting guidance governing such awards, to calculate the expected holding period for options granted to employees as we do not have sufficient historical evidence data to provide a reasonable basis upon which to estimate the expected holding period. For options issued prior to or during the Predecessor period ended March 31, 2014, the expected holding period was based on a probability-weighted assessment of an anticipated liquidity event. For options valued by the Successor for the years ended December 31, 2016 and 2015 and the Successor Period ended December 31, 2014, the expected holding period is based on an average between the midpoint of the vesting date and the expiration date of the options. The Company estimates expected volatility primarily by using the historical volatility of a publicly traded peer group that operates in the clinical research and development industry. The Company does not have adequate history to calculate its own historical or implied volatility and believes the Company’s expected volatility will approximate the historical experience of the peer group. The risk-free interest rate is based on the yield on U.S. Treasury obligations with remaining durations equal to the expected holding period of the options. The expected dividend yield is assumed to be zero based on recent and anticipated dividend activity. Subsequent to the IPO, the fair value of common stock is based upon the market price of the Company’s common stock on the date of grant as listed on the NASDAQ. Due to the absence of an active market for the Company’s common stock prior to the IPO, the Company determined the fair value of restricted shares by obtaining an independent valuation of the fair value of the Company’s equity, applying a discount for lack of marketability, and then calculating the implied share price. The fair value of the Company was estimated primarily using an income approach which is based on assumptions and estimates made by management and, secondarily, using other market-related factors in current industry trends as well as observed transaction values. In determining the estimated future cash flows used in the income approach, the Company developed and applied certain estimates and judgments, including current and projected future levels of income based on management’s plans, business trends, prospects and market and economic conditions, including market-participant considerations. Significant assumptions utilized in the income approach were based on company specific information and projections, which were not observable in the market and are thus considered Level 3 measurements by authoritative guidance (see discussion of fair value measurements). The discount for lack of marketability (the “Marketability Discount”) was applied to reflect what a market participant would consider in relation to the post-vesting restrictions imposed regarding the inability to sell, transfer, or pledge the shares during the restriction period. The Marketability Discount was estimated by using the BSM Model to calculate the cost of a theoretical put option to hedge the fluctuation in value of the investment between the valuation date and an anticipated liquidity date. The following table summarizes the grant date fair values of stock options and restricted shares issued during the period as well as the allocation of stock-based compensation expense to Direct costs, excluding depreciation and amortization, and Selling, general and administrative reported in the consolidated statements of operations: SUCCESSOR PREDECESSOR Year Ended Year Ended Period Ended Period Ended December 31, December 31, December 31, March 31, 2016 2015 2014 2014 Weighted average, grant date fair value Stock Options $ 6.91 $ 3.81 $ 4.33 N/A Restricted shares (RSAs and RSUs) $ 15.08 $ 12.53 $ 10.80 N/A Stock-based compensation expense allocated to: Direct costs, excluding depreciation and amortization $ 5,555 $ 9,243 $ 4,399 $ 5,422 Selling, general, and administrative 4,260 13,081 1,024 1,918 Total stock-based compensation expense $ 9,815 $ 22,324 $ 5,423 $ 7,340 Award Activity The following table sets forth the Successor’s and Predecessor’s stock option activity: SUCCESSOR PREDECESSOR Year Ended Year Ended Period Ended Period Ended December 31, December 31, December 31, March 31, 2016 2015 2014 2014 Weighted Weighted Average Weighted Average Weighted Average Options Exercise Price Shares Exercise Price Shares Exercise Price Shares Exercise Price Outstanding - beginning of Period 1,794,709 $ 15.42 1,091,048 $ 14.40 - $ - 1,438,800 $ 11.03 Granted 683,001 $ 22.80 889,849 $ 16.67 1,131,895 $ 14.40 - $ - Exercised (36,980 ) $ - (17,404 ) $ - - $ - (1,388,000 ) $ 10.97 Forfeited (90,564 ) $ 15.85 (168,784 ) $ 15.53 (40,847 ) $ 14.40 (32,200 ) $ 12.53 Expired - $ - - $ - - $ - (18,600 ) $ 11.27 Outstanding - end of period 2,350,166 $ 17.57 1,794,709 $ 15.42 1,091,048 $ 14.40 - $ - Exercisable - end of period 647,343 $ 15.22 242,777 $ 14.40 - $ - - $ - The following table sets forth the Successor and Predecessor’s Restricted Share activity: SUCCESSOR PREDECESSOR Year Ended Year Ended Period Ended Period Ended December 31, December 31, December 31, March 31, 2016 2015 2014 2014 Shares Shares Shares Shares Outstanding and unvested - beginning of period 90,697 407,171 - 176,643 Granted 11,111 1,253,924 707,721 - Vested (41,069 ) (1,530,547 ) (283,042 ) (172,492 ) Forfeited (1,481 ) (39,851 ) (17,508 ) (4,151 ) Outstanding and unvested - end of period 59,258 90,697 407,171 - Cumulative vested shares - end of period 1,854,658 1,813,589 283,042 263,490 During the Successor years ended December 31, 2016 and 2015 and the Successor Period ended December 31, 2014, 11,111, 583,021 and 283,042 Restricted Shares were granted and immediately vested upon issuance (the “Vested Shares”), respectively. There was no stock-based compensation liability related to Restricted Shares as of the Successor year ended December 31, 2016, The stock-based compensation liability related to 231,229 and 283,042 Vested Shares granted during the Successor year ended December 31, 2015 and the Successor Period ended December 31, 2014, respectively, were settled by exchanging the awards for Medpace Investors’ Incentive Units. The stock-based liability related to the residual 351,851 Vested Shares granted during the Successor year ended December 31, 2015 was settled by exchanging the awards for the Company’s common stock. The following table summarizes information about stock options expected to vest, stock options exercisable, and unvested restricted share awards expected to vest at December 31, 2016: Weighted Average Weighted Average Exercise Stock Restricted Remaining Issued in Successor Year Ended Price Options Shares Life (Years) December 31, 2016 Number of stock options expected to vest $ 17.51 2,304,229 - 5.4 Number of Restricted Shares expected to vest - 59,258 Total expected to vest - December 31, 2016 2,304,229 59,258 Total stock options exercisable - December 31, 2016 $ 15.22 647,343 4.8 Unrecognized compensation cost - December 31, 2016 (in thousands) $ 7,909 $ 538 Weighted average years over which unrecognized compensation cost will be recognized 2.4 2.0 The following table sets forth the aggregate intrinsic value of stock options exercised, the fair values of awards vested, and share based liabilities settled during the respective periods (in thousands): SUCCESSOR PREDECESSOR Year Ended Year Ended Period Ended Period Ended December 31, December 31, December 31, March 31, 2016 2015 2014 2014 Total intrinsic value of stock options exercised $ 403 $ (36 ) $ - $ 25,378 Total grant-date fair value of stock options vested $ 1,384 $ 1,168 $ - $ 3,446 Total grant-date fair value of restricted shares vested $ 614 $ 18,284 $ 3,057 $ 1,466 Total settlement date fair value of restricted shares vested $ 1,236 $ 21,134 $ 3,057 N/A Total share-based liabilities settled $ 76 $ 16,858 $ 3,057 N/A There was no stock-based compensation liability at December 31, 2016. The stock-based compensation liability of $3.6 million at December 31, 2015 is related to outstanding stock options. Further, $1.7 million is included in Other current liabilities and $1.9 million is included in Other long-term liabilities in the consolidated balance sheets at December 31, 2015. The actual tax benefits recognized related to stock-based compensation totaled $1.0 million, $4.6 million, $3.3 million and $8.2 million for the Successor years ended December 31, 2016 and 2015, the Successor Period ended December 31, 2014 and the Predecessor Period ended March 31, 2014, respectively.

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2016
Compensation Related Costs [Abstract]
Employee Benefit Plans	11. EMPLOYEE BENEFIT PLANS The Company provides a 401(k) plan that covers substantially all U.S. employees. Participants can elect to contribute up to 50% of their eligible earnings on a pre-tax basis, subject to Internal Revenue Service annual limitations. The U.S.-based plan offers a year-end employer matching contribution, requiring the participant to be an employee at year-end to qualify for the match. Participants with one year or more of service are eligible for the matching contribution. Participants fully vest in the employer contributions after three years of service. The employer contribution represents a percentage of a participant’s eligible compensation. The Company’s 401(k) Plan costs were $2.0 million, $1.7 million, $1.1 million and $0.3 million during the Successor years ended December 31, 2016 and 2015, the Successor Period ended December 31, 2014 and the Predecessor Period ended March 31, 2014, respectively, and were allocated between Direct costs, excluding depreciation and amortization, and Selling, general and administrative in the consolidated statements of operations. The Company has various defined contribution arrangements for eligible employees of non-U.S. entities. These defined contribution arrangements provide employees with retirement savings and life insurance benefits. The Company incurred expenses related to these arrangements of $0.7 million, $0.7 million, $0.5 million and $0.2 million in the Successor years ended December 31, 2016 and 2015, the Successor Period ended December 31, 2014 and the Predecessor Period ended March 31, 2014, respectively, and were allocated between Direct costs, excluding depreciation and amortization, and Selling, general and administrative in the consolidated statements of operations. The Company is also required to pay certain minimum statutory post-employment benefits. The Company recognizes a liability and the associated expense for these benefits when it is probable that employees are entitled to the benefit.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	12. INCOME TAXES The Company files income tax returns for U.S. federal and various U.S. states, as well as various foreign jurisdictions. The liabilities for unrecognized tax benefits are carried in Other long-term liabilities on the consolidated balance sheets because the payment of cash is not anticipated within one year of the balance sheet date. The components of income (loss) before income taxes consisted of the following (in thousands): SUCCESSOR PREDECESSOR Year Ended Year Ended Period Ended Period Ended December 31, December 31, December 31, March 31, 2016 2015 2014 2014 Domestic $ 18,016 $ (12,294 ) $ (23,893 ) $ (1,069 ) Foreign jurisdictions $ 3,941 $ 4,464 $ 2,854 $ 847 Income (loss) before income taxes $ 21,957 $ (7,830 ) $ (21,039 ) $ (222 ) Income tax provision (benefit) consisted of the following (in thousands): Current Deferred Total Successor Year ended December 31, 2016 U.S. Federal $ 15,105 $ (8,784 ) $ 6,321 U.S. state and local 1,636 (524 ) 1,112 Foreign jurisdictions 710 389 1,099 $ 17,451 $ (8,919 ) $ 8,532 Successor Year ended December 31, 2015 U.S. Federal $ 11,067 $ (11,995 ) $ (928 ) U.S. state and local 1,119 (761 ) 358 Foreign jurisdictions 1,372 41 1,413 $ 13,558 $ (12,715 ) $ 843 Successor Period ended December 31, 2014 U.S. Federal $ 1,817 $ (8,941 ) $ (7,124 ) U.S. state and local 245 (606 ) (361 ) Foreign jurisdictions 853 (71 ) 782 $ 2,915 $ (9,618 ) $ (6,703 ) Predecessor Period ended March 31, 2014 U.S. Federal $ 342 $ 659 $ 1,001 U.S. state and local 52 (38 ) 14 Foreign jurisdictions 320 (321 ) (1 ) $ 714 $ 300 $ 1,014 The difference between the statutory rate for federal income tax and the effective income tax rate was as follows (in thousands): SUCCESSOR PREDECESSOR Year Ended Year Ended Period Ended Period Ended December 31, December 31, December 31, March 31, 2016 2015 2014 2014 Income tax expense calculated at the federal statutory rate $ 7,685 35.0 % $ (2,740 ) 35.0 % $ (7,363 ) 35.0 % $ (78 ) 35.0 % Effect of: State and local taxes, net of federal benefit 912 4.2 487 (6.2 ) 219 (1.0 ) 208 (93.8 ) Tax on foreign earnings, net of tax credits and deductions (26 ) (0.1 ) (330 ) 4.2 (261 ) 1.2 (440 ) 197.8 Change in valuation allowance - - - - - - 789 (354.3 ) Permanent items: Goodwill impairment - - 2,106 (26.9 ) - - - - Stock-based awards (534 ) (2.4 ) 778 (9.9 ) 332 (1.6 ) 278 (125.2 ) Other 174 0.8 185 (2.4 ) 730 (3.5 ) 296 (133.1 ) State/Local tax credits (1,049 ) (4.8 ) (931 ) 11.9 (573 ) 2.7 (208 ) 93.6 Change in liability for uncertain tax positions 1,212 5.5 1,250 (16.0 ) 249 (1.2 ) 169 (76.1 ) Other 158 0.7 38 (0.5 ) (36 ) 0.2 - - $ 8,532 38.9 % $ 843 (10.8)% $ (6,703 ) 31.8 % $ 1,014 (456.1)% The undistributed earnings of foreign subsidiaries at December 31, 2016 and 2015 were approximately $15.1 million and $10.4 million, respectively, and have been permanently reinvested. It is not practicable to determine the amount of the additional taxes that would result if these earnings were repatriated. Components of the Company’s net deferred tax liability included in the consolidated balance sheets consisted of the following at December 31 (in thousands): SUCCESSOR 2016 2015 Deferred tax assets: Accrued liabilities $ 19,393 $ 15,746 Depreciation and amortization 1,787 1,995 Foreign operating loss carryforward 246 250 U.S. state and local tax credits and carryforward 385 153 Other 1,209 1,132 Valuation allowance (987 ) (1,021 ) Total deferred tax assets 22,033 18,255 Deferred tax liabilities: Depreciation and amortization (33,436 ) (38,970 ) Prepaid expenses (310 ) (161 ) Other (220 ) (71 ) Total deferred tax liabilities (33,966 ) (39,202 ) Net deferred tax liability $ (11,933 ) $ (20,947 ) The deferred tax asset attributable to U.S. state and local tax credits and carryforwards above includes less than $0.1 million for U.S. state and local operating loss carryforwards that will expire in 2029 if not utilized. The Company has foreign operating loss carryforwards for which a deferred tax asset of $0.2 million has been established. The Company has a valuation allowance of $0.2 million against this deferred tax asset based upon its assessment that it is more likely than not that this amount will not be realized. The ultimate realization of this tax benefit is dependent upon the generation of sufficient operating income in the respective tax jurisdictions. Approximately 74% of the foreign net operating loss carryforwards can be utilized over an indefinite period whereas the remainder will expire at various times from 2020 to 2025 if not utilized. In December 2013, the Company recorded an impairment loss of $2.3 million and an associated deferred tax asset of $0.8 million on its cost method investment in a related party. In March 2014, the investment was sold and the company incurred a capital loss. This loss is limited to offset future capital gains which the Company does not anticipate will be generated, thus a valuation allowance of $0.8 million has been recorded as it is more likely than not that realization cannot be assured. Annual activity related to the Company’s valuation allowance is as follows (in thousands): SUCCESSOR PREDECESSOR Year Ended Year Ended Period Ended Period Ended December 31, December 31, December 31, March 31, 2016 2015 2014 2014 Beginning Balance $ 1,021 $ 1,086 $ 1,103 $ 305 Additions charged to expense - - - 798 Reductions from utilization, reassessments and expirations (34 ) (65 ) (17 ) - Ending Balance $ 987 $ 1,021 $ 1,086 $ 1,103 A reconciliation of the beginning and ending balances of the total amounts of gross unrecognized tax benefits is as follows (in thousands): SUCCESSOR PREDECESSOR Year Ended Year Ended Period Ended Period Ended December 31, December 31, December 31, March 31, 2016 2015 2014 2014 Beginning Balance $ 2,604 $ 1,353 $ 1,092 $ 938 Increases in tax positions for prior years - - 31 134 Decreases in tax positions for prior years (196 ) (14 ) (8 ) - Increases in tax positions for current year 3,365 1,265 238 20 Lapse in statute of limitations (75 ) - - - Ending Balance $ 5,698 $ 2,604 $ 1,353 $ 1,092 Interest and penalties associated with uncertain tax positions are recognized as components of Income tax provision (benefit) in the consolidated statements of operations. There was no material change to tax-related interest and penalties during the Successor years ended December 31, 2016 and 2015, the Successor Period ended December 31, 2014 and the Predecessor Period ended March 31, 2014. As of December 31, 2016 and 2015, respectively, the Company has a liability for interest and penalties of $1.0 million and $0.6 million that is associated with related tax liabilities of $4.3 million and $1.8 million for uncertain tax positions. The Company operates in various foreign, state and local jurisdictions. The number of tax years for which the statute of limitations remains open for foreign, state and local jurisdictions varies by jurisdiction and is approximately four years (2012 through 2016). For federal tax purposes, the Company’s open tax years are 2012 through 2016.

Miscellaneous (Expense) Income,

Miscellaneous (Expense) Income, Net	12 Months Ended
	Dec. 31, 2016
Other Income And Expenses [Abstract]
Miscellaneous (Expense) Income, Net	13. MISCELLANEOUS (EXPENSE) INCOME, NET Miscellaneous (expense) income, net consisted of the following (in thousands): SUCCESSOR PREDECESSOR Year Ended Year Ended Period Ended Period Ended December 31, December 31, December 31, March 31, 2016 2015 2014 2014 Net loss on foreign-currency transactions $ (660 ) $ (1,307 ) $ (1,156 ) $ (114 ) Other income 237 174 855 1,327 Miscellaneous (expense) income, net $ (423 ) $ (1,133 ) $ (301 ) $ 1,213

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions	14. RELATED PARTY TRANSACTIONS Employee Loans The Company periodically extends short term loans or advances to employees, typically upon commencement of employment. Total receivables as a result of these employee advances of $0.2 million and 0.2 million existed at December 31, 2016 and December 31, 2015, respectively, and are included in the Prepaid expenses and other current assets and Other assets line items of the consolidated balance sheets, respectively, depending on the contractual repayment date. Management Fees In conjunction with the IPO, the Advisory Services Agreement with Cinven Capital Management (V) General Partner Limited (“Cinven”) expired. Subsequent to the IPO, the Company will pay fees for director services provided by Cinven employees that are members of the Company’s Board of Directors and any related committees. The director fees will be paid directly to Cinven in accordance with the Company’s non-employee director compensation policy. During the Successor years ended December 31, 2016 and 2015, and the Successor nine month period ended December 31, 2014, the Company incurred management fees to Cinven of $0.2 million, $0.3 million and $0.2 million, respectively, and related travel expenses of $0.1 million, $0.1 million and $0.1 million, respectively. During the Successor year ended December 31, 2016, the Company incurred director fees of $0.1 million. As of December 31, 2016 and 2015, the Company had outstanding accounts payable to Cinven of $0.1 million and $0.1 million, respectively. Consulting Fees During the Successor period ended December 31, 2014, the Company paid $1.7 million in consulting fees to an investment banking firm in connection with the Transaction. A managing member of this firm was previously a Medpace board member. Service Agreements Symplmed Pharmaceuticals, LLC (“Symplmed”) Medpace Investors LLC, a noncontrolling shareholder of the Company that is owned by employees of the Company and managed by our chief executive officer, has a majority ownership interest in Symplmed Pharmaceuticals, LLC (“Symplmed”), a private pharmaceutical development company. In addition, the chief executive officer and other executives of the Company are board members of Symplmed. The Company has operated under a Master Services Agreement (“MSA”) with Symplmed since 2013 (amended in 2014) to perform clinical trials and related activities. Certain task orders governed by this arrangement were amended in the third quarter of 2016, changing the fee structure from unitized in nature to time and materials and revised pricing based on the Company’s leveraging of this work to develop and enhance certain new service capabilities. The Company has evaluated its relationship with Symplmed and concluded that Symplmed is not a variable interest entity because the Company has no direct ownership interest or relationship other than the MSA. During the Successor years ended December 31, 2016 and 2015 and the Successor Period ended December 31, 2014, the Company recognized related party transactions of less than $(0.1) million, $1.2 million and $1.2 million as service revenue in the consolidated statements of operations, respectively. As of December 31, 2016 and 2015 the Company had accounts receivable from Symplmed of less than $0.1 million and $0.3 million recorded in the consolidated balance sheet. Coherus BioSciences, Inc. (“Coherus”) and MX II Associates, LLC (“MXII”) The chief executive officer of the Company is a member of Coherus BioSciences, Inc.’s (“Coherus”) board of directors. During 2011 a related party of the Company in which the Company’s chief executive officer is the managing member, MXII, made an investment in Coherus. In early 2012 the Company made a $2.5 million investment in Coherus. Concurrent with the initial investment, MXII secured the exclusive rights for Medpace to perform Phase I through Phase III clinical trial work for certain Coherus’ “bio-similar” drug compounds executed through a MSA. In return, Medpace agreed to pay a 10% sales commission to MXII on cash received from Coherus. The commission agreement between the Company and MXII was terminated during 2015 but did not impact the MSA between the Company and Coherus. During the Successor years ended December 31, 2016 and 2015, the Successor Period ended December 31, 2014 and the Predecessor Period ended March 31, 2014, the Company recognized service revenue of $22.3 million, $22.1 million, $10.6 million and $2.0 million from Coherus in the Company’s consolidated statements of operations, respectively. In addition, the company recognized Reimbursed out-of-pocket revenue and Reimbursed out-of-pocket expenses with Coherus in the consolidated statements of operations of $5.1 million, $6.9 million, $2.0 million and $0.1 million during the Successor years ended December 31, 2016 and 2015, the Successor Period ended December 31, 2014 and the Predecessor Period ended March 31, 2014, respectively. As of December 31, 2016 and December 31, 2015 the Company had Accounts receivable and unbilled, net from Coherus of $2.0 million and $2.3 million recorded in the consolidated balance sheets, respectively. In addition, the Company had Advanced billings of $6.3 million and $8.4 million and Pre-funded study costs of $3.8 million and $3.5 million with Coherus recorded in the consolidated balance sheets at December 31, 2016 and 2015, respectively. In March 2014, the Predecessor’s cost method investment in Coherus was sold to Medpace Investors for $0.3 million and was reflected in the other income component of Miscellaneous (expense) income, net in the consolidated statements of operations for the Predecessor Period ended March 31, 2014. Xenon Pharmaceuticals, Inc. (“Xenon”) Certain executives and employees of the Company, including the chief executive officer, have equity investments in Xenon, a clinical-stage biopharmaceutical company. In addition, a Medpace employee was a director of Xenon until May 2015. During July 2015 the Company and Xenon entered into an amended MSA agreement for the Company to provide certain clinical development services. The Company recognized service revenue from Xenon of $1.3 million and $0.7 million during the Successor years ended December 31, 2016 and 2015, respectively, in the Company’s consolidated statements of operations. In addition, the company recognized Reimbursed out-of-pocket revenue and Reimbursed out-of-pocket expenses with Xenon in the consolidated statements of operations of $0.2 million and less than $0.1 million during the Successor years ended December 31, 2016 and 2015, respectively. As of December 31, 2016 and December 31, 2015 the Company had Accounts receivable and unbilled, net from Xenon of $0.3 million and less than $0.1 million recorded in the consolidated balance sheets, respectively. Cymabay Therapeutics, Inc. (“Cymabay”) Cymabay is a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. During the first quarter of 2016, it was announced that a Medpace employee would join Cymabay’s board of directors. The Company and Cymabay entered into a MSA dated October 21, 2016. Subsequently, the Company and Cymabay have entered into several task orders for the Company to perform various central laboratory services. The Company recognized service revenue from Cymabay of $0.3 million and $0.1 million during the Successor years ended December 31, 2016 and 2015, respectively, in the Company’s consolidated statements of operations. LIB Therapeutics LLC (“LIB”) Certain executives and employees of the Company, including the chief executive officer, are members of LIB’s board of directors. The Company entered into a MSA dated November 24, 2015 with LIB, a company that engages in research, development, marketing and commercialization of pharmaceutical drugs. Subsequently, the Company and LIB have entered into several task orders for the Company to perform various clinical development and central laboratory services. The Company recognized service revenue from LIB of $0.2 million during the Successor year ended December 31, 2016 in the Company’s consolidated statements of operations. Medpace Investors, LLC Medpace Investors is a noncontrolling shareholder and related party of Medpace Holdings, Inc. Medpace Investors is owned and managed by employees of the Company. The Company’s chief executive officer is also the manager and majority unit holder of Medpace Investors. The Successor acts as a paying agent for Medpace Investors with taxing authorities principally in instances when employee tax payments or remittance of withholdings related to equity compensation are required. During the Successor years ended December 31, 2016 and 2015, and the Successor Period ended December 31, 2014, the Company paid $0.8 million, $0.9 million and $1.4 million to various taxing authorities on behalf of Medpace Investors. During the Successor year ended December 31, 2016, the Company received $0.3 million from Medpace Investors for receivables owed to the Company from Symplmed. Additionally, the Company paid approximately $0.3 million to Medpace Investors due to the settlement of certain liabilities related to the Merger Agreement between the sellers (led by CCMP) and the buyers (led by Cinven). See Note 2 for further information. Leased Real Estate Headquarters Lease The Company has entered into operating leases for its corporate headquarters and a storage space facility with an entity that is wholly owned by the Company’s chief executive officer. The Company has evaluated its relationship with the related party and concluded that the related party is not a variable interest entity because the Company has no direct ownership interest or relationship other than the leases. The lease for headquarters is for an initial term of twelve years through November 2022 with a renewal option for one 10-year term at prevailing market rates. The lease for storage space was through June 2016 and was leased on a month to month basis, thereafter. The Company pays rent, taxes, insurance, and maintenance expenses that arise from the use of the properties. Annual base rent for the corporate headquarters is $2.1 million and allows for adjustments to the rental rate annually for increases in the consumer price index. Lease expense recognized for the Successor years ended December 31, 2016 and 2015, the Successor Period ended December 31, 2014 and the Predecessor Period ended March 31, 2014 was $2.1 million, $2.1 million, $1.6 million and $0.5 million. The lease expense was allocated between Direct costs, excluding depreciation and amortization, and Selling, general and administrative in the consolidated statements of operations. Deemed Assets and Deemed Landlord Liabilities The Company entered into two multi-year lease agreements governing the occupancy of space of two buildings in Cincinnati, Ohio with an entity that is wholly owned by the Company’s chief executive officer and certain members of his immediate family. In accordance with the accounting guidance related to leases, the Company was deemed in substance to be the owner of the property during the construction phase and at completion. Accordingly, the Company reflected the buildings and related liabilities as deemed assets from landlord building construction in Property and equipment, net, Other current liabilities, and Deemed landlord liabilities, respectively, on the consolidated balance sheets. The Company assumed occupancy in 2012 and the leases expire in 2027 with the Company having one 10-year option to extend the lease term. The deemed assets are being fully depreciated, on a straight line basis, over the 15-year term of the lease. Deemed landlord liabilities are recorded at their net present value when the Company enters into qualifying leases and are reduced as the Company makes periodic lease payments on the properties. Accretion expense is being recorded over the term of the lease as a component of Interest expense, net in the Company’s consolidated statements of operations. The Company paid $3.7 million, $3.4 million, $3.1 million and $0.9 million during the Successor years ended December 31, 2016 and 2015, the Successor Period ended December 31, 2014, the Predecessor Period ended March 31, 2014, respectively. The current and long-term portions of the Deemed landlord liability at December 31, 2016 were $1.7 million and $28.5 million, respectively. The current and long-term portions of the Deemed landlord liability at December 31, 2015 were $1.6 million and $30.3 million, respectively. The Company has recognized $18.1 million and $19.8 million, respectively, of deemed assets, net at December 31, 2016 and 2015 in the consolidated balance sheets. Travel Services Reynolds Jet Management The Company incurs expenses for travel services for company executives provided by a private aviation charter company that is owned by the chief executive officer and the senior vice president of operations of the Company (“private aviation charter”). The Company may contract directly with the private aviation charter for the use of its aircraft or indirectly through a third party aircraft management and jet charter company (the “Aircraft Management Company”). The travel services provided are primarily for business purposes, with certain personal travel paid for as part of the executives’ compensation arrangements. The Aircraft Management Company also makes the private aviation charter aircraft available to third parties. The Company incurred travel expenses of $1.0 million, $0.9 million, $0.5 million and $0.1 million during the Successor years ended December 31, 2016 and 2015, the Successor Period ended December 31, 2014 and the Predecessor Period ended March 31, 2014, respectively. These travel expenses are recorded in Selling, general and administrative in the Company’s consolidated statements of operations. Common Stock Purchases During 2015, an employee of the Company entered into a stock purchase agreement (“SPA”) with the Company that permitted the purchase of 37,037 shares of the Company’s common stock at the then-current value for those shares. There was no stock-based compensation expense recognized in relation to the SPA due to no required services to be rendered in exchange for shares. The proceeds from this SPA are reflected as Proceeds from sale of common stock in the consolidated statement of cash flows for the Successor year ended 2015. Assets and Obligations Related to Former Owners Pursuant to the Medpace, Inc. Stock Purchase Agreement dated June 17, 2011 (the “Predecessor Purchase Agreement”), certain tax indemnifications between the sellers (a group led by the former majority shareholder who is the current chief executive officer, the “Former Owners”) and the buyers (led by CCMP) were entered into regarding contingencies that could arise after the June 17, 2011 transaction, as well as tax payments or refunds that were finalized after June 17, 2011 but which relate to periods prior to the Predecessor Purchase Agreement date. In February 2015, a settlement was reached with a local taxing authority regarding the refund of income tax payments made by the Company prior to June 17, 2011. On the consolidated balance sheets at December 31, 2016 and 2015, the Successor has $0.1 million and $0.4 million in Prepaid expenses and other current assets and Other assets related to the tax refund due from the local taxing authority and $0.1 million and $0.4 million in Other current liabilities and Other long-term liabilities representing the obligation to the Former Owners. The Successor has less than $0.1 million and $0.1 million in Prepaid expenses and other current assets and $0.0 million and $0.1 million in Other current liabilities on the consolidated balance sheets at December 31, 2016 and 2015, associated with refunds from various other taxing authorities that were generated prior to June 17, 2011.

Acquisition and Integration Exp

Acquisition and Integration Expenses	12 Months Ended
	Dec. 31, 2016
Business Combinations [Abstract]
Acquisition and Integration Expenses	15. ACQUISITION AND INTEGRATION EXPENSES The Successor and the Predecessor incurred $9.3 million and $12.4 million of one-time Acquisition and integration expenses related to the Transaction during the Successor Period ended December 31, 2014 and the Predecessor Period ended March 31, 2014, respectively, primarily for investment banking, legal, accounting, consulting and other advisory fees.

Entity Wide Disclosures

Entity Wide Disclosures	12 Months Ended
	Dec. 31, 2016
Segment Reporting Entity Wide Disclosures [Abstract]
Entity Wide Disclosure	16. ENTITY WIDE DISCLOSURES Operations By Geographic Location The Company conducts operations in North America, Europe, Africa, Asia-Pacific and Latin America through wholly-owned subsidiaries and representative sales offices. The Company attributes service revenue to geographical locations based upon the location of the contracting entity. For the Successor years ended December 31, 2016 and 2015, service revenue attributable to the U.S. represented approximately 98% of total consolidated service revenue, net. No other country or region represents more than 5% of service revenue, net. The following table summarizes property and equipment, net by geographic region and is further broken down to show countries which account for 10% or more of total as of December 31, (in thousands): SUCCESSOR 2016 2015 Property and equipment, net: United States $ 34,817 $ 28,152 Europe Belgium 3,672 3,896 Other 3,764 3,968 Total Europe 7,436 7,864 Other 1,552 1,496 Total property and equipment, net $ 43,805 $ 37,512 Products & Services Clinical research services and laboratory services represented approximately 87% and 13%, 87% and 13%, 85% and 15% and 85% and 15% of consolidated service revenue, net for the Successor years ended December 31, 2016 and 2015, the Successor period ended December 31, 2014 and the Predecessor Period ended March 31, 2014, respectively.

Quarterly Financial Data (Unaud

Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Data (Unaudited)	17. QUARTERLY FINANCIAL DATA (unaudited) The following table summarizes the Company's unaudited quarterly results of operations (in thousands, except per share data): 2016 First Second Quarter Third Quarter Fourth Quarter Service revenue, net $ 87,800 $ 92,633 $ 94,812 $ 95,376 Direct costs, excluding depreciation and amortization 46,981 49,234 51,221 51,074 Income from operations 12,869 14,114 12,617 12,890 Net income (loss) 3,448 4,962 5,036 (21 ) Net income (loss) per share attributable to common shareholders - Basic $ 0.11 $ 0.15 $ 0.14 $ (0.00 ) Net income (loss) per share attributable to common shareholders - Diluted $ 0.11 $ 0.15 $ 0.13 $ (0.00 ) 2015 First Quarter Second Quarter Third Quarter Fourth Quarter Service revenue, net $ 76,030 $ 76,752 $ 81,638 $ 85,681 Direct costs, excluding depreciation and amortization 39,125 38,600 41,763 44,219 Income (loss) from operations 6,389 7,867 7,195 (889 ) Net (loss) income (59 ) 95 (133 ) (8,576 ) Net (loss) income per share attributable to common shareholders - Basic $ (0.00 ) $ 0.00 $ (0.00 ) $ (0.27 ) Net (loss) income per share attributable to common shareholders - Diluted $ (0.00 ) $ 0.00 $ (0.00 ) $ (0.27 )

Summary of Significant Accoun26

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Principles of Consolidation and Presentation	Principles of Consolidation and Presentation The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and include the accounts and operations of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The Company’s consolidated balance sheets as of December 31, 2016 and 2015 and its related statements of operations, comprehensive (loss) income, shareholders’ equity, and cash flows presented subsequent to the Transaction for the years ended December 31, 2016 and 2015 and the period from April 1 through December 31, 2014 are referenced herein as the successor financial statements (the “Successor” or “Successor Financial Statements”). The period April 1 through December 31, 2014 is referenced herein as the “Successor Period ended December 31, 2014.” The Company’s consolidated statements of operations, comprehensive (loss) income, shareholders’ equity and cash flows for the period from January 1 through March 31, 2014 is referenced herein as the predecessor financial statements (the “Predecessor” or “Predecessor Financial Statements”). The January 1 through March 31, 2014 period is referenced herein as the “Predecessor Period ended March 31, 2014.”
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates. Significant items that are subject to management estimates and assumptions include service revenue, net, allowances for doubtful accounts, acquisition purchase price allocations, long-lived asset impairment and useful lives, exit liabilities, stock-based compensation, uncertain income tax positions and contingencies.
Reportable Segments	Reportable Segments The Company emphasizes its full service outsourcing model, providing services focused on the development, management and execution of clinical trials. As part of this full service approach, the Company utilizes centralized systems, customer interface technology, support functions and processes that cross service offerings and align resources to deliver efficient clinical trial services. Given the full service approach, the chief executive officer, who is the chief operating decision maker (“CODM”) assesses the allocation of resources based on key metrics including revenue, backlog, and net awards by service offering and consolidated profitability and consolidated cash flows. Based on the Company’s full service model, internal management and reporting structure, and key metrics used by the CODM to make resource allocation decisions, management has determined that the Company’s operations consist of a single operating segment. Therefore, results of operations are presented as a single reportable segment.
Foreign Currencies	Foreign Currencies Assets and liabilities recorded in foreign currencies on foreign subsidiary financial statements are translated at the exchange rate on the balance sheet date, while equity accounts are translated at historical exchange rates. Revenue and expenses are recorded at average rates of exchange during the year. Translation adjustments are recorded to Accumulated other comprehensive loss in the consolidated statements of shareholders’ equity and consolidated statements of comprehensive (loss) income. Separately, net realized gains and losses on foreign currency transactions are included in Miscellaneous (expense) income, net, on the consolidated statements of operations. Foreign currency transactions resulted in net losses of $0.7 million, $1.3 million, $1.2 million and $0.1 million during the Successor years ended December 31, 2016 and 2015, the Successor Period ended December 31, 2014 and the Predecessor Period ended March 31, 2014, respectively.
Revenue Recognition	Revenue Recognition The Company generally enters into contracts with customers to provide services ranging in duration from a few months to several years. The contract terms generally provide for payments based on a fixed fee or unit-of-service arrangement. Revenue on these arrangements is recognized when there is persuasive evidence of an arrangement, the service offering has been delivered to the customer, the arrangement consideration is determinable and the collection of the fees is reasonably assured. The Company recognizes revenue for services provided on fixed fee arrangements based on the proportional performance methodology, which is determined by assessing the proportion of performance completed or delivered to date compared to total specific measures to be delivered or completed under the terms of the arrangement. The measures utilized to assess performance are specific to the service provided, and the Company generally compares the ratio of hours completed to the total estimated hours necessary to complete the contract. A detailed project budget by hours is developed based on many factors, including but not limited to the scope of the work, the complexity of the study, the participating geographic locations, and the Company’s historical experience. Management believes the reporting and estimation of hours is the best available measure of progress on many of the services provided and best reflects the pattern in which obligations to customers are fulfilled. To assist with the estimation of hours expected to complete a project, regular contract reviews for each project are performed in which performance to date is compared to the most current estimate to complete assumptions. The reviews include an assessment of effort incurred to date compared to expectations based on budget assumptions and other circumstances specific to the project. The total estimated hours necessary to complete a fixed-fee contract, based on these reviews, are updated and any revisions to the existing hours budget result in cumulative adjustments to the amount of revenue recognized in the period in which the revisions are identified. Fixed-fee contracts provide for pricing modifications upon scope of work changes. The Company recognizes revenue related to work performed in connection with scope changes when the underlying services are performed, a binding contractual commitment has been executed with the customer and collectability is reasonably assured. Costs are not deferred in anticipation of contracts being awarded or amendments being finalized, but are expensed as incurred. For unit-of-service arrangements, the Company recognizes revenue in the period in which the unit is delivered. Service unit elements largely consist of various project management, consulting and analytical testing services. Many contractual arrangements combine multiple service elements. For these contracts, arrangement consideration is allocated to identified units of account based on the relative selling price of each unit of account. The best evidence of selling price of a unit of account is vendor specific objective evidence (“VSOE”), which is the price charged when the deliverable is sold separately. When VSOE is not available to determine selling price, management uses relative third party evidence, if available. When neither VSOE nor third party evidence of selling price exists, management uses its best estimate of selling price considering all relevant information that is available. Most contracts are terminable by the customer, either immediately or according to advance notice terms specified within the contracts. These contracts require payment of fees to the Company for services rendered through the date of termination and may require payment for subsequent services necessary to conclude the study or close out the contract. Final settlement amounts are typically subject to negotiation with the customer. These amounts are included in Service revenue, net when realization is reasonably assured. The Company occasionally enters into volume rebate arrangements with customers that provide for rebates if certain specified spending thresholds are met. These rebate obligations are recorded as a reduction of revenue when it appears probable that the customer will earn the rebates and the related amount is estimable. Service revenue is presented net of rebates of less than $0.1 million, $0.1 million, $0.4 million and $0.1 million in the consolidated statements of operations during the Successor years ended December 31, 2016 and 2015, the Successor Period ended December 31, 2014 and the Predecessor Period ended March 31, 2014. The Company records revenue net of any tax assessments by governmental authorities that are imposed and concurrent with specific revenue generating transactions.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents and accounts receivable. The cash and cash equivalent balances are held and maintained with financial institutions with reputable credit ratings and, consequently, the Company believes that such funds are subject to minimal credit risk. The Company generally does not require collateral or other securities to support customer receivables. In the Successor years ended December 31, 2016 and 2015, the Successor Period ended December 31, 2014 and the Predecessor Period ended March 31, 2014, credit losses have been immaterial and within management’s expectations. At December 31, 2016 and 2015, there were no customers accounting for more than 10% of the Company’s accounts receivable.
Costs and Expenses	Costs and Expenses Direct costs, excluding depreciation and amortization, include direct labor and related employee benefits, laboratory supplies, and other expenses contributing to service delivery. Direct costs, excluding depreciation and amortization, are expensed as incurred and are not deferred in anticipation of contracts being awarded or finalization of changes in scope. Selling, general and administrative includes administrative payroll and related employee benefits, sales and marketing expenses, administrative travel, and other expenses not directly related to service delivery. Rent, utilities, supplies, and software license expenses are allocated between Direct costs, excluding depreciation and amortization, and Selling, general and administrative based on the estimated contribution among service delivery and support function efforts on a percentage basis. Depreciation and amortization is reported separately in the accompanying consolidated statements of operations. Costs of sales and marketing activities not subject to recovery pursuant to customer contracts, such as feasibility assessments and negotiation of contracts, are expensed as incurred and recorded as a component of Selling, general and administrative in the accompanying consolidated statements of operations. Advertising expenses are recorded as a component of Selling, general and administrative expenses in the accompanying consolidated statements of operations. Total advertising expenses of $0.6 million, $0.4 million, $0.2 million and $0.1 million were incurred during the Successor years ended December 31, 2016 and 2015, the Successor Period ended December 31, 2014 and the Predecessor Period ended March 31, 2014, respectively.
Reimbursed Out-of-Pocket Expenses	Reimbursed Out-of-Pocket Expenses The Company incurs on behalf of its clients various out-of-pocket expenditures including, but not limited to, travel, meetings, printing, and shipping and handling fees, which are reflected as a separate component of operating expenses and recorded in Reimbursed out-of-pocket expenses in the accompanying consolidated statements of operations. Reimbursements received are reflected in Reimbursed out-of-pocket revenue without mark-up or profit in the consolidated statements of operations. Fees paid to investigators and other disbursements in which the Company acts as an agent on behalf of the client are recorded net in the consolidated statements of operations with no impact on the Company’s revenue or expenses. Funds received in advance of study expenditures are recorded as Pre-funded study cost liabilities on the consolidated balance sheets. Any pre-funded amounts remaining at the conclusion of a study are returned to the client. Pre-funded study cost disbursements of $150.3 million, $114.4 million, $92.5 million and $30.9 million were made during the Successor years ended December 31, 2016 and 2015, the Successor Period ended December 31, 2014 and the Predecessor Period ended March 31, 2014, respectively.
Income Taxes	Income Taxes The Company’s consolidated U.S. federal income tax return is comprised of its U.S. subsidiaries and one of its foreign subsidiaries located in Korea. All foreign subsidiaries of the Company file tax returns in their local jurisdictions. The Company provides for income taxes on all transactions that have been recognized in the consolidated financial statements in accordance with accounting guidance governing income tax accounting. Accordingly, the impact of changes in income tax laws on deferred tax assets and deferred tax liabilities are recognized in net earnings in the period during which such changes are enacted. The Company records deferred tax assets and liabilities based on temporary differences between the financial statement bases and tax bases of assets and liabilities. Deferred tax assets are recorded for tax benefit carryforwards using tax rates anticipated to be in effect in the year in which the temporary differences are expected to reverse. If it does not appear more likely than not that the full value of a deferred tax asset will be realized, the Company records a valuation allowance against the deferred tax asset, with an offsetting charge to the Company’s income tax provision or benefit. The value of the Company’s deferred tax assets is estimated based on, among other things, the Company’s ability to generate a sufficient level of future taxable income. In estimating future taxable income, the Company has considered both positive and negative evidence, such as historical and forecasted results of operations, and has considered the implementation of prudent and feasible tax planning strategies. A provision has not been made for U.S. or additional foreign taxes on the undistributed portion of earnings of foreign subsidiaries as those earnings of $15.1 million as of December 31, 2016, have been permanently reinvested. The Company follows accounting guidance related to accounting for uncertainty in income taxes which requires significant judgment in determining what constitutes an individual tax position as well as assessing the possible outcome of each tax position. Changes in judgments as to recognition or measurement of tax positions can materially affect the estimate of the effective tax rate, and, consequently, the Company’s consolidated financial results. The Company considers many factors when evaluating and estimating tax positions and tax benefits, which may require periodic adjustments and which may not accurately anticipate actual outcomes. In addition, the calculation of tax liabilities involves dealing with uncertainties in the application of complex tax regulations in a multitude of jurisdictions. The Company determines its liability for uncertain tax positions globally. If the payment of these amounts ultimately proves to be unnecessary, the reversal of liabilities would result in tax benefits being recognized in the period when it is determined the liabilities are no longer necessary. If the calculation of the liability related to uncertain tax positions proves to be more or less than the ultimate assessment, a tax expense or tax benefit would result. Interest and penalties associated with uncertain tax positions are recognized as components of the Company’s Income tax provision (benefit).
Research and Development Credits	Research and Development Credits Research and development credits are available to the Company under tax laws in certain jurisdictions, based on qualifying research and development spend as defined under those tax laws. Certain tax jurisdictions provide refundable credits that are not wholly dependent on the Company’s income tax status or income tax position. In these circumstances the benefit of the credits is recorded as a reduction of operating expense. When they are wholly dependent upon the Company’s income tax position, research and development credits are recognized as a reduction of income tax expense.
Stock-Based Compensation	Stock-Based Compensation The Company has stock-based employee compensation plans for which it incurs compensation expense. Successor Equity Awards In connection with the Company's IPO, the Board approved the formation of the 2016 Incentive Award Plan (the “2016 Plan”), which replaced our 2014 Equity Incentive Plan (the “2014 Plan”). The 2016 Plan provides for long-term equity incentive compensation for key employees, officers and non-employee directors. A variety of discretionary awards (collectively, the “Awards”) for employees and non-employee directors are authorized under the 2016 Plan, including vested common shares, stock options, stock appreciation rights (“SARs”), restricted stock awards (“RSAs”), restricted stock units (“RSUs”), or other cash based or stock dividend equivalent awards. The vesting of such awards may be conditioned upon either a specified period of time or the attainment of specific performance goals as determined by the administrator of the 2016 Plan. The option price and term are also subject to determination by the administrator with respect to each grant. Option prices are generally expected to be set at the market price of our common stock at the date of grant and option terms are not expected to exceed ten years. All outstanding Awards under the 2016 Plan are equity classified awards. The Successor, coinciding with the Transaction, created the 2014 Plan, providing for the future issuance of vested shares, stock options, RSAs and RSUs in Medpace Holdings, Inc.’s common stock (the “2014 Plan Awards”). The 2014 Plan Awards were subject to either equity or liability-classification pursuant to the terms of the participant’s award agreement and the Successor Plan based on accounting guidance which governs such transactions. Stock-based compensation expense for both the 2016 Plan and 2014 Plan is calculated using the fair value method on the grant date. The Successor expenses stock-based compensation using a graded vesting schedule. For liability-classified awards under the 2014 Plan, the Company recorded fair value adjustments up to and including the settlement date. Changes in the fair value of the stock compensation liability that occurred during the requisite service period were recognized as compensation cost over the vesting period. Changes in the fair value of the stock compensation liability that occurred after the end of the requisite service period but before settlement, were compensation cost of the period in which the change occurred. As a result of the Company’s IPO, a condition of all outstanding stock options issued before August 10, 2016 under the 2014 Plan that previously required the exchange of the shares issued for incentive units in the equity of a non-consolidated related party was dissolved. All future exercises of options issued pursuant to the 2014 Plan will settle in unregistered shares of the Company. As a result of the modification in the settlement condition, the options are equity-classified instruments and changes in the fair value of the stock compensation liability that occur during the requisite service period are no longer recognized. Stock-based compensation expense is allocated between Direct costs, excluding depreciation and amortization, and Selling, general and administrative in the consolidated statements of operations based on the underlying classification and scope of work for the employees receiving the Successor Awards. The stock-based compensation expense represents awards ultimately expected to vest and, as such, has been reduced for estimated forfeitures. Predecessor Equity Awards The Predecessor awards, consisting of stock options and restricted share awards, are equity-classified instruments based on the terms of the Predecessor’s equity incentive plans and on accounting guidance which governs such transactions. The Predecessor determined the fair value of stock options and restricted shares on the grant date and recognized the associated compensation expense, net of assumed forfeitures, according to a graded vesting schedule as the requisite services were rendered. Restricted shares and stock options vested ratably over three and four years, respectively, from the date of grant.
Net Income (Loss) Per Share	Net Income (Loss) Per Share Basic and diluted earnings or loss per share (“EPS”) are computed using the two-class method, which is an earnings allocation that determines EPS for each class of common stock and participating securities according to dividends declared and participation rights in undistributed earnings. The Successor’s RSAs are considered participating securities because they are legally issued at the date of grant and holders are entitled to receive non-forfeitable dividends during the vesting term. The computation of diluted EPS includes additional common shares, such as unvested RSUs and stock options with exercise prices less than the average market price of the Company’s common stock during the period (“in-the-money options”), which would be considered outstanding under the treasury stock method. The treasury stock method assumes that additional shares would have to be issued in cases where the exercise price of stock options is less than the value of the common stock being acquired because the cash proceeds received from the stock option holder would not be sufficient to acquire that same number of shares. The Company does not compute diluted EPS in cases where the inclusion of such additional shares would be anti-dilutive in effect. The following table sets forth the computation of basic and diluted earnings per share for the Successor years ended December 31, 2016 and 2015, the Successor Period ended December 31, 2014 and the Predecessor Period ended March 31, 2014 (in thousands, except for earnings per share): SUCCESSOR PREDECESSOR Year Ended Year Ended Period Ended Period Ended December 31, December 31, December 31, March 31, 2016 2015 2014 2014 Weighted-average shares: Common shares outstanding 35,690 31,346 30,869 25,047 RSAs 88 - - - Total weighted-average shares 35,778 31,346 30,869 25,047 Earnings per common share—Basic Net income (loss) $ 13,425 $ (8,673 ) $ (14,336 ) $ (1,236 ) Less: Undistributed earnings allocated to RSAs 33 - - - Net income (loss) available to common shareholders—Basic $ 13,392 $ (8,673 ) $ (14,336 ) $ (1,236 ) Net income (loss) per common share—Basic $ 0.38 $ (0.28 ) $ (0.46 ) $ (0.05 ) Basic weighted-average common shares outstanding 35,690 31,346 30,869 25,047 Effect of diluted shares 639 - - - Diluted weighted-average shares outstanding 36,329 31,346 30,869 25,047 Net income (loss) per common share—Diluted $ 0.37 $ (0.28 ) $ (0.46 ) $ (0.05 ) During the Successor year ended December 31, 2016, there was fewer than one thousand shares excluded from the computation of EPS because they were antidilutive under the treasury method calculation of diluted weighted average shares outstanding. For the Successor year ended December 31, 2015, the Successor Period ended December 31, 2014 and the Predecessor Period ended March 31, 2014, the computation of diluted EPS excludes the effect of (in thousands) 660, 302 and 237 combined RSAs and RSUs, and 1,794, 1,091 and 0 stock options, respectively, due to the Company’s net loss position as well as the respective period’s average fair value of the Company’s common stock exceeded the exercise prices.
Fair Value Measurements	Fair Value Measurements The Company follows accounting guidance related to fair value measurements that defines fair value, establishes a framework for measuring fair value, and establishes a hierarchy for inputs used in measuring fair value. This hierarchy maximizes the use of “observable” inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. The hierarchy specifies three levels based on the inputs, as follows: Level 1: Valuations based on quoted prices in active markets for identical assets or liabilities. Level 2: Valuations based on directly observable inputs or unobservable inputs corroborated by market data. Level 3: Valuations based on unobservable inputs supported by little or no market activity representing management’s determination of assumptions of how market participants would price the assets or liabilities. The fair value of financial instruments such as cash and cash equivalents, accounts receivable and unbilled, net, accounts payable, accrued expenses, and advanced billings approximate their carrying amounts due to their short term maturities. The Company does not have any recurring fair value measurements as of December 31, 2016. There were no transfers between Level 1, Level 2, or Level 3 during the Successor years ended December 31, 2016 and 2015, the Successor Period ended December 31, 2014 or the Predecessor Period ended March 31, 2014.
Cash and Cash Equivalents, including Restricted Cash	Cash and Cash Equivalents, including Restricted Cash Cash and cash equivalents, including restricted cash, are invested in demand deposits, all of which have an original maturity of three months or less. Restricted cash consists of customer funds received in advance and subject to specific restrictions, as well as amounts placed in escrow for contingent payments resulting from acquisitions or other contractual arrangements. In addition, Prepaid expenses and other current assets and Other assets in the consolidated balance sheets include $0.7 million of cash held as collateral in support of a property mortgage in Leuven, Belgium at December 31, 2015. The property mortgage was fully repaid during 2015 and the Company received a full refund during the first quarter of 2016.
Accounts Receivable and Unbilled, Net	Accounts Receivable and Unbilled, Net Accounts receivable represent amounts due from the Company’s customers who are concentrated primarily in the pharmaceutical, biotechnology, and medical device industries. Unbilled services represent service revenue recognized to date that is currently not billable to the customer pursuant to contractual terms. In general, amounts become billable upon the achievement of negotiated contractual events or in accordance with predetermined payment schedules. Amounts classified to Unbilled services are those billable to customers within one year from the respective balance sheet date. The Company grants credit terms to its customers prior to signing a service contract and monitors the creditworthiness of its customers on an ongoing basis. The Company maintains an allowance for doubtful accounts based on specific identification of accounts receivable that are at risk of not being collected. Uncollectible accounts receivable are written off only after all reasonable collection efforts have been exhausted. Moreover, in some cases the Company requires advance payment from its customers for a portion of the study contract price upon the signing of a service contract. These advance payments are deferred and recognized as revenue as services are performed.
Inventory	Inventory Inventory, which consists primarily of laboratory supplies, is valued at the lower of cost or market. Inventory is stated at purchased cost using the first-in, first out (FIFO) cost method. The inventory balance is included in Prepaid expenses and other current assets in the consolidated balance sheets.
Property and Equipment	Property and Equipment Property and equipment is recorded at cost. Depreciation is provided on the straight-line method at rates adequate to allocate the cost of the applicable assets over their estimated useful lives, which is three to five years for computer hardware, software, phone, and medical imaging equipment, five to seven years for furniture and fixtures and other equipment, and thirty to forty years for buildings. The Company capitalizes costs of computer software developed for internal use and amortizes these costs on a straight-line basis over the estimated useful life, not to exceed three years. Leasehold improvements and deemed assets from landlord building construction are capitalized and amortized on a straight-line basis over the shorter of the estimated useful life of the improvement or the associated remaining lease term. Repairs and maintenance are expensed as incurred.
Leases	Leases The Company leases facilities and equipment to be used in its operations, some of which require capitalization in accordance with US GAAP. Upon the execution of new leases, the Company determines the appropriate classification of the lease as operating or capital and reflects the impact of this classification in its consolidated financial statements.
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill Goodwill represents the excess of purchase price over the fair value of net assets acquired in business combinations. The carrying value of goodwill is reviewed at least annually for impairment, or as indicators of potential impairment are identified, at the reporting unit level. The reporting units are Phase II-IV clinical research services, Laboratories, and Clinics as of December 31, 2016. The Company performs its annual impairment tests during the fourth quarter each year, utilizing the quantitative two step model defined by accounting guidance which governs such assessments. The first step involves the Company comparing each of its reporting unit carrying values, inclusive of assigned goodwill, to their respective estimated fair values. Fair value is estimated using a combination of the income approach, a discounted cash flow analysis, and the market approach, utilizing the guideline company method. If the calculation in the first step results in any of the reporting units’ carrying values exceeding their respective estimated fair values, a second step is performed. The second step requires the Company to allocate the fair value of the reporting unit derived in the first step to the fair value of the reporting unit’s net assets. Any fair value in excess of amounts allocated to such net assets represent the implied fair value of goodwill for that reporting unit. Any excess of reporting unit carrying value of goodwill over the implied fair value of goodwill results in an impairment. There was no indication of impairment related to goodwill based on the fourth quarter 2016 assessment. Intangible Assets The Company has an indefinite lived intangible asset related to its trade name. The carrying value of the trade name asset is reviewed at least annually for impairment, or as indicators of potential impairment are identified. The Company performs its annual impairment test in the fourth quarter each year in conjunction with its annual assessment of goodwill. The assessment consists of comparing the carrying value of the indefinite lived intangible asset to its estimated fair value, utilizing the relief from royalty method, an income approach valuation. There was no indication of impairment related to the trade name asset based on the fourth quarter 2016 assessment. Finite-lived intangible assets consist mainly of the value assigned to customer relationships, backlog and developed technologies. Finite-lived intangible assets are amortized straight-line or using an accelerated method over their estimated useful lives, which range in term from seventeen months to fifteen years.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets, primarily property and equipment and finite-lived intangible assets, are reviewed for impairment and the reasonableness of the estimated useful lives whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be recoverable or that a change in useful life may be appropriate. Recoverability for long-lived assets is determined by comparing the forecasted undiscounted cash flows of the operation to which the assets relate to the carrying amount of the assets. If the undiscounted cash flows are less than the carrying amount of the assets, then the Company reduces the carrying value of the assets to estimated fair values, which are primarily based upon forecasted discounted cash flows. Fair value of long-lived assets is determined based on a combination of discounted cash flows and market multiples.
Advanced Billings	Advanced Billings Advanced billings represents cash received from customers, or billed amounts per an agreed upon payment schedule, in advance of services being performed or revenue being recognized.
Deemed Landlord Liabilities	Deemed Landlord Liabilities Deemed landlord liabilities are recorded at their net present value when the Company enters into qualifying leases and are reduced as the Company makes periodic lease payments on the properties.
Other Current Liabilities and Other Long-Term Liabilities	Other Current Liabilities and Other Long-Term Liabilities Deferred rent represents the cumulative additional portion of rent expense recognized on a straight line basis in conjunction with the Company’s current leases at the balance sheet date. The Company defers incentives received from landlords for the purpose of making leasehold improvements. These liabilities are amortized as a component of rent expense over the term of the respective lease. Exit liabilities, if any exist, are recorded at their net present value to the extent the Company no longer receives any benefit from the related property and when the Company has ceased all use of the property. Asset retirement obligations, to the extent they exist, are recorded at their net present value and accreted to the Company’s estimate of liability at the time the obligation would be required to be satisfied.
Recently Adopted and Issued Accounting Standards	Recently Adopted Accounting Standards In August 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern In April 2015, the FASB issued ASU 2015-05, Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash The Company, as permitted by ASU 2016-18, early adopted ASU 2016-15 in the fourth quarter of 2016. As a result of this adoption, cash flows resulting from changes in restricted cash balances, are no longer presented as a component of net cash provided by operating activities in the Company’s consolidated statements of cash flows, but have been reclassified and combined within Increases/(Decreases) in Cash and Cash Equivalents and Restricted Cash. This reclassification was retrospectively applied to all periods presented within the consolidated statements of cash flows. Recently Issued Accounting Standards In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). Leases (FAS 13) In May 2014, the FASB issued ASU No. 2014-09 ‘‘Revenue from Contracts with Customers,’’ to clarify the principles of recognizing revenue and create common revenue recognition guidance between US GAAP and International Financial Reporting Standards. In May 2016, the FASB issued ASU 2016-12, Narrow-Scope Improvements and Practical Expedients. In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net). In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. ASUs’ 2016-12, 2016-10 and 2016-08 all clarify the interpretation guidance in ASU No. 2014-09, “Revenue from Contracts with Customers” specifically related to narrowing specific aspects of Topic 606 and adding illustrative examples to assist in the application of the guidance. The effective date and transition requirements in ASUs’ 2016-12, 2016-10, and 2016-08 are the same as the effective date and transition requirements of ASU 2014-09. ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, defers the effective date of ASU 2014-09 by one year. The new standard allows for either a retrospective or modified retrospective approach to transition upon adoption. The new standard will be effective for annual reporting periods beginning after December 15, 2017. Early adoption is permitted for annual reporting periods beginning after December 15, 2016. The Company will adopt ASU 2014-09 as well as the clarified guidance in ASUs’ 2016-12, 2016-10, 2016-08 during the first quarter of 2018, as required, but is still evaluating its transition approach upon adoption. The Company is currently evaluating the impact of this new standard on its consolidated financial statements. In 2017, the Company will be rewriting its revenue recognition accounting policy and drafting new revenue disclosures to reflect the requirements of this standard. The Company also continues to evaluate the impact this guidance will have on our consolidated financial statements including but not limited to review of its performance obligations in its fixed fee contracts.

Change in Control (Tables)

Change in Control (Tables)	12 Months Ended
	Dec. 31, 2016
Change In Control [Abstract]
Schedule of Sources and Uses of Purchase Price Consideration	The sources and uses of the purchase price consideration were as follows (in thousands): Sources of cash consideration: Sale of Successor common stock $ 414,000 Long-term debt issuance 530,000 Revolving loan 1,575 Original issue discount (2,650 ) Loan origination fees (15,487 ) Debt proceeds, net 513,438 Total sources of consideration paid $ 927,438 Uses of cash consideration: Purchase of Predecessor common stock 780,829 Proceeds from stock option exercise (15,221 ) Payment of Predecessor debt 143,728 Payment of Predecessor's selling expenses 11,962 Total uses of consideration paid $ 921,298
Schedule of Fair Value of Assets Acquired and Liabilities Assumed	The following table reconciles the fair value of the assets acquired and liabilities assumed to the total purchase price (in thousands): Assets Acquired: Cash and cash equivalents $ 17,845 Restricted cash 1,648 Accounts receivable 39,311 Unbilled services 13,065 Reimbursable pass-through expenses 12,184 Prepaid expenses and other current assets 12,205 Property and equipment 39,661 Goodwill 670,294 Intangible assets 306,307 Deferred income taxes 26,246 Other assets 3,237 Total assets acquired 1,142,003 Liabilities assumed: Accounts payable and accrued expenses 16,608 Pre-funded study costs 36,483 Advanced billings 52,475 Deemed landlord liability 34,251 Debt 1,551 Deferred income taxes 69,448 Other liabilities 9,889 Total liabilities assumed 220,705 Net assets acquired $ 921,298

Summary of Significant Accoun28

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
Earnings Per Share [Abstract]
Schedule of Reconciliation of Denominators and Additional Shares that are Excluded from the Calculation of EPS	The following table sets forth the computation of basic and diluted earnings per share for the Successor years ended December 31, 2016 and 2015, the Successor Period ended December 31, 2014 and the Predecessor Period ended March 31, 2014 (in thousands, except for earnings per share): SUCCESSOR PREDECESSOR Year Ended Year Ended Period Ended Period Ended December 31, December 31, December 31, March 31, 2016 2015 2014 2014 Weighted-average shares: Common shares outstanding 35,690 31,346 30,869 25,047 RSAs 88 - - - Total weighted-average shares 35,778 31,346 30,869 25,047 Earnings per common share—Basic Net income (loss) $ 13,425 $ (8,673 ) $ (14,336 ) $ (1,236 ) Less: Undistributed earnings allocated to RSAs 33 - - - Net income (loss) available to common shareholders—Basic $ 13,392 $ (8,673 ) $ (14,336 ) $ (1,236 ) Net income (loss) per common share—Basic $ 0.38 $ (0.28 ) $ (0.46 ) $ (0.05 ) Basic weighted-average common shares outstanding 35,690 31,346 30,869 25,047 Effect of diluted shares 639 - - - Diluted weighted-average shares outstanding 36,329 31,346 30,869 25,047 Net income (loss) per common share—Diluted $ 0.37 $ (0.28 ) $ (0.46 ) $ (0.05 )

Accounts Receivable And Unbil29

Accounts Receivable And Unbilled, Net (Tables)	12 Months Ended
	Dec. 31, 2016
Receivables [Abstract]
Schedule of Accounts Receivable and Unbilled, Net	Accounts receivable and unbilled, net consisted of the following at December 31 (in thousands): SUCCESSOR 2016 2015 Accounts receivable $ 48,270 $ 40,721 Unbilled 34,719 26,091 Less allowance for doubtful accounts (3,222) (1,724) Total accounts receivable and unbilled, net $ 79,767 $ 65,088
Schedule of Allowance for Doubtful Account Activity	A rollforward of allowance for doubtful account activity is as follows: SUCCESSOR PREDECESSOR Year December 31, Year Ended December 31, Period Ended December 31, Period Ended March 31, 2016 2015 2014 2014 Allowance for doubtful accounts - beginning balance $ (1,724 ) $ (5,855 ) $ (5,595 ) $ (5,573 ) Current year provision (2,166) (642 ) (624 ) (49 ) Write-offs and recoveries 668 4,773 364 27 Allowance for doubtful accounts - ending balance $ (3,222 ) $ (1,724 ) $ (5,855 ) $ (5,595 )

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2016
Property Plant And Equipment [Abstract]
Summary of Property and Equipment, Net	Property and equipment, net consisted of the following at December 31 (in thousands): SUCCESSOR 2016 2015 Land $ 543 $ 940 Equipment 10,094 8,218 Furniture, fixtures, and leasehold improvements 15,415 8,563 Computer hardware, software, and phone equipment 7,535 4,569 Buildings 2,253 2,839 Deemed assets from landlord building construction 22,752 22,752 Construction-in-progress 2,840 304 Property and equipment at cost 61,432 48,185 Less: Accumulated depreciation (17,627 ) (10,673 ) Property and equipment, net $ 43,805 $ 37,512

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule of Changes in Carrying Amount of Goodwill	The changes in the carrying amount of goodwill are as follows (in thousands): Balance as of December 31, 2014 - Successor $ 670,294 Impairment of Goodwill (9,313) Balance as of December 31, 2016 and 2015 - Successor $ 660,981
Schedule of Intangible Assets, Net	Intangible assets, net consisted of the following (in thousands): Gross Accumulated Amount Amortization Net Balances as of December 31, 2016 - Successor: Backlog $ 72,630 $ 72,630 $ - Customer relationships 145,051 66,267 78,784 Developed technologies 54,475 29,961 24,514 Trade name (indefinite-lived) 31,646 - 31,646 Other 2,505 1,378 1,127 $ 306,307 $ 170,236 $ 136,071 Balances as of December 31, 2015 - Successor: Backlog $ 72,630 $ 72,630 $ - Customer relationships 145,051 26,991 118,060 Developed technologies 54,475 19,066 35,409 Trade name (indefinite-lived) 31,646 - 31,646 Other 2,505 877 1,628 $ 306,307 $ 119,564 $ 186,743
Schedule of Estimated Amortization Expense of Intangible Assets	As of December 31, 2016, estimated amortization expense of the Company’s intangible assets for each of the next five years and thereafter is as follows (in thousands): Amortization 2017 $ 37,790 2018 29,371 2019 14,639 2020 7,797 2021 5,114 Later years 9,714 Total $ 104,425

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2016
Payables And Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consisted of the following at December 31 (in thousands): SUCCESSOR 2016 2015 Employee compensation and benefits $ 21,453 $ 17,195 Other 2,964 2,916 Total accrued expenses $ 24,417 $ 20,111

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Schedule of Debt	Debt consisted of the following at December 31 (in thousands): SUCCESSOR 2016 2015 Term loan $ 165,000 $ 390,000 Capital lease - 59 165,000 390,059 Less unamortized discount (534 ) (1,984 ) Less unamortized term loan debt issuance costs (824 ) (10,134 ) Less current portion of long-term debt (12,375 ) (59 ) Long-term debt, net, less current portion $ 151,267 $ 377,882
Schedule of Principal Payments on Debt Due	Principal payments on debt are due as follows (in thousands): 2017 $ 12,375 2018 16,500 2019 16,500 2020 20,625 2021 99,000 Total $ 165,000

Commitments, Contingencies, a34

Commitments, Contingencies, and Guarantees (Tables)	12 Months Ended
	Dec. 31, 2016
Commitments And Contingencies Disclosure [Abstract]
Schedule of Minimum Future Lease Payments	As of December 31, 2016, minimum future lease payments required under these leases are as follows (in thousands): Non-Related Total Related Party Parties Operating Operating Operating Lease Leases Leases 2017 $ 2,112 $ 4,844 $ 6,956 2018 2,112 3,715 5,827 2019 2,112 2,206 4,318 2020 2,112 1,559 3,671 2021 2,112 1,368 3,480 Thereafter 1,760 3,340 5,100 Total minimum lease payments $ 12,320 $ 17,032 $ 29,352
Schedule of Minimum Annual Payments Required in Conjunction with Landlord Liability	As of December 31, 2016, minimum annual payments required in conjunction with the Deemed landlord liabilities are as follows (in thousands): Related Party Total Minimum Lease Less: Principal Payments Interest Amounts Due 2017 $ 3,792 $ 2,089 $ 1,703 2018 3,886 1,961 1,925 2019 3,937 1,819 2,118 2020 3,988 1,662 2,326 2021 4,040 1,490 2,550 Thereafter 23,934 4,326 19,608 Total $ 43,577 $ 13,347 $ 30,230

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Schedule of Weighted-Average Assumptions Used in BSM Model to Calculate Fair Value of Options	The following table sets forth the key weighted-average assumptions used in the BSM Model to calculate the fair value of options: SUCCESSOR PREDECESSOR Year Ended Year Ended Period Ended Period Ended December 31, December 31, December 31, March 31, 2016 2015 2014 2014 Expected holding period - years 3.6 4.2 5.4 N/A Expected volatility 30.2% 36.4% 41.8% N/A Risk-free interest rate 1.0% 1.2% 1.7% N/A Expected dividend yield 0.0% 0.0% 0.0% N/A
Schedule of Grant Date Fair Value and Stock-based Compensation Expense Allocated	The following table summarizes the grant date fair values of stock options and restricted shares issued during the period as well as the allocation of stock-based compensation expense to Direct costs, excluding depreciation and amortization, and Selling, general and administrative reported in the consolidated statements of operations: SUCCESSOR PREDECESSOR Year Ended Year Ended Period Ended Period Ended December 31, December 31, December 31, March 31, 2016 2015 2014 2014 Weighted average, grant date fair value Stock Options $ 6.91 $ 3.81 $ 4.33 N/A Restricted shares (RSAs and RSUs) $ 15.08 $ 12.53 $ 10.80 N/A Stock-based compensation expense allocated to: Direct costs, excluding depreciation and amortization $ 5,555 $ 9,243 $ 4,399 $ 5,422 Selling, general, and administrative 4,260 13,081 1,024 1,918 Total stock-based compensation expense $ 9,815 $ 22,324 $ 5,423 $ 7,340
Schedule of Successor and Predecessor's Stock Option Activity	The following table sets forth the Successor’s and Predecessor’s stock option activity: SUCCESSOR PREDECESSOR Year Ended Year Ended Period Ended Period Ended December 31, December 31, December 31, March 31, 2016 2015 2014 2014 Weighted Weighted Average Weighted Average Weighted Average Options Exercise Price Shares Exercise Price Shares Exercise Price Shares Exercise Price Outstanding - beginning of Period 1,794,709 $ 15.42 1,091,048 $ 14.40 - $ - 1,438,800 $ 11.03 Granted 683,001 $ 22.80 889,849 $ 16.67 1,131,895 $ 14.40 - $ - Exercised (36,980 ) $ - (17,404 ) $ - - $ - (1,388,000 ) $ 10.97 Forfeited (90,564 ) $ 15.85 (168,784 ) $ 15.53 (40,847 ) $ 14.40 (32,200 ) $ 12.53 Expired - $ - - $ - - $ - (18,600 ) $ 11.27 Outstanding - end of period 2,350,166 $ 17.57 1,794,709 $ 15.42 1,091,048 $ 14.40 - $ - Exercisable - end of period 647,343 $ 15.22 242,777 $ 14.40 - $ - - $ -
Schedule of Successor and Predecessor's Restricted Share Activity	The following table sets forth the Successor and Predecessor’s Restricted Share activity: SUCCESSOR PREDECESSOR Year Ended Year Ended Period Ended Period Ended December 31, December 31, December 31, March 31, 2016 2015 2014 2014 Shares Shares Shares Shares Outstanding and unvested - beginning of period 90,697 407,171 - 176,643 Granted 11,111 1,253,924 707,721 - Vested (41,069 ) (1,530,547 ) (283,042 ) (172,492 ) Forfeited (1,481 ) (39,851 ) (17,508 ) (4,151 ) Outstanding and unvested - end of period 59,258 90,697 407,171 - Cumulative vested shares - end of period 1,854,658 1,813,589 283,042 263,490
Schedule of Stock Options Expected To Vest, Stock Options Exercisable, and Unvested Restricted Share Awards Expected To Vest	The following table summarizes information about stock options expected to vest, stock options exercisable, and unvested restricted share awards expected to vest at December 31, 2016: Weighted Average Weighted Average Exercise Stock Restricted Remaining Issued in Successor Year Ended Price Options Shares Life (Years) December 31, 2016 Number of stock options expected to vest $ 17.51 2,304,229 - 5.4 Number of Restricted Shares expected to vest - 59,258 Total expected to vest - December 31, 2016 2,304,229 59,258 Total stock options exercisable - December 31, 2016 $ 15.22 647,343 4.8 Unrecognized compensation cost - December 31, 2016 (in thousands) $ 7,909 $ 538 Weighted average years over which unrecognized compensation cost will be recognized 2.4 2.0
Schedule of Aggregate Intrinsic Value of Stock Options Exercised, Fair Values of Awards Vested, and Share Based Liabilities Settled	The following table sets forth the aggregate intrinsic value of stock options exercised, the fair values of awards vested, and share based liabilities settled during the respective periods (in thousands): SUCCESSOR PREDECESSOR Year Ended Year Ended Period Ended Period Ended December 31, December 31, December 31, March 31, 2016 2015 2014 2014 Total intrinsic value of stock options exercised $ 403 $ (36 ) $ - $ 25,378 Total grant-date fair value of stock options vested $ 1,384 $ 1,168 $ - $ 3,446 Total grant-date fair value of restricted shares vested $ 614 $ 18,284 $ 3,057 $ 1,466 Total settlement date fair value of restricted shares vested $ 1,236 $ 21,134 $ 3,057 N/A Total share-based liabilities settled $ 76 $ 16,858 $ 3,057 N/A

Income Taxes - (Tables)

Income Taxes - (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Schedule of Components of (Loss) Income Before Income Taxes	The components of income (loss) before income taxes consisted of the following (in thousands): SUCCESSOR PREDECESSOR Year Ended Year Ended Period Ended Period Ended December 31, December 31, December 31, March 31, 2016 2015 2014 2014 Domestic $ 18,016 $ (12,294 ) $ (23,893 ) $ (1,069 ) Foreign jurisdictions $ 3,941 $ 4,464 $ 2,854 $ 847 Income (loss) before income taxes $ 21,957 $ (7,830 ) $ (21,039 ) $ (222 )
Schedule of Income Tax Provision (Benefit)	Income tax provision (benefit) consisted of the following (in thousands): Current Deferred Total Successor Year ended December 31, 2016 U.S. Federal $ 15,105 $ (8,784 ) $ 6,321 U.S. state and local 1,636 (524 ) 1,112 Foreign jurisdictions 710 389 1,099 $ 17,451 $ (8,919 ) $ 8,532 Successor Year ended December 31, 2015 U.S. Federal $ 11,067 $ (11,995 ) $ (928 ) U.S. state and local 1,119 (761 ) 358 Foreign jurisdictions 1,372 41 1,413 $ 13,558 $ (12,715 ) $ 843 Successor Period ended December 31, 2014 U.S. Federal $ 1,817 $ (8,941 ) $ (7,124 ) U.S. state and local 245 (606 ) (361 ) Foreign jurisdictions 853 (71 ) 782 $ 2,915 $ (9,618 ) $ (6,703 ) Predecessor Period ended March 31, 2014 U.S. Federal $ 342 $ 659 $ 1,001 U.S. state and local 52 (38 ) 14 Foreign jurisdictions 320 (321 ) (1 ) $ 714 $ 300 $ 1,014
Summary Of Difference Between Statutory Rate for Federal Income Tax and Effective Income Tax Rate	The difference between the statutory rate for federal income tax and the effective income tax rate was as follows (in thousands): SUCCESSOR PREDECESSOR Year Ended Year Ended Period Ended Period Ended December 31, December 31, December 31, March 31, 2016 2015 2014 2014 Income tax expense calculated at the federal statutory rate $ 7,685 35.0 % $ (2,740 ) 35.0 % $ (7,363 ) 35.0 % $ (78 ) 35.0 % Effect of: State and local taxes, net of federal benefit 912 4.2 487 (6.2 ) 219 (1.0 ) 208 (93.8 ) Tax on foreign earnings, net of tax credits and deductions (26 ) (0.1 ) (330 ) 4.2 (261 ) 1.2 (440 ) 197.8 Change in valuation allowance - - - - - - 789 (354.3 ) Permanent items: Goodwill impairment - - 2,106 (26.9 ) - - - - Stock-based awards (534 ) (2.4 ) 778 (9.9 ) 332 (1.6 ) 278 (125.2 ) Other 174 0.8 185 (2.4 ) 730 (3.5 ) 296 (133.1 ) State/Local tax credits (1,049 ) (4.8 ) (931 ) 11.9 (573 ) 2.7 (208 ) 93.6 Change in liability for uncertain tax positions 1,212 5.5 1,250 (16.0 ) 249 (1.2 ) 169 (76.1 ) Other 158 0.7 38 (0.5 ) (36 ) 0.2 - - $ 8,532 38.9 % $ 843 (10.8)% $ (6,703 ) 31.8 % $ 1,014 (456.1)%
Schedule of Components of Company's Net Deferred Tax Liability	Components of the Company’s net deferred tax liability included in the consolidated balance sheets consisted of the following at December 31 (in thousands): SUCCESSOR 2016 2015 Deferred tax assets: Accrued liabilities $ 19,393 $ 15,746 Depreciation and amortization 1,787 1,995 Foreign operating loss carryforward 246 250 U.S. state and local tax credits and carryforward 385 153 Other 1,209 1,132 Valuation allowance (987 ) (1,021 ) Total deferred tax assets 22,033 18,255 Deferred tax liabilities: Depreciation and amortization (33,436 ) (38,970 ) Prepaid expenses (310 ) (161 ) Other (220 ) (71 ) Total deferred tax liabilities (33,966 ) (39,202 ) Net deferred tax liability $ (11,933 ) $ (20,947 )
Schedule of Annual Activity Related to Valuation Allowance	Annual activity related to the Company’s valuation allowance is as follows (in thousands): SUCCESSOR PREDECESSOR Year Ended Year Ended Period Ended Period Ended December 31, December 31, December 31, March 31, 2016 2015 2014 2014 Beginning Balance $ 1,021 $ 1,086 $ 1,103 $ 305 Additions charged to expense - - - 798 Reductions from utilization, reassessments and expirations (34 ) (65 ) (17 ) - Ending Balance $ 987 $ 1,021 $ 1,086 $ 1,103
Schedule of Gross Unrecognized Tax Benefits	A reconciliation of the beginning and ending balances of the total amounts of gross unrecognized tax benefits is as follows (in thousands): SUCCESSOR PREDECESSOR Year Ended Year Ended Period Ended Period Ended December 31, December 31, December 31, March 31, 2016 2015 2014 2014 Beginning Balance $ 2,604 $ 1,353 $ 1,092 $ 938 Increases in tax positions for prior years - - 31 134 Decreases in tax positions for prior years (196 ) (14 ) (8 ) - Increases in tax positions for current year 3,365 1,265 238 20 Lapse in statute of limitations (75 ) - - - Ending Balance $ 5,698 $ 2,604 $ 1,353 $ 1,092

Miscellaneous (Expense) Incom37

Miscellaneous (Expense) Income, Net (Tables)	12 Months Ended
	Dec. 31, 2016
Other Income And Expenses [Abstract]
Components of Miscellaneous (Expense) Income, Net	Miscellaneous (expense) income, net consisted of the following (in thousands): SUCCESSOR PREDECESSOR Year Ended Year Ended Period Ended Period Ended December 31, December 31, December 31, March 31, 2016 2015 2014 2014 Net loss on foreign-currency transactions $ (660 ) $ (1,307 ) $ (1,156 ) $ (114 ) Other income 237 174 855 1,327 Miscellaneous (expense) income, net $ (423 ) $ (1,133 ) $ (301 ) $ 1,213

Entity Wide Disclosures (Tables

Entity Wide Disclosures (Tables)	12 Months Ended
	Dec. 31, 2016
Segment Reporting Entity Wide Disclosures [Abstract]
Summary of Property and Equipment, Net by Geographic Region	The following table summarizes property and equipment, net by geographic region and is further broken down to show countries which account for 10% or more of total as of December 31, (in thousands): SUCCESSOR 2016 2015 Property and equipment, net: United States $ 34,817 $ 28,152 Europe Belgium 3,672 3,896 Other 3,764 3,968 Total Europe 7,436 7,864 Other 1,552 1,496 Total property and equipment, net $ 43,805 $ 37,512

Quarterly Financial Data (Una39

Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Schedule of Unaudited Quarterly Results of Operations	The following table summarizes the Company's unaudited quarterly results of operations (in thousands, except per share data): 2016 First Second Quarter Third Quarter Fourth Quarter Service revenue, net $ 87,800 $ 92,633 $ 94,812 $ 95,376 Direct costs, excluding depreciation and amortization 46,981 49,234 51,221 51,074 Income from operations 12,869 14,114 12,617 12,890 Net income (loss) 3,448 4,962 5,036 (21 ) Net income (loss) per share attributable to common shareholders - Basic $ 0.11 $ 0.15 $ 0.14 $ (0.00 ) Net income (loss) per share attributable to common shareholders - Diluted $ 0.11 $ 0.15 $ 0.13 $ (0.00 ) 2015 First Quarter Second Quarter Third Quarter Fourth Quarter Service revenue, net $ 76,030 $ 76,752 $ 81,638 $ 85,681 Direct costs, excluding depreciation and amortization 39,125 38,600 41,763 44,219 Income (loss) from operations 6,389 7,867 7,195 (889 ) Net (loss) income (59 ) 95 (133 ) (8,576 ) Net (loss) income per share attributable to common shareholders - Basic $ (0.00 ) $ 0.00 $ (0.00 ) $ (0.27 ) Net (loss) income per share attributable to common shareholders - Diluted $ (0.00 ) $ 0.00 $ (0.00 ) $ (0.27 )

Basis of Presentation - Additio

Basis of Presentation - Additional Information (Details) $ / shares in Units, $ in Thousands	Aug. 16, 2016USD ($)$ / sharesshares	Jul. 25, 2016	Dec. 31, 2014USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Basis Of Presentation [Line Items]
Reverse stock split of common stock		0.74
Repayments of outstanding borrowings			$ 1,575	$ 0	$ 0
Offering expenses			$ 0	$ 2,719	$ 0
2014 Senior Secured Term Loan Facility
Basis Of Presentation [Line Items]
Repayments of outstanding borrowings	$ 175,000
Initial Public Offering
Basis Of Presentation [Line Items]
Shares issued and sold, price per share | $ / shares	$ 23
Shares issued and sold | shares	8,050,000
Net proceeds from issuance IPO	$ 173,600
Offering expenses	$ 2,700
Exercise of Underwriters' Option
Basis Of Presentation [Line Items]
Shares issued and sold | shares	1,050,000

Change In Control - Additional

Change In Control - Additional Information (Details) - USD ($)	Apr. 02, 2014	Mar. 31, 2014	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	May 31, 2014	Apr. 01, 2014
Business Acquisition [Line Items]
Purchase of outstanding shares								100.00%
Aggregate purchase price	$ 921,300,000
Acquisition and integration expenses				$ 9,297,000	$ 0	$ 0
Advisory fees				$ 3,300,000
Amount of excess cash generated								$ 6,100,000
Prepaid expenses and other current assets					16,074,000	11,896,000
Other assets					4,903,000	3,927,000
Other current liabilities					3,284,000	7,469,000
Other long-term liabilities					7,968,000	7,291,000
Merger Agreement
Business Acquisition [Line Items]
Aggregate purchase price		$ 921,298,000
Gain on final settlement of indemnifications					500,000
Prepaid expenses and other current assets					0	300,000
Other assets					0	500,000
Other current liabilities						1,400,000
Other long-term liabilities					0	$ 500,000
Merger Agreement | Maximum
Business Acquisition [Line Items]
Other current liabilities					$ 100,000
Predecessor
Business Acquisition [Line Items]
Acquisition and integration expenses			$ 12,420,000
Advisory fees			$ 10,100,000
Prior Acquisition | Cinven
Business Acquisition [Line Items]
Noncontrolling interest ownership percentage owned by parent		80.00%	80.00%
Post Acquisition | Cinven
Business Acquisition [Line Items]
Noncontrolling interest ownership percentage owned by parent							75.00%
Post Acquisition | Medpace Investors
Business Acquisition [Line Items]
Noncontrolling interest ownership percentage owned by noncontrolling							25.00%

Change in Control - Schedule of

Change in Control - Schedule of Sources and Uses of Purchase Price Consideration (Details) - USD ($) $ in Thousands	Apr. 02, 2014	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Sources of cash consideration:
Sale of Successor common stock			$ 414,000	$ 173,578	$ 608
Revolving loan			1,575	0	0
Original issue discount			2,064	2,576	2,687
Uses of cash consideration:
Proceeds from stock option exercise			$ 0	$ (537)	$ (250)
Total uses of consideration paid	$ 921,300
Merger Agreement
Sources of cash consideration:
Sale of Successor common stock		$ 414,000
Long-term debt issuance		530,000
Revolving loan		1,575
Original issue discount		(2,650)
Loan origination fees		(15,487)
Debt proceeds, net		513,438
Total sources of consideration paid		927,438
Uses of cash consideration:
Purchase of Predecessor common stock		780,829
Proceeds from stock option exercise		(15,221)
Payment of Predecessor debt		143,728
Payment of Predecessor's selling expenses		11,962
Total uses of consideration paid		$ 921,298

Change in Control - Schedule 43

Change in Control - Schedule of Fair Value of Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Apr. 01, 2014
Assets Acquired:
Goodwill	$ 660,981	$ 660,981	$ 670,294
Merger Agreement
Assets Acquired:
Cash and cash equivalents				$ 17,845
Restricted cash				1,648
Accounts receivable				39,311
Unbilled services				13,065
Reimbursable pass-through expenses				12,184
Prepaid expenses and other current assets				12,205
Property and equipment				39,661
Goodwill				670,294
Intangible assets				306,307
Deferred income taxes				26,246
Other assets				3,237
Total assets acquired				1,142,003
Liabilities assumed:
Accounts payable and accrued expenses				16,608
Pre-funded study costs				36,483
Advanced billings				52,475
Deemed landlord liability				34,251
Debt				1,551
Deferred income taxes				69,448
Other liabilities				9,889
Total liabilities assumed				220,705
Net assets acquired				$ 921,298

Summary of Significant Accoun44

Summary of Significant Accounting Policies - Additional Information (Details)	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2014USD ($)shares	Dec. 31, 2014USD ($)shares	Dec. 31, 2016USD ($)Customershares	Dec. 31, 2015USD ($)Customershares
Summary Of Significant Accounting Policies [Line Items]
Sales rebates		$ 400,000		$ 100,000
Number of customers accounted for more than 10% of accounts receivable | Customer			0	0
Disbursement of pre-funded study costs		$ 92,500,000	$ 150,300,000	$ 114,400,000
Undistributed earnings of foreign subsidiaries			15,100,000	$ 10,400,000
Antidilutive securities excluded from computation of diluted EPS | shares		0		0
Fair value measurements transfers between level 1, level 2, or level 3		$ 0	0	$ 0
Prepaid expenses and other current assets			16,074,000	11,896,000
Other assets, noncurrent			4,903,000	3,927,000
Property Mortgage in Leuven, Belgium
Summary Of Significant Accounting Policies [Line Items]
Prepaid expenses and other current assets				700,000
Other assets, noncurrent				$ 700,000
Stock Options
Summary Of Significant Accounting Policies [Line Items]
Antidilutive securities excluded from computation of diluted EPS | shares		1,091,000		1,794,000
RSAs and RSUs
Summary Of Significant Accounting Policies [Line Items]
Antidilutive securities excluded from computation of diluted EPS | shares		302,000		660,000
Maximum
Summary Of Significant Accounting Policies [Line Items]
Sales rebates			$ 100,000
Antidilutive securities excluded from computation of diluted EPS | shares			1,000
Estimated useful life of intangible assets			15 years
Maximum | Computer Hardware Software Phone and Medical Imaging Equipment
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life of assets			5 years
Maximum | Furniture and Fixtures and Other Equipment
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life of assets			7 years
Maximum | Buildings
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life of assets			40 years
Maximum | Computer Software Developed Costs
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life of assets			3 years
Maximum | Stock Options
Summary Of Significant Accounting Policies [Line Items]
Antidilutive securities excluded from computation of diluted EPS | shares			0
Maximum | RSAs and RSUs
Summary Of Significant Accounting Policies [Line Items]
Antidilutive securities excluded from computation of diluted EPS | shares			0
Minimum
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life of intangible assets			17 months
Minimum | Computer Hardware Software Phone and Medical Imaging Equipment
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life of assets			3 years
Minimum | Furniture and Fixtures and Other Equipment
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life of assets			5 years
Minimum | Buildings
Summary Of Significant Accounting Policies [Line Items]
Estimated useful life of assets			30 years
Miscellaneous (Expense) Income, Net
Summary Of Significant Accounting Policies [Line Items]
Net loss on foreign currency transactions		$ (1,200,000)	$ (700,000)	$ (1,300,000)
Selling, General and Administrative
Summary Of Significant Accounting Policies [Line Items]
Advertisement expenses		$ 200,000	$ 600,000	$ 400,000
Predecessor
Summary Of Significant Accounting Policies [Line Items]
Sales rebates	$ 100,000
Disbursement of pre-funded study costs	$ 30,900,000
Antidilutive securities excluded from computation of diluted EPS | shares	0
Fair value measurements transfers between level 1, level 2, or level 3	$ 0
Predecessor | Stock Options
Summary Of Significant Accounting Policies [Line Items]
Antidilutive securities excluded from computation of diluted EPS | shares	0
Predecessor | RSAs and RSUs
Summary Of Significant Accounting Policies [Line Items]
Antidilutive securities excluded from computation of diluted EPS | shares	237,000
Predecessor | Miscellaneous (Expense) Income, Net
Summary Of Significant Accounting Policies [Line Items]
Net loss on foreign currency transactions	$ (100,000)
Predecessor | Selling, General and Administrative
Summary Of Significant Accounting Policies [Line Items]
Advertisement expenses	$ 100,000

Summary of Significant Accoun45

Summary of Significant Accounting Policies - Schedule of Reconciliation of Denominators and Additional Shares that are Excluded from the Calculation of EPS (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended									9 Months Ended	12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Weighted-average shares:
Basic weighted-average common shares outstanding										30,869	35,690	31,346
Total weighted-average shares										30,869	35,778	31,346
Earnings per common share—Basic
Net income (loss)	$ (21)	$ 5,036	$ 4,962	$ 3,448	$ (8,576)	$ (133)	$ 95	$ (59)		$ (14,336)	$ 13,425	$ (8,673)
Net income (loss) available to common shareholders—Basic										$ (14,336)	$ 13,392	$ (8,673)
Net income (loss) per common share—Basic	$ 0	$ 0.14	$ 0.15	$ 0.11	$ (0.27)	$ 0	$ 0	$ 0		$ (0.46)	$ 0.38	$ (0.28)
Basic weighted-average common shares outstanding										30,869	35,690	31,346
Effect of diluted shares										0	639	0
Diluted weighted-average shares outstanding										30,869	36,329	31,346
Net income (loss) per common share—Diluted	$ 0	$ 0.13	$ 0.15	$ 0.11	$ (0.27)	$ 0	$ 0	$ 0		$ (0.46)	$ 0.37	$ (0.28)
RSAs
Weighted-average shares:
Basic weighted-average common shares outstanding										0	88	0
Earnings per common share—Basic
Less: Undistributed earnings allocated to RSAs										$ 0	$ 33	$ 0
Basic weighted-average common shares outstanding										0	88	0
Predecessor
Weighted-average shares:
Basic weighted-average common shares outstanding									25,047
Total weighted-average shares									25,047
Earnings per common share—Basic
Net income (loss)									$ (1,236)
Net income (loss) available to common shareholders—Basic									$ (1,236)
Net income (loss) per common share—Basic									$ (0.05)
Basic weighted-average common shares outstanding									25,047
Effect of diluted shares									0
Diluted weighted-average shares outstanding									25,047
Net income (loss) per common share—Diluted									$ (0.05)
Predecessor | RSAs
Weighted-average shares:
Basic weighted-average common shares outstanding									0
Earnings per common share—Basic
Less: Undistributed earnings allocated to RSAs									$ 0
Basic weighted-average common shares outstanding									0
Common Stock
Weighted-average shares:
Basic weighted-average common shares outstanding										30,869	35,690	31,346
Earnings per common share—Basic
Basic weighted-average common shares outstanding										30,869	35,690	31,346
Common Stock | Predecessor
Weighted-average shares:
Basic weighted-average common shares outstanding									25,047
Earnings per common share—Basic
Basic weighted-average common shares outstanding									25,047

Accounts Receivable And Unbil46

Accounts Receivable And Unbilled, Net - Schedule of Accounts Receivable and Unbilled, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Mar. 31, 2014
Accounts Notes And Loans Receivable Net Current [Abstract]
Accounts receivable	$ 48,270	$ 40,721
Unbilled	34,719	26,091
Less allowance for doubtful accounts	(3,222)	(1,724)	$ (5,855)	$ (5,595)
Total accounts receivable and unbilled, net	$ 79,767	$ 65,088

Accounts Receivable And Unbil47

Accounts Receivable And Unbilled, Net - Schedule of Allowance for Doubtful Account Activity (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Allowance for Doubtful Accounts Receivable [Roll Forward]
Allowance for doubtful accounts - beginning balance		$ (5,595)	$ (1,724)	$ (5,855)
Current year provision		(624)	(2,166)	(642)
Write-offs and recoveries		364	668	4,773
Allowance for doubtful accounts - ending balance	$ (5,595)	(5,855)	$ (3,222)	$ (1,724)
Predecessor
Allowance for Doubtful Accounts Receivable [Roll Forward]
Allowance for doubtful accounts - beginning balance	(5,573)	$ (5,595)
Current year provision	(49)
Write-offs and recoveries	27
Allowance for doubtful accounts - ending balance	$ (5,595)

Property and Equipment, Net - S

Property and Equipment, Net - Summary of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Property Plant and Equipment [Line Items]
Property and equipment at cost	$ 61,432	$ 48,185
Less: Accumulated depreciation	(17,627)	(10,673)
Property and equipment, net	43,805	37,512
Land
Property Plant and Equipment [Line Items]
Property and equipment at cost	543	940
Equipment
Property Plant and Equipment [Line Items]
Property and equipment at cost	10,094	8,218
Furniture, fixtures, and leasehold improvements
Property Plant and Equipment [Line Items]
Property and equipment at cost	15,415	8,563
Computer hardware, software, and phone equipment
Property Plant and Equipment [Line Items]
Property and equipment at cost	7,535	4,569
Buildings
Property Plant and Equipment [Line Items]
Property and equipment at cost	2,253	2,839
Deemed assets from landlord building construction
Property Plant and Equipment [Line Items]
Property and equipment at cost	22,752	22,752
Construction-in-Progress
Property Plant and Equipment [Line Items]
Property and equipment at cost	$ 2,840	$ 304

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Details) $ in Thousands	9 Months Ended	12 Months Ended
	Dec. 31, 2014USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2011Lease
Property Plant And Equipment [Abstract]
Depreciation | $	$ 4,610	$ 7,442	$ 6,379
Description of operating leases		The leases expire in 2027 and the Company has one 10-year option to extend the term of the leases
Number of lease agreements | Lease				2
Description of capital leases		The Deemed Assets are being fully depreciated, on a straight line basis, over the 15-year term of the lease.

Goodwill and Intangible Asset50

Goodwill and Intangible Assets - Schedule of Changes in Carrying Amount of Goodwill (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended		24 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill, Beginning Balance			$ 660,981	$ 670,294	$ 670,294
Impairment of Goodwill	$ (9,300)	$ 0	0	(9,313)	(9,313)
Goodwill, Ending Balance	$ 660,981	$ 670,294	$ 660,981	$ 660,981	$ 660,981

Goodwill and Intangible Asset51

Goodwill and Intangible Assets - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended		24 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016
Goodwill and Intangible Assets [Line Items]
Goodwill, impairment charge	$ 9,300	$ 0	$ 0	$ 9,313	$ 9,313
Fair value assets measured on non-recurring basis	984,041		979,105	984,041	979,105
Goodwill	$ 660,981	$ 670,294	660,981	$ 660,981	660,981
Fair Value Measurement Non-Recurring | Level 3
Goodwill and Intangible Assets [Line Items]
Fair value assets measured on non-recurring basis			692,600		692,600
Goodwill			661,000		661,000
Indefinite-lived intangible assets			$ 31,600		$ 31,600

Goodwill and Intangible Asset52

Goodwill and Intangible Assets - Schedule of Intangible Assets, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Total finite-lived intangible assets	$ 306,307	$ 306,307
Total accumulated amortization	170,236	119,564
Total intangible assets, net	136,071	186,743
Trade Names
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Total indefinite-lived intangible assets	31,646	31,646
Total indefinite-lived accumulated amortization	0	0
Indefinite-lived intangible assets	31,646	31,646
Backlog
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Total finite-lived intangible assets	72,630	72,630
Total accumulated amortization	72,630	72,630
Total intangible assets, net	0	0
Customer Relationships
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Total finite-lived intangible assets	145,051	145,051
Total accumulated amortization	66,267	26,991
Total intangible assets, net	78,784	118,060
Developed Technologies
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Total finite-lived intangible assets	54,475	54,475
Total accumulated amortization	29,961	19,066
Total intangible assets, net	24,514	35,409
Other
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Total finite-lived intangible assets	2,505	2,505
Total accumulated amortization	1,378	877
Total intangible assets, net	$ 1,127	$ 1,628

Goodwill and Intangible Asset53

Goodwill and Intangible Assets - Schedule of Estimated Amortization Expense of Intangible Assets (Details) $ in Thousands	Dec. 31, 2016USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
2,017	$ 37,790
2,018	29,371
2,019	14,639
2,020	7,797
2,021	5,114
Later years	9,714
Total	$ 104,425

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Accrued Liabilities And Other Liabilities [Abstract]
Employee compensation and benefits	$ 21,453	$ 17,195
Other	2,964	2,916
Total accrued expenses	$ 24,417	$ 20,111

Debt - Schedule of Debt (Detail

Debt - Schedule of Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Long-term debt, gross	$ 165,000	$ 390,059
Less unamortized discount	(534)	(1,984)
Less unamortized term loan debt issuance costs	(824)	(10,134)
Less current portion of long-term debt	(12,375)	(59)
Long-term debt, net, less current portion	151,267	377,882
Term Loan
Debt Instrument [Line Items]
Long-term debt, gross	165,000	390,000
Capital Lease
Debt Instrument [Line Items]
Long-term debt, gross	$ 0	$ 59

Debt - Schedule of Principal Pa

Debt - Schedule of Principal Payments on Debt Due (Details) $ in Thousands	Dec. 31, 2016USD ($)
Debt Disclosure [Abstract]
2,017	$ 12,375
2,018	16,500
2,019	16,500
2,020	20,625
2,021	99,000
Total	$ 165,000

Debt - Additional Information (

Debt - Additional Information (Details) - USD ($)	Dec. 08, 2016	Apr. 02, 2014	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Apr. 01, 2014
Debt Instrument [Line Items]
Carrying value of debt				$ 165,000,000
Description of variable interest rate basis				Borrowings under the 2014 Senior Secured Credit Facilities incurred interest at a rate equal to, at our option, either (a) a Eurocurrency rate based on LIBOR for U.S. dollar deposits for loans denominated in dollars, EURIBOR for Euro deposits for loans denominated in Euros and the offer rate for any other currencies for loans denominated in such other currencies for the relevant interest period, plus 4.00% per annum if our total net leverage ratio was greater than 4.75:1.00, or 3.75% if our total net leverage ratio was less than or equal to 4.75:1.00; provided that the relevant Eurocurrency rate was deemed to be no less than 1.00% per annum; (b) a base rate, which was defined as the highest of (i) the Federal Funds Rate on such day plus ½ of 1.00%, (ii) the Prime Lending Rate on such day, (iii) the Adjusted Eurocurrency Rate for loans denominated in U.S. dollars published on such day for an Interest Period of one month plus 1.00% and (iv) 2.00%, plus 3.00% per annum if our total net leverage ratio was greater than 4.75:1.00, or 2.75% if our total leverage ratio was less than or equal to 4.75:1.00; provided that the base rate was deemed to be no less than 2.00% per annum.
Original issue discount				$ 534,000	$ 1,984,000
Cash and cash equivalents				37,099,000	14,880,000
Cash consideration		$ 921,300,000
Loss on extinguishment of debt			$ 0	$ 10,726,000	0
Fixed annual interest rate on mortgage				4.90%
Eurocurrency Rate | 2014 Senior Secured Credit Facilities Bear Interest - Scenario 1
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)				4.00%
Federal Funds Rate
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)				0.50%
Base Rate
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)				1.00%
Base Rate | 2014 Senior Secured Credit Facilities Bear Interest - Scenario 1
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)				2.00%
Base Rate | 2014 Senior Secured Credit Facilities Bear Interest - Scenario 2
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)				3.00%
Minimum | Eurocurrency Rate
Debt Instrument [Line Items]
Debt instrument, total net leverage ratio				475.00%
Minimum | Base Rate
Debt Instrument [Line Items]
Debt instrument, total net leverage ratio				475.00%
Maximum | Eurocurrency Rate
Debt Instrument [Line Items]
Debt instrument, total net leverage ratio				475.00%
Debt instrument, deemed interest rate				1.00%
Maximum | Eurocurrency Rate | 2014 Senior Secured Credit Facilities Bear Interest - Scenario 2
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)				3.75%
Maximum | Base Rate
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)				2.75%
Debt instrument, total net leverage ratio				475.00%
Debt instrument, deemed interest rate				2.00%
2014 Senior Secured Credit Facilities
Debt Instrument [Line Items]
Origination fees				$ 15,500,000
Senior Secured Credit Facilities
Debt Instrument [Line Items]
Description of variable interest rate basis				Borrowings under the Senior Secured Credit Facilities bear interest at a rate equal to, at our option, either (i) the adjusted Eurocurrency rate based on LIBOR for U.S. dollar deposits for loans denominated in dollars, EURIBOR for Euro deposits for loans denominated in Euros and the offer rate for any other currencies for loans denominated in such other currencies for the relevant interest period plus an applicable margin from 1.25% to 2.25% based on the total net leverage ratio from less than 1.50:1.00 to greater than 3.75:1:00, or (ii) an alternative base rate (determined by reference to the highest of (a) the prime commercial lending rate of the administrative agent, as established from time to time, (b) the Federal Funds Rate plus 0.50% and (c) the one-month adjusted Eurocurrency rate for loans in U.S. dollars plus 1.00%) plus an applicable margin from 0.25% to 1.25% based on the total net leverage ratio from less than 1.50:1.00 to greater than 3.75:1:00. The applicable margin as of December 31, 2016 was 1.50% for eurocurrency loans and 0.5% for base rate loans.
Ratio of consolidated funded indebtedness to consolidated EBITDA				400.00%
Loss on extinguishment of debt				$ 10,700,000
Debt instrument, third party fees				500,000
Debt instrument unamortized loan origination fee				$ 10,200,000
Senior Secured Credit Facilities | Eurocurrency Rate
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)				1.50%
Senior Secured Credit Facilities | Federal Funds Rate
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)				0.50%
Senior Secured Credit Facilities | One-Month Adjusted Eurocurrency Rate
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)				1.00%
Senior Secured Credit Facilities | Base Rate
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)				0.50%
Senior Secured Credit Facilities | Minimum | Eurocurrency Rate
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)				1.25%
Debt instrument, total net leverage ratio				3.75%
Senior Secured Credit Facilities | Minimum | Base Rate
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)				0.25%
Debt instrument, total net leverage ratio				1.50%
Senior Secured Credit Facilities | Maximum
Debt Instrument [Line Items]
Ratio of consolidated funded indebtedness to consolidated EBITDA				450.00%
Cash consideration				$ 25,000,000
Ratio of consolidated EBITDA to consolidated interest expense				300.00%
Senior Secured Credit Facilities | Maximum | Unrestricted
Debt Instrument [Line Items]
Cash and cash equivalents				$ 50,000,000
Senior Secured Credit Facilities | Maximum | Foreign | Unrestricted
Debt Instrument [Line Items]
Cash and cash equivalents				$ 25,000,000
Senior Secured Credit Facilities | Maximum | Eurocurrency Rate
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)				2.25%
Debt instrument, total net leverage ratio				1.50%
Senior Secured Credit Facilities | Maximum | Base Rate
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)				1.25%
Debt instrument, total net leverage ratio				3.75%
Senior Secured Credit Facilities | Senior Secured Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 150,000,000
Expiration date	2021-12
Debt instrument, total net leverage ratio				300.00%
Commitment fee percentage			0.375%
Outstanding borrowings				$ 0
Undrawn capacity				150,000,000
Outstanding letters of credit undrawn				100,000
Origination fees				1,600,000
Unamortized origination fees				$ 1,600,000
Senior Secured Credit Facilities | Senior Secured Revolving Credit Facility | Senior Secured Credit Facilities Bear Interest - Scenario 1
Debt Instrument [Line Items]
Commitment fee percentage				0.50%
Senior Secured Credit Facilities | Senior Secured Revolving Credit Facility | Senior Secured Credit Facilities Bear Interest - Scenario 2
Debt Instrument [Line Items]
Commitment fee percentage				0.375%
2014 Senior Secured Credit Facilities | 2014 Senior Secured Term Loan Facility
Debt Instrument [Line Items]
Maximum borrowing capacity						$ 530,000,000
Credit facility expiration year				2,016
2014 Senior Secured Credit Facilities | 2014 Senior Secured Revolving Credit Facility
Debt Instrument [Line Items]
Outstanding borrowings					0
Undrawn capacity					60,000,000
Outstanding letters of credit undrawn					0
2014 Senior Secured Credit Facilities | 2014 Senior Secured Revolving Credit Facility | Minimum
Debt Instrument [Line Items]
Commitment fee percentage				0.375%
2014 Senior Secured Credit Facilities | 2014 Senior Secured Revolving Credit Facility | Maximum
Debt Instrument [Line Items]
Commitment fee percentage				0.50%
2014 Senior Secured Term Loan Facility | 2014 Senior Secured Credit Facilities
Debt Instrument [Line Items]
Unamortized origination fees					10,100,000
2014 Senior Secured Revolving Credit Facility | 2014 Senior Secured Credit Facilities
Debt Instrument [Line Items]
Unamortized origination fees					1,300,000
Term Loan
Debt Instrument [Line Items]
Carrying value of debt				$ 164,500,000	388,000,000
Term Loan | Senior Secured Credit Facilities
Debt Instrument [Line Items]
Applicable margin on variable rate (percent)				2.15%
Term Loan | Level 2
Debt Instrument [Line Items]
Estimated fair value of debt				$ 164,500,000
Term Loan | Level 1
Debt Instrument [Line Items]
Estimated fair value of debt					$ 386,300,000
Senior Secured Term Loan Facility
Debt Instrument [Line Items]
Original issue discount				500,000
Senior Secured Term Loan Facility | Senior Secured Credit Facilities
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 165,000,000
Debt instrument percentage of face value issued	99.70%
Expiration date	2021-12
Origination fees				800,000
Unamortized origination fees				$ 800,000
2014 Senior Secured Revolving Credit Facility | 2014 Senior Secured Credit Facilities
Debt Instrument [Line Items]
Maximum borrowing capacity						$ 60,000,000

Commitments, Contingencies, a58

Commitments, Contingencies, and Guarantees - Schedule of Minimum Future Lease Payments (Details) $ in Thousands	Dec. 31, 2016USD ($)
Related Party Transaction [Line Items]
Operating Lease, 2017	$ 6,956
Operating Lease, 2018	5,827
Operating Lease, 2019	4,318
Operating Lease, 2020	3,671
Operating Lease, 2021	3,480
Operating Lease, Thereafter	5,100
Operating Lease, Total minimum lease payments	29,352
Related Party
Related Party Transaction [Line Items]
Operating Lease, 2017	2,112
Operating Lease, 2018	2,112
Operating Lease, 2019	2,112
Operating Lease, 2020	2,112
Operating Lease, 2021	2,112
Operating Lease, Thereafter	1,760
Operating Lease, Total minimum lease payments	12,320
Non-Related Party
Related Party Transaction [Line Items]
Operating Lease, 2017	4,844
Operating Lease, 2018	3,715
Operating Lease, 2019	2,206
Operating Lease, 2020	1,559
Operating Lease, 2021	1,368
Operating Lease, Thereafter	3,340
Operating Lease, Total minimum lease payments	$ 17,032

Commitments, Contingencies, a59

Commitments, Contingencies, and Guarantees - Additional Information (Details)	1 Months Ended	3 Months Ended	9 Months Ended	12 Months Ended
	May 31, 2013USD ($)	Mar. 31, 2014USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2016USD ($)Building	Dec. 31, 2015USD ($)	Mar. 31, 2012USD ($)
Commitments Contingencies And Guarantees [Line Items]
Number of buildings in corporate headquarters | Building				3
Operating leases rental expense total			$ 4,300,000	$ 6,700,000	$ 5,800,000
Purchase commitments	$ 2,000,000			$ 0
Purchase commitments discount percentage	5.00%
Purchase commitments term	3 years
Outstanding claims for payment					2,000,000
Proceeds from legal settlements					2,000,000
Minimum
Commitments Contingencies And Guarantees [Line Items]
Non-payment of outstanding invoices						$ 6,500,000
Selling, General and Administrative
Commitments Contingencies And Guarantees [Line Items]
Bad debt recovery					$ 2,000,000
Predecessor
Commitments Contingencies And Guarantees [Line Items]
Operating leases rental expense total		$ 1,400,000

Commitments, Contingencies, a60

Commitments, Contingencies, and Guarantees - Schedule of Minimum Annual Payments Required in Conjunction with Landlord Liability (Details) $ in Thousands	Dec. 31, 2016USD ($)
Commitments Contingencies And Guarantees [Line Items]
Capital Leases, 2017	$ 1,703
Capital Leases, 2018	1,925
Capital Leases, 2019	2,118
Capital Leases, 2020	2,326
Capital Leases, 2021	2,550
Capital Leases, Thereafter	19,608
Capital Leases, Total minimum lease payments	30,230
Related Party
Commitments Contingencies And Guarantees [Line Items]
Capital Leases, 2017	3,792
Capital Leases, 2018	3,886
Capital Leases, 2019	3,937
Capital Leases, 2020	3,988
Capital Leases, 2021	4,040
Capital Leases, Thereafter	23,934
Capital Leases, Total minimum lease payments	43,577
Interest Payments
Commitments Contingencies And Guarantees [Line Items]
Capital Leases, 2017	2,089
Capital Leases, 2018	1,961
Capital Leases, 2019	1,819
Capital Leases, 2020	1,662
Capital Leases, 2021	1,490
Capital Leases, Thereafter	4,326
Capital Leases, Total minimum lease payments	$ 13,347

Shareholders' Equity - Addition

Shareholders' Equity - Additional Information (Details)	Mar. 24, 2014USD ($)employeeshares	Mar. 31, 2014USD ($)shares	Dec. 31, 2014USD ($)shares	Dec. 31, 2016USD ($)shares	Dec. 31, 2015USD ($)employeeshares	Dec. 31, 2011	Aug. 16, 2016shares	Aug. 11, 2016shares	Dec. 31, 2012shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock shares authorized				250,000,000	60,000,000		250,000,000
Preferred stock, shares authorized				5,000,000	0		5,000,000
Stock options granted			1,131,895	683,001	889,849
Share-based payment award description				If Medpace Investors exercised the call right, it could do so up to the later of twelve months following the employee’s departure date or six months following the determination that the former employee was directly or indirectly engaged in competitive business activities
Incremental stock based compensation expense | $				$ 3,100,000
Stock-based compensation expense | $			$ 5,423,000	9,815,000	$ 22,324,000
Stock-based compensation liability reclassified to additional paid in capital | $				10,500,000
Stock-based compensation liability | $				0
Proceeds from stock option exercises | $			0	537,000	250,000
Actual tax benefits recognized related to stock-based compensation | $			$ 3,300,000	$ 1,000,000	4,600,000
Predecessor
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted		0
Stock-based compensation expense | $		$ 7,340,000
Proceeds from stock option exercises | $		0
Actual tax benefits recognized related to stock-based compensation | $		$ 8,200,000
Other Current Liabilities
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation liability | $					1,700,000
Other Long-term Liabilities [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation liability | $					$ 1,900,000
RSAs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unvested restricted stock awards held by employees					688,599
Number of current employees holding unvested restricted stock | employee					158
Incremental stock based compensation expense | $					$ 0
Stock-based compensation expense | $					$ 5,700,000
Restricted Shares (RSAs and RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares granted			283,042	11,111	583,021
Stock-based compensation liability			283,042	0	231,229
Number of remaining shares granted				0	351,851
Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation liability | $					$ 3,600,000
2016 Incentive Award Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares registered and available for grant								6,000,000
Stock options granted				648,180
Shares available for future stock compensation grants				5,400,000
Plan expiration year				2,026
2016 Incentive Award Plan | RSAs and RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares registered and available for grant				6,000,000
2016 Incentive Award Plan | RSAs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares available for future stock compensation grants				5,400,000
2016 Incentive Award Plan | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation option terms				10 years
2016 Incentive Award Plan | Vesting After Four Years
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted				626,650
Award vesting period				4 years
2016 Incentive Award Plan | Vesting on October 31, 2016 and Eight equal monthly Installments
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted				21,530
Vesting percentage				33.00%
Award vesting description				stock options with various vesting schedules, but all of which vest within a calendar year of the respective grant date
2014 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation option terms				7 years
Stock options granted				45,932
2014 Equity Incentive Plan | Fully Vested Shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares granted				11,111
2014 Equity Incentive Plan | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted				0
Award vesting period				4 years
2014 Equity Incentive Plan | Maximum | Fully Vested Shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares granted				0
2014 Equity Incentive Plan | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted				0
Award vesting period				3 years
2014 Equity Incentive Plan | Minimum | Fully Vested Shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares granted				0
2014 Equity Incentive Plan | Vesting Equally Over Four Years
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted				34,821
Award vesting period				4 years
2014 Equity Incentive Plan | Vesting Equally Over Four Years | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted				0
2014 Equity Incentive Plan | Vesting Equally Over Four Years | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted				0
2011 Stock Option Plan | Predecessor
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting period						10 years
Predecessor Equity Plans
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Incremental stock based compensation expense | $	$ 7,100,000
Proceeds from stock option exercises | $	$ 15,200,000
Number of employees impacted by the modification of plan | employee	266
Predecessor Equity Plans | Restricted Shares (RSAs and RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option vested	172,492
Predecessor Equity Plans | Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option vested	992,412
Predecessor Equity Plans | Maximum | Restricted Shares (RSAs and RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock shares authorized									350,000

Shareholders' Equity -Schedule

Shareholders' Equity -Schedule of Weighted-Average Assumptions Used in BSM Model to Calculate Fair Value of Options (Details)	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected holding period - years		5 years 4 months 24 days	3 years 7 months 6 days	4 years 2 months 12 days
Expected volatility		41.80%	30.20%	36.40%
Risk-free interest rate		1.70%	1.00%	1.20%
Expected dividend yield		0.00%	0.00%	0.00%
Predecessor
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected holding period - years	0 years
Expected volatility	0.00%
Risk-free interest rate	0.00%
Expected dividend yield	0.00%

Shareholders' Equity - Schedule

Shareholders' Equity - Schedule of Grant Date Fair Value and Stock-based Compensation Expense Allocated (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense		$ 5,423	$ 9,815	$ 22,324
Stock Options
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Weighted average, grant date fair value		$ 4.33	$ 6.91	$ 3.81
Restricted Shares (RSAs and RSUs)
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Weighted average, grant date fair value		$ 10.80	$ 15.08	$ 12.53
Direct Costs, Excluding Depreciation and Amortization
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense		$ 4,399	$ 5,555	$ 9,243
Selling, General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense		$ 1,024	$ 4,260	$ 13,081
Predecessor
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 7,340
Predecessor | Direct Costs, Excluding Depreciation and Amortization
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	5,422
Predecessor | Selling, General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 1,918

Shareholders' Equity - Schedu64

Shareholders' Equity - Schedule of Successor and Predecessor's Stock Option Activity (Details) - $ / shares	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options, Outstanding - beginning of Period		0	1,794,709	1,091,048
Number of Options, Granted		1,131,895	683,001	889,849
Number of Options, Exercised		0	(36,980)	(17,404)
Number of Options, Forfeited		(40,847)	(90,564)	(168,784)
Number of Options, Expired		0	0	0
Number of Options, Outstanding - end of period	0	1,091,048	2,350,166	1,794,709
Number of Options, Exercisable - end of period		0	647,343	242,777
Weighted average exercise price, Outstanding - beginning of Period		$ 0	$ 15.42	$ 14.40
Weighted average exercise price, Granted		14.40	22.80	16.67
Weighted average exercise price, Exercised		0	0	0
Weighted average exercise price, Forfeited		14.40	15.85	15.53
Weighted average exercise price, Expired		0	0	0
Weighted average exercise price, Outstanding - end of period	$ 0	14.40	17.57	15.42
Weighted average exercise price, Exercisable - end of period		$ 0	$ 15.22	$ 14.40
Predecessor
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options, Outstanding - beginning of Period	1,438,800	0
Number of Options, Granted	0
Number of Options, Exercised	(1,388,000)
Number of Options, Forfeited	(32,200)
Number of Options, Expired	(18,600)
Number of Options, Outstanding - end of period	0
Number of Options, Exercisable - end of period	0
Weighted average exercise price, Outstanding - beginning of Period	$ 11.03	$ 0
Weighted average exercise price, Granted	0
Weighted average exercise price, Exercised	10.97
Weighted average exercise price, Forfeited	12.53
Weighted average exercise price, Expired	11.27
Weighted average exercise price, Outstanding - end of period	0
Weighted average exercise price, Exercisable - end of period	$ 0

Shareholders' Equity - Schedu65

Shareholders' Equity - Schedule of Successor and Predecessor's Restricted Share Activity (Details) - Restricted Stock Units - shares	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding and unvested - beginning of period		0	90,697	407,171
Granted		707,721	11,111	1,253,924
Vested		(283,042)	(41,069)	(1,530,547)
Forfeited		(17,508)	(1,481)	(39,851)
Outstanding and unvested - end of period	0	407,171	59,258	90,697
Cumulative vested shares - end of period		283,042	1,854,658	1,813,589
Predecessor
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding and unvested - beginning of period	176,643	0
Granted	0
Vested	(172,492)
Forfeited	(4,151)
Outstanding and unvested - end of period	0
Cumulative vested shares - end of period	263,490

Shareholders' Equity - Schedu66

Shareholders' Equity - Schedule of Stock Options Expected To Vest, Stock Options Exercisable, and Unvested Restricted Share Awards Expected To Vest (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted Average Exercise Price, Number of stock options expected to vest	$ 17.51
Weighted Average Exercise Price, Total stock options exercisable - December 31, 2016	$ 15.22	$ 14.40	$ 0
Number of stock options expected to vest	2,304,229
Number of Restricted Shares expected to vest	59,258
Weighted Average Remaining Life (Years), Number of stock options expected to vest	5 years 4 months 24 days
Weighted Average Remaining Life (Years), Total stock options exercisable - December 31, 2016	4 years 9 months 18 days
Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of stock options expected to vest	2,304,229
Total stock options exercisable - December 31, 2016	647,343
Unrecognized compensation cost - December 31, 2016	$ 7,909
Weighted average years over which unrecognized compensation cost will be recognized	2 years 4 months 24 days
RSAs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted average years over which unrecognized compensation cost will be recognized	2 years
Number of Restricted Shares expected to vest	59,258
Unrecognized compensation cost - December 31, 2016	$ 538

Shareholder's Equity - Schedule

Shareholder's Equity - Schedule of Aggregate Intrinsic Value of Stock Options Exercised, Fair Values of Awards Vested, and Share Based Liabilities Settled (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total intrinsic value of stock options exercised		$ 0	$ 403	$ (36)
Total grant-date fair value of stock options vested		0	1,384	1,168
Total share-based liabilities settled		3,057	76	16,858
Restricted Shares (RSAs and RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total grant-date fair value of restricted shares vested		3,057	614	18,284
Total settlement date fair value of restricted shares vested		$ 3,057	$ 1,236	$ 21,134
Predecessor
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total intrinsic value of stock options exercised	$ 25,378
Total grant-date fair value of stock options vested	3,446
Total share-based liabilities settled	0
Predecessor | Restricted Shares (RSAs and RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total grant-date fair value of restricted shares vested	1,466
Total settlement date fair value of restricted shares vested	$ 0

Employee Benefit Plans - Additi

Employee Benefit Plans - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
401(k) Plan
Defined Benefit Plan Disclosure [Line Items]
Maximum annual contribution by employee, percentage of pre-tax earnings			50.00%
401(k) Plan | U.S. Employees
Defined Benefit Plan Disclosure [Line Items]
Recognized cost of employee benefit plan		$ 1.1	$ 2	$ 1.7
Minimum period of service required for matching contribution eligibility			1 year
Minimum required period of service for employer contributions to fully vest			3 years
401(k) Plan | U.S. Employees | Predecessor
Defined Benefit Plan Disclosure [Line Items]
Recognized cost of employee benefit plan	$ 0.3
Defined Contribution Arrangements | Non-U.S. Employees
Defined Benefit Plan Disclosure [Line Items]
Recognized cost of employee benefit plan		$ 0.5	$ 0.7	$ 0.7
Defined Contribution Arrangements | Non-U.S. Employees | Predecessor
Defined Benefit Plan Disclosure [Line Items]
Recognized cost of employee benefit plan	$ 0.2

Income Taxes - Schedule of Comp

Income Taxes - Schedule of Components of Income (Loss) Before Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Line Items]
Domestic		$ (23,893)	$ 18,016	$ (12,294)
Foreign jurisdictions		2,854	3,941	4,464
Income (loss) before income taxes		$ (21,039)	$ 21,957	$ (7,830)
Predecessor
Income Tax Disclosure [Line Items]
Domestic	$ (1,069)
Foreign jurisdictions	847
Income (loss) before income taxes	$ (222)

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income Tax Provision (Benefit) (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Line Items]
U.S. Federal, Current		$ 1,817	$ 15,105	$ 11,067
U.S. Federal, Deferred		(8,941)	(8,784)	(11,995)
U.S. Federal, Total		(7,124)	6,321	(928)
U.S. state and local, Current		245	1,636	1,119
U.S. state and local, Deferred		(606)	(524)	(761)
U.S. state and local, Total		(361)	1,112	358
Foreign jurisdictions, Current		853	710	1,372
Foreign jurisdictions, Deferred		(71)	389	41
Foreign jurisdictions, Total		782	1,099	1,413
Income tax provision (benefit), Current		2,915	17,451	13,558
Income tax provision (benefit), Deferred		(9,618)	(8,919)	(12,715)
Income tax provision (benefit), Total		$ (6,703)	$ 8,532	$ 843
Predecessor
Income Tax Disclosure [Line Items]
U.S. Federal, Current	$ 342
U.S. Federal, Deferred	659
U.S. Federal, Total	1,001
U.S. state and local, Current	52
U.S. state and local, Deferred	(38)
U.S. state and local, Total	14
Foreign jurisdictions, Current	320
Foreign jurisdictions, Deferred	(321)
Foreign jurisdictions, Total	(1)
Income tax provision (benefit), Current	714
Income tax provision (benefit), Deferred	300
Income tax provision (benefit), Total	$ 1,014

Income Taxes - Summary Of Diffe

Income Taxes - Summary Of Difference Between Statutory Rate for Federal Income Tax and Effective Income Tax Rate (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Line Items]
Income tax expense calculated at the federal statutory rate		$ (7,363)	$ 7,685	$ (2,740)
State and local taxes, net of federal benefit		219	912	487
Tax on foreign earnings, net of tax credits and deductions		(261)	(26)	(330)
Change in valuation allowance		0	0	0
Goodwill impairment		0	0	2,106
Stock-based awards		332	(534)	778
Other		730	174	185
State/Local tax credits		(573)	(1,049)	(931)
Change in liability for uncertain tax positions		249	1,212	1,250
Other		(36)	158	38
Income Tax Expense (Benefit)		$ (6,703)	$ 8,532	$ 843
Income tax expense calculated at the federal statutory rate		35.00%	35.00%	35.00%
State and local taxes, net of federal benefit		(1.00%)	4.20%	(6.20%)
Tax on foreign earnings, net of tax credits and deductions		1.20%	(0.10%)	4.20%
Change in valuation allowance		0.00%	0.00%	0.00%
Goodwill impairment		0.00%	0.00%	(26.90%)
Stock-based awards		(1.60%)	(2.40%)	(9.90%)
Other		(3.50%)	0.80%	(2.40%)
State/Local tax credits		2.70%	(4.80%)	11.90%
Change in liability for uncertain tax positions		(1.20%)	5.50%	(16.00%)
Other		0.20%	0.70%	(0.50%)
Effective Income Tax Rate Reconciliation, Percent		31.80%	38.90%	(10.80%)
Predecessor
Income Tax Disclosure [Line Items]
Income tax expense calculated at the federal statutory rate	$ (78)
State and local taxes, net of federal benefit	208
Tax on foreign earnings, net of tax credits and deductions	(440)
Change in valuation allowance	789
Goodwill impairment	0
Stock-based awards	278
Other	296
State/Local tax credits	(208)
Change in liability for uncertain tax positions	169
Other	0
Income Tax Expense (Benefit)	$ 1,014
Income tax expense calculated at the federal statutory rate	35.00%
State and local taxes, net of federal benefit	(93.80%)
Tax on foreign earnings, net of tax credits and deductions	197.80%
Change in valuation allowance	(354.30%)
Goodwill impairment	0.00%
Stock-based awards	(125.20%)
Other	(133.10%)
State/Local tax credits	93.60%
Change in liability for uncertain tax positions	(76.10%)
Other	0.00%
Effective Income Tax Rate Reconciliation, Percent	(456.10%)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Mar. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Line Items]
Undistributed earnings of foreign subsidiaries	$ 15,100,000	$ 10,400,000
Foreign operating loss carryforward	246,000	250,000
Deferred tax assets, valuation allowance	$ 987,000	1,021,000	$ 800,000
Percentage of foreign net operating loss carryforward	74.00%
Impairment Loss				$ 2,300,000
Deferred tax asset				$ 800,000
Liability for interest and penalties	$ 1,000,000	600,000
Liability for uncertain tax position	$ 4,300,000	$ 1,800,000
Number of tax years	4 years
Tax Year 2012
Income Tax Disclosure [Line Items]
Open tax year	2,012
Tax Year 2016
Income Tax Disclosure [Line Items]
Open tax year	2,016
Maximum
Income Tax Disclosure [Line Items]
Foreign net operating loss carryforwards expiration year	2,025
Minimum
Income Tax Disclosure [Line Items]
Foreign net operating loss carryforwards expiration year	2,020
U.S. State and Local
Income Tax Disclosure [Line Items]
Operating loss carryforwards expiration year	2,029
U.S. State and Local | Maximum
Income Tax Disclosure [Line Items]
Deferred tax assets, operating loss carryforwards	$ 100,000
Foreign Tax Authority
Income Tax Disclosure [Line Items]
Deferred tax assets, valuation allowance	$ 200,000

Income Taxes - Schedule of Co73

Income Taxes - Schedule of Components of Company's Net Deferred Tax Liability (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015	Mar. 31, 2014
Deferred tax assets:
Accrued liabilities	$ 19,393	$ 15,746
Depreciation and amortization	1,787	1,995
Foreign operating loss carryforward	246	250
U.S. state and local tax credits and carryforward	385	153
Other	1,209	1,132
Valuation allowance	(987)	(1,021)	$ (800)
Total deferred tax assets	22,033	18,255
Deferred tax liabilities:
Depreciation and amortization	(33,436)	(38,970)
Prepaid expenses	(310)	(161)
Other	(220)	(71)
Total deferred tax liabilities	(33,966)	(39,202)
Net deferred tax liability	$ (11,933)	$ (20,947)

Income Taxes - Schedule of Annu

Income Taxes - Schedule of Annual Activity Related to Valuation Allowance(Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Line Items]
Beginning Balance		$ 1,103	$ 1,021	$ 1,086
Additions charged to expense		0	0	0
Reductions from utilization, reassessments and expirations		(17)	(34)	(65)
Ending Balance	$ 1,103	1,086	$ 987	$ 1,021
Predecessor
Income Tax Disclosure [Line Items]
Beginning Balance	305	$ 1,103
Additions charged to expense	798
Reductions from utilization, reassessments and expirations	0
Ending Balance	$ 1,103

Income Taxes - Schedule of Gros

Income Taxes - Schedule of Gross Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Line Items]
Beginning balance		$ 1,092	$ 2,604	$ 1,353
Increases in tax positions for prior years		31	0	0
Decreases in tax positions for prior years		(8)	(196)	(14)
Increases in tax positions for current year		238	3,365	1,265
Lapse in statute of limitations		0	(75)	0
Ending Balance	$ 1,092	1,353	$ 5,698	$ 2,604
Predecessor
Income Tax Disclosure [Line Items]
Beginning balance	938	$ 1,092
Increases in tax positions for prior years	134
Decreases in tax positions for prior years	0
Increases in tax positions for current year	20
Lapse in statute of limitations	0
Ending Balance	$ 1,092

Miscellaneous (Expense) Incom76

Miscellaneous (Expense) Income, Net - Components of Miscellaneous (Expense) Income, Net (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Net loss on foreign-currency transactions		$ (1,156)	$ (660)	$ (1,307)
Other income		855	237	174
Miscellaneous (expense) income, net		$ (301)	$ (423)	$ (1,133)
Predecessor
Net loss on foreign-currency transactions	$ (114)
Other income	1,327
Miscellaneous (expense) income, net	$ 1,213

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details)	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2014USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2016USD ($)BuildingRenewalOptionAgreement	Dec. 31, 2015USD ($)shares	Dec. 31, 2014USD ($)	Dec. 13, 2016USD ($)
Related Party Transaction [Line Items]
Consulting fees paid in connection with related party transaction					$ 1,700,000
Service revenue with related parties		$ 11,800,000	$ 24,100,000	$ 24,000,000
Reimbursed out-of-pocket revenue with related parties		2,000,000	5,400,000	6,900,000
Reimbursed out-of-pocket expenses with related parties		2,000,000	5,400,000	6,900,000
Accounts receivable, unbilled services with related parties			2,300,000	2,900,000
Advanced billings			65,668,000	51,051,000
Pre-funded study costs with related parties			3,900,000	3,700,000
Deemed landlord liability, long-term portions			28,527,000	30,273,000
Stock-based compensation expense		5,423,000	9,815,000	$ 22,324,000
Employee Stock Purchase Agreement
Related Party Transaction [Line Items]
Number of common stock purchase by employee | shares				37,037
Stock-based compensation expense				$ 0
Predecessor
Related Party Transaction [Line Items]
Service revenue with related parties	$ 2,000,000
Reimbursed out-of-pocket revenue with related parties	100,000
Reimbursed out-of-pocket expenses with related parties	100,000
Stock-based compensation expense	7,340,000
Cinven
Related Party Transaction [Line Items]
Management fees expense with related party		200,000	200,000	300,000
Travel expenses with related party		100,000	100,000	100,000
Accounts payable to related party			100,000	100,000
Director fees with related party			100,000
Medpace Investors
Related Party Transaction [Line Items]
Accounts payable to related party			300,000
Receivables from related party			300,000
Related party tax expense		1,400,000	800,000	900,000
Prepaid Expenses and Other Current Assets | U.S. State and Local
Related Party Transaction [Line Items]
Due from related party			100,000	400,000
Prepaid Expenses and Other Current Assets | Maximum | Other Taxing Authorities
Related Party Transaction [Line Items]
Due from related party			100,000	100,000
Other Assets | U.S. State and Local
Related Party Transaction [Line Items]
Due from related party			100,000	400,000
Other Current Liabilities | Maximum | Other Taxing Authorities
Related Party Transaction [Line Items]
Due to related party			0	100,000
Other Current Liabilities | Former Owner Member
Related Party Transaction [Line Items]
Due to related party			100,000	400,000
Other Long-term Liabilities [Member] | Former Owner Member
Related Party Transaction [Line Items]
Due to related party			100,000	400,000
Employee Loans | Prepaid Expenses and Other Current Assets
Related Party Transaction [Line Items]
Employee advances receivables						$ 200,000
Employee Loans | Other Assets
Related Party Transaction [Line Items]
Employee advances receivables				200,000
Service Agreements | Symplmed
Related Party Transaction [Line Items]
Service revenue with related parties		1,200,000		1,200,000
Receivables from related party				300,000
Service Agreements | Symplmed | Maximum
Related Party Transaction [Line Items]
Service revenue with related parties			(100,000)
Receivables from related party			100,000
Service Agreements | Coherus Bio Sciences Inc
Related Party Transaction [Line Items]
Service revenue with related parties		10,600,000	22,300,000	22,100,000
Amount of investment			$ 2,500,000
Service agreement cancellation notice period			30 days
Reimbursed out-of-pocket revenue with related parties		2,000,000	$ 5,100,000	6,900,000
Reimbursed out-of-pocket expenses with related parties		2,000,000	5,100,000	6,900,000
Accounts receivable, unbilled services with related parties			2,000,000	2,300,000
Advanced billings			6,300,000	8,400,000
Pre-funded study costs with related parties			$ 3,800,000	3,500,000
Service Agreements | Coherus Bio Sciences Inc | Predecessor
Related Party Transaction [Line Items]
Service revenue with related parties	2,000,000
Reimbursed out-of-pocket revenue with related parties	100,000
Reimbursed out-of-pocket expenses with related parties	100,000
Service Agreements | Coherus Bio Sciences Inc | Predecessor | Miscellaneous (Expense) Income, Net
Related Party Transaction [Line Items]
Service revenue with related parties	300,000
Service Agreements | MX II Associates LLC
Related Party Transaction [Line Items]
Percentage of sales commission			10.00%
Commission paid		600,000		1,100,000
Service Agreements | MX II Associates LLC | Predecessor
Related Party Transaction [Line Items]
Commission paid	300,000
Service Agreements | Xenon
Related Party Transaction [Line Items]
Service revenue with related parties			$ 1,300,000	700,000
Reimbursed out-of-pocket revenue with related parties			200,000
Reimbursed out-of-pocket expenses with related parties			200,000
Accounts receivable, unbilled services with related parties			300,000
Advanced billings			1,300,000	1,800,000
Pre-funded study costs with related parties			100,000	200,000
Service Agreements | Xenon | Maximum
Related Party Transaction [Line Items]
Reimbursed out-of-pocket revenue with related parties				100,000
Reimbursed out-of-pocket expenses with related parties				100,000
Accounts receivable, unbilled services with related parties				100,000
Service Agreements | Cymabay
Related Party Transaction [Line Items]
Service revenue with related parties			300,000	100,000
Service Agreements | LIB
Related Party Transaction [Line Items]
Service revenue with related parties			$ 200,000
Leased Real Estate | Chief Executive Officer
Related Party Transaction [Line Items]
Term of lease			12 years
Lease expiration period			2022-11
Number of lease renewal, 10-year option | RenewalOption			1
Lease term upon renewal			10 years
Annual base rent			$ 2,100,000
Lease expense recognized		1,600,000	$ 2,100,000	2,100,000
Storage space lease basis			month to month basis
Leased Real Estate | Chief Executive Officer | Predecessor
Related Party Transaction [Line Items]
Lease expense recognized	500,000
Leased Real Estate | Chief Executive Officer And Immediate Family
Related Party Transaction [Line Items]
Term of lease			15 years
Number of lease renewal, 10-year option | RenewalOption			1
Lease term upon renewal			10 years
Number of lease agreements | Agreement			2
Number of buildings | Building			2
Lease occupancy year			2,012
Lease expiration year			2,027
Accretion expense paid		3,100,000	$ 3,700,000	3,400,000
Deemed landlord liability, current			1,700,000	1,600,000
Deemed landlord liability, long-term portions			28,500,000	30,300,000
Leased Real Estate | Chief Executive Officer And Immediate Family | Predecessor
Related Party Transaction [Line Items]
Accretion expense paid	900,000
Leased Real Estate | Property and Equipment, Net | Chief Executive Officer And Immediate Family | Building
Related Party Transaction [Line Items]
Deemed assets, net			18,100,000	19,800,000
Travel Services | Chief Executive Officer
Related Party Transaction [Line Items]
Travel expenses with related party		$ 500,000	$ 1,000,000	$ 900,000
Travel Services | Chief Executive Officer | Predecessor
Related Party Transaction [Line Items]
Travel expenses with related party	$ 100,000

Acquisition and Integration E78

Acquisition and Integration Expenses - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Acquisition and integration expenses		$ 9,297	$ 0	$ 0
Predecessor
Acquisition and integration expenses	$ 12,420

Entity Wide Disclosures - Addit

Entity Wide Disclosures - Additional Information (Details) - Service Revenue, Net	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Geographical Locations | Maximum
Segment Reporting Information [Line Items]
Percentage of service revenue to consolidated service revenue			5.00%
Products And Services | Clinical Research Service
Segment Reporting Information [Line Items]
Percentage of service revenue to consolidated service revenue		85.00%	87.00%	87.00%
Products And Services | Clinical Research Service | Predecessor
Segment Reporting Information [Line Items]
Percentage of service revenue to consolidated service revenue	85.00%
Products And Services | Laboratory Services
Segment Reporting Information [Line Items]
Percentage of service revenue to consolidated service revenue		15.00%	13.00%	13.00%
Products And Services | Laboratory Services | Predecessor
Segment Reporting Information [Line Items]
Percentage of service revenue to consolidated service revenue	15.00%
U.S. | Geographical Locations
Segment Reporting Information [Line Items]
Percentage of service revenue to consolidated service revenue			98.00%	98.00%

Entity Wide Disclosures - Summa

Entity Wide Disclosures - Summary of Property and Equipment, Net by Geographic Region (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Property and equipment, net:
Property and equipment, net	$ 43,805	$ 37,512
U.S.
Property and equipment, net:
Property and equipment, net	34,817	28,152
BELGIUM
Property and equipment, net:
Property and equipment, net	3,672	3,896
Other Europe Countries
Property and equipment, net:
Property and equipment, net	3,764	3,968
Europe [Member]
Property and equipment, net:
Property and equipment, net	7,436	7,864
Other
Property and equipment, net:
Property and equipment, net	$ 1,552	$ 1,496

Quarterly Financial Data (Una81

Quarterly Financial Data (Unaudited) - Schedule of Unaudited Quarterly Results of Operations (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								9 Months Ended	12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Service revenue, net	$ 95,376	$ 94,812	$ 92,633	$ 87,800	$ 85,681	$ 81,638	$ 76,752	$ 76,030	$ 219,791	$ 370,621	$ 320,101
Direct costs, excluding depreciation and amortization	51,074	51,221	49,234	46,981	44,219	41,763	38,600	39,125	117,550	198,510	163,707
Income (loss) from operations	12,890	12,617	14,114	12,869	(889)	7,195	7,867	6,389	2,447	52,490	20,562
Net income (loss)	$ (21)	$ 5,036	$ 4,962	$ 3,448	$ (8,576)	$ (133)	$ 95	$ (59)	$ (14,336)	$ 13,425	$ (8,673)
Net income (loss) per common share—Basic	$ 0	$ 0.14	$ 0.15	$ 0.11	$ (0.27)	$ 0	$ 0	$ 0	$ (0.46)	$ 0.38	$ (0.28)
Net income (loss) per common share—Diluted	$ 0	$ 0.13	$ 0.15	$ 0.11	$ (0.27)	$ 0	$ 0	$ 0	$ (0.46)	$ 0.37	$ (0.28)